

BRITISH THORACIC ONCOLOGY GROUP

England & Wales · Charity number 1166012

Details

Other names	BTOG
Status	Registered
Legal form	Charitable company
Company number	09816385
Registered	2016-03-11
Register	View on the Charity Commission register

Contact

Address	British Thoracic Oncology Group 235 Loughborough Road Mountsorrel Loughborough Leicestershire LE12 7AS
Phone	07810016414
Email	dawn.mckinley@btog.org
Website	http://www.btog.org

Activities

Objects: THE OBJECTS OF THE CHARITY ARE: (1) THE PROMOTION AND ADVANCEMENT OF HEALTH OR THE SAVING OF LIVES BY WAY OF IMPROVING THE CARE OF PATIENTS WITH THORACIC MALIGNANCIES THROUGH MULTIDISCIPLINARY EDUCATION AND CLINICAL AND SCIENTIFIC RESEARCH FOR THE BENEFIT OF THE PUBLIC; (2) TO ADVANCE PUBLIC EDUCATION AND RESEARCH INTO LUNG CANCER AND MESOTHELIOMA, IN PARTICULAR BUT NOT EXCLUSIVELY BY FACILITATION OF EXCHANGE OF INFORMATION ON THORACIC ONCOLOGY INCLUDING DISSEMINATING RESULTS OF RESEARCH AND OTHER NEWS RELATED TO LUNG CANCER AND MESOTHELIOMA;(3) SUCH OTHER CHARITABLE PURPOSES BENEFICIAL TO THE COMMUNITY CONSISTENT WITH THE OBJECTS ABOVE AS THE TRUSTEES SHALL IN THEIR ABSOLUTE DISCRETION DETERMINE.

Activities: To support and educate thoracic oncology healthcare professionals, creating a professional community to exchange ideas, information and innovation and to foster the development of research. The overall aim is to represent the needs of people with thoracic malignancies in the UK and ensure they have

equitable access to optimal care.

Classification

- **How:** Provides Advocacy/advice/information, Acts As An Umbrella Or Resource Body
- **What:** Education/training, The Advancement Of Health Or Saving Of Lives
- **Who:** The General Public/mankind

Geography

- Northern Ireland
- Scotland
- Throughout England And Wales

Finances

Period end	Income	Expenditure	Assets	Employees
2025-03-31	£1,696,222	£1,524,010	£717,889	2
2024-03-31	£764,573	£779,727	£545,677	2
2023-03-31	£137,691	£316,575	-	-
2022-03-31	£526,534	£286,940	£739,715	2
2021-03-31	£19,500	£143,766	-	-

Trustees

Name	Role	Appointed
Denis Talbot		2020-05-17
Jacqueline Fenemore		2024-11-18
Nicholas Roberts		2026-01-01
Professor Corinne Faivre-Finn		2024-11-14
Professor Michael Peake OBE		2016-03-11
Vanessa Beattie		2024-11-26

Accounts

Charity Registration No. 1166012

Company Registration No. 9816385 (England and Wales)

BRITISH THORACIC ONCOLOGY GROUP

**TRUSTEES' REPORT AND
FINANCIAL STATEMENTS**

**FOR THE YEAR ENDED
31 MARCH 2025**

BRITISH THORACIC ONCOLOGY GROUP

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees	Professor D Talbot (Chairman)	
	Mr C Kerr (Treasurer)	
	Professor M D Peake	
	Ms V Beattie	(Appointed 26 November 2024)
	Professor C Faivre-Finn	(Appointed 14 November 2024)
	Ms J Fenemore	(Appointed 18 November 2024)
Chief Operating Officer	Ms D E McKinley	
Steering Committee Chair	Professor S Popat	(to 5 March 2025)
	Dr T Newsom-Davis	(from 6 March 2025)
Charity number	1166012	
Company number	9816385	
Principal address	235 Loughborough Road Mountsorrel Loughborough Leicestershire LE12 7AS	
Registered office	235 Loughborough Road Mountsorrel Loughborough Leicestershire LE12 7AS	
Auditor	P T Barnett FCCA Newby Castleman LLP West Walk Building 110 Regent Road Leicester LE1 7LT	
Bankers	Santander UK plc Bridle Road Bootle Merseyside L30 4GB	

BRITISH THORACIC ONCOLOGY GROUP

CONTENTS

	Page
Trustees' report	1 - 32
Independent auditor's report	33 - 35
Statement of financial activities	36
Balance sheet	37
Statement of cash flows	38
Notes to the financial statements	39 - 48

BRITISH THORACIC ONCOLOGY GROUP



TRUSTEES' REPORT

FOR THE YEAR ENDED 31 MARCH 2025

The trustees, who are the directors of the charitable company, present their report and financial statements for the year ended 31 March 2025. The BTOG Board of Trustees ("trustees") are responsible for safeguarding the values and purpose of BTOG and ensuring that activities contribute to achieving the objects of the charity and that BTOG follows its legal obligations.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the charity's governing document, the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102), Accounting and Reporting by Charities: Statement of Recommended Practice for Charities applying FRS 102 (2019), the Charities Act 2011, the Companies Act 2006 and UK Generally Accepted Accounting Practice.

The legal and administrative information forms part of this report.

OBJECTIVES AND ACTIVITIES

The charitable objects are:

- (1) The promotion and advancement of health or the saving of lives by way of improving the care of patients with thoracic malignancies through multi-disciplinary education and clinical and scientific research for the benefit of the public;
- (2) To advance public education and research into lung cancer and mesothelioma, in particular but not exclusively by facilitation of exchange of information on thoracic oncology including disseminating results of research and other news related to lung cancer and mesothelioma;
- (3) Such other charitable purposes beneficial to the community consistent with the objects as above as the trustees shall in their absolute discretion determine.



The British Thoracic Oncology Group (BTOG) is the multi-disciplinary group for healthcare professionals involved with thoracic malignancies throughout the UK.

Our Vision

To contribute to achieving survival rates equal to the best in the world.

Our Mission

To support and educate thoracic oncology healthcare professionals, creating a professional community to exchange ideas, information and innovation and to foster the development of research. The overall aim is to represent the needs of people with thoracic malignancies in the UK and ensure they have equitable access to optimal care.

Our Values



Commitment

We are committed to achieving our mission and vision.



Pride

We are proud to be an important part of the thoracic oncology professional community.



Collaboration

We work collaboratively with other groups who in their own ways are also striving to improve outcomes for this group of patients.



Engagement

We engage with our stakeholders to ensure what we do is relevant and effective.



Professionalism

We maintain professional independence from commercial organisations.



Focussed

We hold patients at the centre of everything we do.

BRITISH THORACIC ONCOLOGY GROUP



TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

Strategic Outcomes

01

To reach all lung /mesothelioma MDTs in the UK to ensure all thoracic oncology healthcare professionals have access to relevant education and resources.

02

To be a leader in thoracic oncology research to focus and support the research agenda.

03

To represent thoracic oncology patients by making contributions and collaborating with others.

Strategic Activities	Make www.btog.org the one-stop resource shop for thoracic oncology healthcare professionals	Identify and communicate with lung and mesothelioma MDTs.	Develop education and resources for trainees e.g. trainee E-news and forum
Education	- Conference (Flagship Event) - Essential Updates - Workshops (ad hoc) - Annual updates from thoracic oncology international conferences - Produce a podcast series on hot topics and recent data releases - Essential Updates for New Consultants e.g. Oncology or Respiratory		- Produce standard slide sets in identified areas of interest e.g. The TNMv9 stage classification for lung cancer - Produce Breaking News/Alerts/Press - Releases for Changes in Practice - Trainee-specific resources including newsletters, Slack channel, dedicated Annual Conference session
Research	- Establish BTOG Special Interest Groups to complement other external subgroups - Ensure BTOG Special Interest Groups report regularly on the delivery of specific objectives		- Develop a Research Strategy to focus and support the thoracic oncology research agenda - Research Group to advise trainees on research proposals - Promote and support trainee research projects
Representation	- Make reactive contributions: NICE appraisals; Specialist Statement of Practice; Endorsements - Make proactive contributions: Guidelines; Position and Consensus Statements; Comment on Public Health England / Department of Health Policy - Support relevant campaigns for equitable access to optimal care and make proactive contributions by commenting on Public Health England and Department of Health Policy		- Partner with specialist societies / groups / organisations (e.g. Surgeons, Nurses, Pathologists, Radiologists) - Engage with advocates by ensuring advocate representation on the BTOG steering committee and making advocate places available at BTOG educational events - Recognise the future Implementation of Screening and ctDNA and the importance of BTOG representation - Represent all the UK including the devolved nations

Activities for achieving objectives for the public benefit

The trustees have had regard to the Charity Commission's guidance on public benefit. The main activities undertaken to further the charitable purposes for the public benefit are set out above.

Criteria to measure success in the reporting period;

We measure our success in achieving our objectives in several of ways by:

- Providing an annual CPD education programme of value to the whole multi-disciplinary team and receiving good feedback from attendees and consistent or increased attendance to the events.
- Keeping in touch with the professional community to encourage networking and collaboration virtually
- Listening to our stakeholders to ensure what we do is relevant and effective through feedback and surveys.
- Working collaboratively with other groups to improve patient outcomes.
- Ensuring that BTOG represents patients in relevant guideline and drug development.

BRITISH THORACIC ONCOLOGY GROUP



TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

The BTOG Steering Committee

The BTOG Steering Committee (pictured below at BTOG 2025) are from the following specialities:

- Medical Oncology
- Clinical Oncology
- Respiratory
- Surgery
- Nursing
- Radiology
- Epidemiology & Statistics
- Advocacy

And they

- Represent the multi-disciplinary team,
- Support the aims and objectives of BTOG and
- Take an active role in education and representation.



During this year, the BTOG steering committee saw 4 steering committee members step-down and 3 new steering committee members join representing Surgery, Medical Oncology and Respiratory Medicine specialities. And after 13 years as chair of the BTOG Steering Committee, Professor Sanjay Popat (left) officially handed over the reins to Dr Tom Newsom-Davis (right). In a heartwarming speech at BTOG's 23rd Annual Conference 2025, Denis Talbot, Chair of BTOG's Board of Trustees gave thanks for Sanjay's vision, leadership and impact on the thoracic oncology community.



Tom said: "It is the greatest honour to be appointed Chair of the Steering Committee. I look forward to working with committee colleagues, and the BTOG executive, to continue the fantastic work that BTOG has already done to improve thoracic oncology care in the UK."

ACHIEVEMENTS AND PERFORMANCE

Review of Activities – Education



Education

Events, podcasts, breaking news, eNews, trainee eNews, and a library of educational material.

During the 2024/25 year, BTOG has provided a relevant Continuing Professional Development (CPD) education programme for the thoracic oncology multi-disciplinary team.

The annual conference is BTOG's flagship event.

It is a 3-day educational event, CPD accredited and involves national and international experts. The programme includes presentations, panel discussions, specialist parallel sessions, poster oral presentations and collaborative sessions. BTOG strives to create an environment at the annual conference that facilitates interaction between colleagues.

Accredited by:

The Federation of the Royal Colleges of Physicians of the United Kingdom



Learning Objectives:

1. To update all attendees on state-of-the-art management of lung cancer and other thoracic malignancies; to develop new national research studies in lung cancer and mesothelioma
2. To give knowledge of new procedures for the management of lung cancer and other thoracic malignancies.
3. To increase understanding of multi-disciplines on the nature of clinical practice and research and to learn from clinical experts about implication on UK practice now and in the future.

BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025



ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities – Education (continued)



BTOG 2024 HIGHLIGHTS

The Lifetime Achievement Award was presented by Professor Michael Peake (left) to Professor David Baldwin (middle)

Professor Charles Swanton (right) delivered the Keynote Lecture



FOR THE YEAR ENDED 31 MARCH 2025



Review of Activities - Education (continued)

The banner for the 23rd BTOG Annual Conference is split into two main sections. The left section has a dark blue background with white text. It features the title '23RD BTOG ANNUAL CONFERENCE' in a large, bold, sans-serif font. Below this, in a smaller font, are the location 'ICC BELFAST', the hashtag '#BTOG25', and the dates 'MON 3RD - WED 5TH MARCH 2025'. A circular logo for the 'British Thoracic Oncology Group' (BTOG) is positioned between the text and the image. The logo contains a stylized red and blue emblem and the text 'British Thoracic Oncology Group' and 'BTOG'. The right section of the banner is a photograph of the ICC Belfast building, a modern structure with a curved facade and large glass windows. Several blue banners with the BTOG logo are hanging from the building's facade. A few people are visible walking in front of the building.



After 13 years as chair of the BTOG Steering Committee, Professor Sanjay Popat officially handed over the reins to Dr Tom Newsom-Davis.



BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025



ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)

Feedback from BTOG 2024 and BTOG 2025 held in Belfast, Northern Ireland



All participants agreed or strongly agreed with all our feedback questions that checked relevance, learning, structure, effectiveness, organisation, time for discussion and avoided undue commercial bias. The main request was for more time for discussion.

Feedback highlights:

- Thoroughly enjoyed my first BTOG. Thank you
- I liked that the talks were not all heavily targeted at oncologists. There were lots of interesting talks aimed more at the respiratory physician. Lots of useful talks about lung cancer screening.
- Excellent event. Superbly well run. Good time keeping in all sessions which was needed as lots of smaller sessions. Very clinically relevant and superb discussions.
- Great conference with the perfect opportunity for networking
- Thought the quality of speakers and information sharing really excellent
- Great multi-professional meeting
- Excellent content.
- Excellent conference as always. Great to meet colleagues face to face and share ideas.
- As always, a great conference with a very friendly and inclusive vibe.
- First time at BTOG and I really loved it. It has a lovely friendly feel, great networking and discussions in the sessions and breaks. Really enjoyed the poster evening.
- Well organised
- Clinically relevant content
- This was my first BTOG I attended and was very impressed with every aspect. It was a well organised event, a great chance to meet new people and share practices.
- As ever BTOG was a great opportunity to learn and network in a relaxed and collegiate atmosphere.

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)



The Mesothelioma Essential Update 2024 was approved for 7 CPD credits from the Federation of the Royal Colleges of Physicians of the United Kingdom (Ref: 149933).

233 delegates attended the Mesothelioma Essential Update 2024 on 9th December 2024 at the Cavendish Conference Centre in London and of these 246 were healthcare professionals. Chaired and led by Dr Riyaz Shah, Consultant Medical Oncologist at the Kent Oncology Centre and BTOG Steering Committee Member (pictured below) and Liz Darlison MBE DL, Consultant Nurse at University Hospitals of Leicester NHS Trust and Chief Executive Officer of Mesothelioma UK.



All participants agreed or strongly agreed with all our feedback questions that checked relevance, learning, structure, effectiveness, organisation, time for discussion and avoided undue commercial bias. The main request was for more time for discussion.

Feedback highlights:

- I found the day very interesting. All the speakers were engaging and informative.
- Great educational day, good variety of topics and fabulous speakers
- Good course. Good mix of topics and very useful update.
- Excellent, well organised
- Informative, interesting and well organised day

BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025



ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)



The Therapeutic Strategies for Stage 4 Essential Update 2024 was approved for 6 CPD credits from the Federation of the Royal Colleges of Physicians of the United Kingdom (Ref: 150266).

141 delegates attended the Therapeutic Strategies for Stage 4 Essential on 31st January 2025 at the Cavendish Conference Centre in London and of these 89 were healthcare professionals. Chaired and led by Professor Sanjay Popat, Chair BTOG Steering Committee and Consultant Thoracic Medical Oncologist at the Royal Marsden Hospital and Professor of Thoracic Oncology at the Institute of Cancer Research (pictured below).



All participants agreed or strongly agreed with all our feedback questions that checked relevance, learning, structure, effectiveness, organisation, time for discussion and avoided undue commercial bias.

Feedback highlights:

- Excellent day. Well organised and topics all very relevant.
- This meeting was very interesting and useful for daily oncology practice as it was an update on Stage 4 NSCLC treatment looking into current evidence from the clinical trial data. The meeting was well-organised and interactive with the discussion between the presenters and the audience.
- Excellent well organised and free education. Well done BTOG. Interesting/engaging speakers.
- I thought this was an excellent study day, it was aimed so that everyone could learn something, or that it could be a refresher. I really enjoyed the breaking down of the meanings from the molecular reports. The message was to collaborate with others who have experience, use the GTAB, other people's experience and all the updates. It was nice to meet up with others in person. Really fabulous event and I would encourage my team to go next time.
- This was excellent - I don't think I've been to another meeting with such a concentrated amount of useful and relevant information.

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)



Lung Cancer Sessions brought to you by the **Video Journal of Oncology (VJOncology)**

At the 23rd BTOG Annual Conference 2025 in Belfast, UK, leading thoracic oncology experts got together to share their highlights and perspectives on molecular testing and clinical decision-making in non-small cell lung cancer (NSCLC). The roundtable discussion on biomarker testing in lung cancer featured BTOG Steering Committee Chair-Elect, **Thomas Newsom-Davis** (Chelsea and Westminster Hospital NHS Foundation Trust, London, UK) and BTOG Steering Committee member, **Alastair Greystoke** (Newcastle University/Northern Centre for Cancer Care, Newcastle, UK).

Lung Cancer Sessions: Molecular testing and clinical decision making in NSCLC - VJOncology

Part 1: The Role of Genomic Testing in Lung Cancer

Part 2: Understanding Biomarker Testing and Its Practical Application

Part 3: Genetic Aberrations and Targeted Therapies in Lung Cancer

Webinars



BTOG continued with its regular short (typically around 1-hour) webinars that were developed when in-person events were not possible. These webinars take account of the latest data released and include a panel of relevant experts in thoracic oncology. Registration at all BTOG webinars is free of charge for health care professionals.

We held three 1-hour webinars during this year, and all events and webinars were accredited by the Federation of the Royal Colleges of Physicians of the UK for category 1 (external) CPD credits. CPD credits were available both live and up to 4 weeks post-event for on-demand and the stats provided below reflect this timeframe. Attendees were encouraged to give feedback on the content and organisation, and any feedback was recorded and analysed to ensure continuous improvement.

Webinars migrated to being hosted directly on btog.org rather than the separate btogwebinars.org site in April 2024; still supported and managed by First Sight Media. Single login simplifies user experience. All BTOG webinars are also available to view 'On Demand' in the BTOG Member Only Resources area and to download as a podcast. Video recordings of in-person events are available in the BTOG Member Only Resources within 2 weeks for attendees of the event and 6 months post-event for other members.

BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025



ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)

Live and on-demand

During this year the webinars released were watched by 250 of this total 225 were health care professionals.



BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025



ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)



Podcasts of all BTOG webinars are available to listen to or download. BTOG also publishes a series of podcasts called “*BTOG does ...*” where we discuss a variety of thoracic oncology topics with a different expert each time. You can subscribe to BTOG podcasts through the Apple App Store and the Google Play Store or listen on Spotify by searching BTOG (CPD points are not available for the podcasts).

During this year a total of 6,330 podcast downloads, compared to 7,863 in the previous year. 24,700 total downloads since podcasts were started in November 2021.

639 downloads



240 downloads



346 downloads



546 downloads

BRITISH THORACIC ONCOLOGY GROUP



TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)

BTOG Membership

During this year BTOG continued to provide relevant and up-to-date member services.

- Free CPD education (e.g. BTOG webinars, study days and essential updates)
- CPD education (annual conference)
- BTOG Resources member area including BTOG presentation/video library, trainee resources and podcasts
- Free access to the full digital edition of *Lung Cancer Journal*
- Bursaries/scholarships for BTOG meeting registration or travel (subject to application process)
- Weekly E-News including relevant information about education, research, research surveys
- BTOG networking and professional community
- Discounted membership rates for International Association for the Study of Lung Cancer (IASLC) membership



- 50 E-News were sent during the 2024–2025-year, weekly cadence (usually Wednesdays)
- 41% average open rate (down slightly from 44% in previous year, 41% and 38% the years before)
- Industry average is 20% for similar emails
- 4.92% click rate in 2024-2025 (down slightly from 6.16% in previous year)
- Industry average is 2-4% for similar emails
- NICE Approval emails: 47.5% open rate, 5.16% click rate (both very high)

1st E-News April 2024



Last E-News March 2025



BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025



ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)




During this year 4 Trainee E-news were released, produced by the BTOG Steering Committee Trainee representatives. The open rate and click rate are well above the industry average which suggests it is widely read.

Issue	Open Rate	Click Rate
Apr 24	74%	4.30%
Aug 24	75%	6.00%
Nov 24	55%	4.88%
Feb 25	56%	4.25%



Trainee Enews April 2024




Trainee Enews August 2024

Apr 15, 2024 | Trainee News


Respiratory: OPTIMUM. Prehabilitation: Pre-treatment optimisation of elderly lung cancer patients with frailty. Medical Oncology: Consolidation Therapy in Stage III EGFR Mutant NSCLC. Clinical oncology: Radiation-Induced Lymphopenia for Protons versus Photons.

Aug 6, 2024 | Trainee News

Respiratory/Clinical Oncology: SEISMIC. Medical Oncology: LAURA. Supportive Care: Mental health and wellbeing in mesothelioma.



Trainee Enews November 2024



Trainee Enews February 2025

Nov 12, 2024 | Trainee News

Respiratory: Accuracy of Clinical Staging for Stage III-Single-station N2 NSCLC. Surgery: MARS 2. Survivorship: ESPATUE. Medical Oncology: ADRIATIC.

Feb 26, 2025 | Trainee News

Respiratory: Clinical Utility of Tumour-Naïve Presurgical Circulating Tumour DNA Detection in Early-Stage NSCLC

BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025



ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)

BTOG Membership Stats

March 2025

- 3,607 members (3,247 HCP, 360 Network) - 33% increase on previous year
- To ensure compliance to General Data Protection Regulation (GDPR), BTOG contacts its members regularly to renew and opt-in to receive information from BTOG. The next renewal is due before the end of 2025

Health Care Professionals Members by Speciality

Respiratory	23%
Nursing	19%
Medical Oncology	12%
Clinical Oncology	12%
Oncology	5%
Science/research/clinical trials	3%
Surgery	4%
Radiology	3%
Pathology	2%
Allied HCP	3%
Pharmacy	1%
Palliative Care	1%
Academic	0.6%
Student	0.7%

Health Care Professionals Members by Geography

Based on the sample of 2,101 members with this field completed

Yorkshire and the Humber	233
North West	193
East Midlands	325
North West London	136
South London	132
South West	140
West Midlands	142
Scotland	130
East of England	122
Kent, Surrey and Sussex	182
North Central and East London	152
Thames Valley	70
Wales	66
Northern Ireland	36
Republic of Ireland	42

BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025



ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)



4,059 followers (3,816 last year, 6% increase)

	New Followers						
	24-25	23-24	22-23	21-22	20-21	19-20	18-19
NEW	242	396	224	467	479	510	602
INCREASE	6.3%	12%	7%	18%	21%	29%	29%

	Mentions						
	24-25	23-24	22-23	21-22	20-21	19-20	18-19
TOTALS	1,201	1,314	706	1,118	902	926	706

	Impressions						
	24-25	23-24	22-23	21-22	20-21	19-20	18-19
TOTALS	202,598	330,975	154,557	437,459	274,800	283,600	184,400

3.67% engagement rate (average across healthcare is 0.98%).

X is event-driven, with 13,000 post impressions on March 3rd, the first day of the Annual Conference.

The April 2024 spike is the Annual Conference, the December spike is the Mesothelioma Essential Update.

Post impressions



Highest Engagement	Most Impressions	Most Retweets

BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT (CONTINUED)


FOR THE YEAR ENDED 31 MARCH 2025



ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)


Website – www.btog.org



	Users	Pageviews	Avg. session duration	Pages per session
18-19	13,818	86,157	02:14	3.29
19-20	19,679	116,303	01:55	3.56
20-21	18,181	82,029	01:35	3.15
21-22	20,648	155,999	01:50	4.56
22-23	20,508	143,117	01:46	4.01
23-24	11,118	63,565	01.56	NA
24-25	14,685	80,700	03.43	2.43

80% of traffic is from the UK, 8% from the US, 2% India then Ireland, China, Germany, Italy, Spain, Netherlands and France.

Website traffic over time



BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025



ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)

53% is desktop and 46% is mobile, an increasing proportion is mobile. Mobile continues to grow in popularity for accessing the website and therefore BTOG will ensure website accessibility for mobile viewers to ensure a good experience for all visitors.

Top Referrers

Traffic Sources	
Google / organic Top search terms: BTOG 2024 and BTOG	43%
(direct) / (none)	38%
Social (96% = Twitter)	4%
Other	14%

TOP PAGES

1. Home
2. 2025 Annual Conference
3. 2024 Annual Conference
4. Mesothelioma Essential Update
5. Events
6. Join BTOG
7. Podcasts
8. Stage 4 Therapeutic Strategies
9. Thymic SIG
10. ASCO 2024 Update

Join BTOG | BTOG | British Thoracic Oncology Group

Membership for 2025 is free of charge.
Benefits of your FREE BTOG HCP membership include:



Free CPD education (e.g. BTOG webinars, study days and essential updates)



CPD education (annual conference)



BTOG Resources member area*



Full digital edition of Lung Cancer Journal



Discounted membership rates for International Association for the Study of Lung Cancer (IASLC) membership



Bursaries/scholarships for BTOG meeting registration or travel (subject to availability and application)



Weekly eNews including relevant information about education, research, surveys and more



BTOG networking and professional community


ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities – Research



Research


Special Interest Groups and a research strategy to focus on and support the thoracic oncology agenda.



During this year two Supplements to Lung Cancer were published at BTOG 2024 and BTOG 2025. The supplements showcased important work in 488 abstracts from colleagues in the UK and beyond – research or audit relevant to thoracic oncology including Basic Science, Diagnosis and Staging, Radiotherapy, Screening, Supportive Care, Surgery and more.

<https://lung-btog2024.elsevierdigitaledge.com/>

<https://lung-btog2025.elsevierdigitaledge.com/>



ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities – Research (continued)

A BTOG Special Interest Group (SIG) is a sub-group of the BTOG steering committee with a shared interest in advancing a specific area of thoracic oncology. Members co-operate to affect change or improvement within that speciality. They may communicate, meet, and organise further training or education and resources for the purpose of advancement. They can use the BTOG logo in relation to the SIG. The aim of the BTOG SIGs is to promote the highest standards of knowledge and facilitate research and representation in that specific area of thoracic oncology.



The BTOG Thymic Malignancies SIG, chaired by Dr David Gilligan. Tumours of the thymus gland constitute a rare but significant part of thoracic oncology. Management of these tumours can be complex and is often poorly understood. The BTOG Thymic Malignancies SIG is a multi-disciplinary group of interested health care professionals, including the patient advocacy group Thymic UK. The aims of this group are to promote understanding, improve knowledge of thymic tumours and to work co-operatively to improve the management pathways for thymic tumours.

During this year the group met 5 times on-line and also in person at the annual meeting in Belfast in April 2024 and March 2025. Highlights of work below:

- Launch of the Anterior Mediastinal Pathway, a new diagnostic algorithm for anterior mediastinal lesions. Anterior mediastinal lesions are an uncommon but increasingly identified finding. Previously, there has been no clear guidance on the initial investigations and management for these lesions leading to significant variation in practice. The BTOG Thymic Malignancy Special Interest Group has developed this pathway through multidisciplinary discussion and identification of best practice under the coordination of Dr Stephen Robinson and Professor Matthew Evison. Through this pathway, and the associated review published in Clinical Radiology, the BTOG Thymic Malignancy Special Interest Group hopes to standardise management across the UK to drive improvements in patient care. Additionally, through the emphasis on appropriate use of thoracic magnetic resonance imaging, the group hopes to provide added justification for development of this service throughout the UK.
- Audit and feedback from publication of Anterior Mediastinal Pathway (Lead: Dr R Duerden) Poster at BTOG 2025
- Radiotherapy outling for post operative treatments. A virtual exercise on UK ProKnow platform (Leads Drs M Harris & S Robinson) Poster at BTOG 2025
- Development of UK Thymic Tumour database with Guys & St Thomas' Hospital (who will be responsible for Information Governance of database) (Leads: Drs E Karapanagiotou & E Josephides)
- Improving links with UK Lung Cancer Nursing (Lead M Colvin) - Thymic Session at their National Conference in 2024
- Discussion on Clinical Trials – presentation by Dr D Portnik, EORTC

Continuing workstreams for 2025/2026 include

- Development of surgical information booklet for patients (Lead C Holmes)
- Guideline development for radiotherapy target volume definition (Leads Drs M Harris & S Robinson) and indications for proton radiotherapy (with Dr C Hiley UCLH)
- Looking at Regional Thymic MDT development

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities – Research (continued)



The BTOG Large Cell Neuroendocrine Carcinoma (LCNEC) SIG, chaired by Dr Colin Lindsay, met 5 times during this year. Members will work together to share knowledge and cases to establish a standard of care for Lung LCNECs including but not limited to:

- Evaluating the pathology of high-grade neuroendocrine carcinomas of lung origin
- Understanding biological basis of high-grade neuroendocrine carcinomas of lung origin
- Developing clinical consensus around optimal management of high-grade neuroendocrine carcinomas of lung origin
- Communicating/circulating information via the LCNEC SIG, BTOG online education resources and BTOG relevant education events

Pathology workflow – The pathology panel has uploaded >20 small biopsy cases, paired with surgically confirmed LCNEC and unconfirmed LCNEC cases, to a central viewing platform. They have now begun blinded anonymous review of these cases using an established Clinical Report Form. The pathology panel convenes every 2-4 weeks to discuss results/problems. In addition, the lead pathologist, Anshuman Chaturvedi, and the new LCNEC Clinical Fellow, Becky Ward, are preparing ~70 historical LCNEC cases for retrospective Rb1 staining and targeted NGS – also due to be uploaded for central review.

Oncology workflow - A protocol has been submitted to REC and CAG for a real-world database study called 'LCNEC Foundations', centrally hosted using RedCap, where UK centres will be able to submit collated clinical outcomes of their LCNEC patients. With the support of the BTOG Research Group, the LCNEC Special Interest Group have also submitted phase II trial proposals to both MSD (I-DXd) and Biontech (BNT-327) – aiming to justify a first national LCNEC clinical trial.

BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025



ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities – Research (continued)



The **BTOG Research Group**, chaired by Professor Sanjay Popat, met 7 times during this year. It is an invited group of health care professionals recognised for their leadership in clinical trials and research aiming to develop and foster clinical research in thoracic oncology, to take over some of the functions of the defunct NCRI Lung CSG.

The purpose of the BTOG Research Group is to:

- Meet regularly to brainstorm and generate ideas for clinical trial research;
- Contribute to and peer review trial design and assist investigators to develop clinical trial protocols;
- Develop Investigator Initiated trials (IITs) – in particular phase 1B-3 randomised clinical trials;
- Develop translational protocols and proof of principle studies;
- To foster and develop relationships with academic trials groups from outside the UK;
- To engage with and work alongside established other UK organisations/research charities;
- Engage and build relationships with industry.

During this year the BTOG Research Group has:

Governance

- Written to UK Collaborative for Cancer Clinical Research (UKCCCR) which is leading on coordinating disease area research groups nationally and established the BTOG Research Group as the official UK thoracic oncology research group.
- Extended membership to clinical oncologists to allow research oversight for radiation studies not otherwise reviewed by SABR Consortium.

Studies

- Reviewed and endorsed several trial submissions proposed to the group.
- Put out a call for junior investigators for a potential IIT of home delivery subcutaneous immunotherapy
- Discussed and reviewed design of IITs of new agents, endorsing 2 submitted IITs pending funding approval
- Endorsed multiple studies submitted for feasibility review and funding application

Grant calls

- Promoted a variety of grant calls via e-News

Meetings

- Planned and delivered a research methods workshop in Birmingham on 23 June 2025 for early career investigators
- Planned research portfolio session during BTOG 26 Annual Meeting
- Planning for UK Trials Update day in 2026

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities – Research (continued)

To support research and represent thoracic oncology patients by making contributions and collaborating with others.

BTOG circulated various surveys during this year to BTOG members via BTOG E-news:

May 2024 - Sheffield Hallam University – survey related to a study "Exploring Oncologists' and Health Care Professionals' Perspectives: Physical Activity in Advanced Cancer Care". Results from this study will be used in conjunction with further patient scoping work in the design and implementation of a patient and health care led PA intervention in patients with advanced cancer.

August 2024 - LCNEC BTOG Special Interest Group – survey to ascertain the current understanding of the standard of care of large cell neuroendocrine carcinoma patients from UK-based centres.

September 2024, Colleagues at Guy's and St Thomas' – survey on real-world attitudes of clinicians towards neoadjuvant and peri-operative chemo immunotherapy in resectable lung cancer.

October and November 2024 - International Thymic Malignancy Interest Group (ITMIG) – survey to look at daily practice to identify areas of agreement and potential controversy in the current global clinical and pathology practice of the diagnosis and treatment of thymic epithelial tumors.

November and December 2024 - Thymic Malignancies BTOG Special Interest Group – survey to ask for feedback on the thymic lesion diagnostic algorithm published earlier in this year.

December 2024 - Professor Matthew Evison and Professor Kevin Blyth – survey for input to map the use of important ancillary diagnostic tests in mesothelioma (BAP-1 and MTAP/P16 FISH) across the UK.

March 2025 - LCNUK – survey to inform the production and implementation of a Navigator Framework to provide clear and consistent guidance on the Navigator role within the Lung Cancer setting.

March 2025 - University of Birmingham – survey which aims to improve understanding of what happens when patients are diagnosed with pulmonary nodules. Speaking to patients, doctors, and administrative staff, they hope to understand the process patients go through and whether this process can be improved to reduce the likelihood of nodules being followed up improperly.

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities – Representation



Representation

Proactive and reactive contributions to guidelines, policies, appraisals, statements of practice

February 2025 - BTOG supported a grant application submitted to Roy Castle Lung Cancer Foundation related to a study looking at improving access and recruitment to clinical trials for cancer patients submitted by Professor Catherine Henshall, Clinical Academic Nurse.

March 2025 – BTOG joined other organisations including British Thoracic Society and Mesothelioma UK in writing to the Secretary of State for Health and Social Care to request intervention to establish a National Mesothelioma Clinical Audit. This is crucial to improving treatment standards, ensuring equitable access to care, and reducing the economic burden of this preventable disease.

Advocates

BTOG recognises the importance of input from advocates in improving outcomes for lung cancer and mesothelioma patients. BTOG defines advocates as those who sit on clinical studies or trial management groups, advisory boards/groups or other related groups related to lung cancer or mesothelioma.

BTOG ensures that ...

- Advocate representatives are included on the BTOG steering committee and BTOG Special Interest Groups.
- Advocates have access to relevant BTOG educational events held for health care professionals and limited funding is available to facilitate this.
- A BTOG Advocate Meeting is held at the Annual Conference with representation from the BTOG Steering Committee and relevant thoracic oncology patient organisations. The remit of the meeting is to provide an informal educational opportunity for advocates; give insight into BTOG, the annual conference and current issues in thoracic oncology and the opportunity to share experiences and feedback.

Collaboration

BTOG works collaboratively with many organisations, societies, and groups, to build close and enduring relationships and to have mutual memberships to ensure representation. Steering Committee members undertake this work on behalf of BTOG and these include the following examples:

- Association of Pulmonary Pathologists
- British Thoracic Society
- Cancer Chemotherapy Interest Group
- European Association for Cardio-Thoracic Surgery (EACTS)
- European Organisation for Research and Treatment of Cancer (EORTC)
- European Thoracic Oncology Platform (ETOP)-IBCSG Partners
- International Association for the Study of Lung Cancer (IASLC)
- James Lind Alliance Priority Setting Partnership (PSP) in Thoracic Surgery
- Mesothelioma UK
- NICE
- National Lung Cancer Audit
- Lung Cancer Nursing UK
- Public Health England Implementation Board for Tobacco
- Roy Castle Lung Cancer Foundation
- Royal College of Physicians Tobacco Advisory Board
- Royal College of Radiologists
- Society for Cardiothoracic Surgery (SCTS)
- Taskforce for Lung Health
- UK Lung Cancer Coalition
- UK SACT Board

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities – Representation (continued)



NICE Representation

NICE appraisals review and make recommendations on the clinical and cost-effectiveness of medicines and treatments in the NHS.

During this period BTOG provided expertise and representation on **57 NICE Scoping and Full Appraisals** to improve access to treatment for patients affected by thoracic malignancies. There were 30 negative/suspended trials not included in the above total.

Participating in a NICE appraisal involves a significant time and effort commitment by the representatives involved including:

- Attending in-person and online appraisal meetings,
- Reviewing lengthy and detailed documents on the efficacy and cost effectiveness of medicines and treatments under review and
- Making comment and recommendations.

During this period **8 NICE appraisals resulted in positive recommendations** for treatment options.

Ref	Appraisal
3907	Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer

Source: <https://x.com/NICEComms>



5094	Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of resectable non-small-cell lung cancer
------	---



ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities – Representation (continued)

NICE Representation (continued)

Ref

Appraisal

Source: <https://x.com/NICEComms>

5120 Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (Review of TA761)



It is estimated just under

600 people

could be set to benefit from final draft guidance recommending osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection.

NICE

6220 Durvalumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer



It is estimated that just over

1,500 people

could be set to benefit after NICE published final draft guidance recommending durvalumab with chemotherapy before surgery, then alone after surgery for treating resectable non-small-cell lung cancer.

NICE

6289 Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer



NICE

New treatment for advanced lung cancer recommended

NICE has published final draft guidance recommending crizotinib for treating ROS1-positive advanced non-small-cell lung cancer.

6293 Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

Review of Activities – Representation (continued)

NICE Representation (continued)

Ref

Appraisal

Source: <https://x.com/NICEComms>

6368 Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer



6404 Durvalumab in combination with platinum-based chemotherapy for untreated extensive stage small-cell lung cancer

BTOG Steering Committee Representatives involved in NICE appraisals

Jason Adhikaree	2	Tom Newsom-Davis	5
Samreen Ahmed	6 (1 joint)	Sanjay Popat	11
Shobhit Baijal	6	Riyaz Shah	2
Alastair Greystoke	3	James Spicer	4
Adam Januszewski	1	Yvonne Summers	2 (1 joint)

Co-opted non-Steering Committee Representatives involved in NICE appraisals

Sanjay Agrawal	3	Matthew Krebbs	1
Martin Forster	1	Mary O'Brien	1
Matthew Hatton	1	Robin Young	1

BRITISH THORACIC ONCOLOGY GROUP



TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

FINANCIAL REVIEW

Going Concern


After making appropriate enquiries, the trustees have a reasonable expectation that BTOG has adequate resources to continue in operational existence for the foreseeable future. For this reason, they continue to adopt the going concern basis in preparing the financial statements.

Finance Overview

Our Annual Conferences over the last few years were held in January 2022, April 2023, April 2024 and March 2025, therefore no annual conferences were held in financial year ending 2023, one was held in financial year ending 2024 and two in the financial year ending 2025. This has had a large impact in both income for sponsorship and registration fees. Total income for the year increased from £764,573 in 2024 to £1,696,222 in 2025.

Total expenditure for the year ended 31 March 2025 increased this year amounting to £1,524,010 (2024 - £779,727). The expenditure was split between charitable activities costs in the sum of £1,470,452 and costs of raising funds in the sum of £53,558.

Net income (expenditure) for the year ended 31 March 2025 amounted to £172,212 compared to £(15,154) in the previous year.



Risk Management

A risk policy and a detailed risk register have been produced. The risk register covers governance, external, financial, operational and regulatory risk and a review of the risk register is a standing item at every trustee meeting. The trustees are satisfied that systems and procedures are in place to mitigate exposure to the major risks. A major risk to BTOG is the reliance on registration fees and external sponsorship income to provide enough funding for BTOG to deliver its aims and objectives. This is particularly relevant given the COVID-19 pandemic. Mitigating actions include strategic planning, operating a reserves policy and ongoing engagement with our key sponsors.

Reserves Policy

BTOG is committed to demonstrate good stewardship and active financial management and to identifying through risk assessment and budgeting any uncertainty in future income streams. A major risk to BTOG is the reliance on registration fees and external sponsorship to provide enough funding for BTOG to deliver its aims and objectives. Therefore, the trustees have agreed that at any one time the charity can hold a maximum of 2 years' normal operating expenditure in reserve. Over recent years the charity has never reached this level of reserves and the trustees have acknowledged that this needs to be discussed and reviewed. Normal operating expenditure is identified in annual budgets which are approved by the trustees. This reserve level will ensure that the current service provided by BTOG is secure in times when income to the charity may be reduced.

BRITISH THORACIC ONCOLOGY GROUP



TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

FINANCIAL REVIEW (CONTINUED)

Reserves Policy (continued)

Total reserves as at 31 March 2025 amounted to £717,889 of which £nil are restricted. As at 31 March 2025 free reserves (total unrestricted reserves less unrestricted tangible fixed assets) amounted to £717,389 which is significantly below the trustees' long term target level of reserves. At current levels of normal activity, the maximum level of reserves would be in the range of £1.5m and £2m.

The trustees are considering measures to try and build up free reserves going forward and they will monitor the level of reserves as part of BTOG's financial processes. If reserves were to exceed the agreed level (2 years' normal operating expenditure) BTOG will take immediate steps to reduce the level of those reserves either by increasing expenditure on charitable activities or by reducing its income (or a combination of both). The time frame for this reduction will be within 2 years of discovery of the excess and during that time the trustees will consider whether some or all the reserves can be invested to obtain a financial return for the charity.

STRUCTURE GOVERNANCE AND MANAGEMENT

Constitution

British Thoracic Oncology Group registered as a company (9816385) on 8th October 2015 and as a charity (1166012) on 11th March 2016. The company is limited by guarantee and has no share capital. Every member of the company undertakes to contribute to the assets of the company, in the event of winding up, such an amount as may be required not exceeding £1. The governing document is the Memorandum of Association.

Trustees

The following trustees have served since 1 April 2024:

Professor D Talbot (Chairman from 7-Oct-24)
Mr AM Grange (Chairman until resigned 7-Oct-24)
Mr Christopher Kerr (Treasurer)
Ms Vanessa Beattie (appointed 26-Nov-24)
Mr G Bland (resigned 5-Jul-24)
Professor Corinne Faivre-Finn (appointed 14-Nov-24)
Ms Jacqueline Fenemore (appointed 18-Nov-24)
Professor Michael D Peake

BTOG welcomed 3 new trustees during this period.



Method of Appointment or Election of Trustees

The management of the charity is the responsibility of the trustees elected under the Memorandum of Association of BTOG. Trustees set the policies for the recruitment, induction and training of new trustees. In selecting individuals for appointment as new trustees, the trustees will consider the skills, knowledge and experience needed for the effective running of the charity. Upon appointment, trustees are provided with an induction pack which includes various items such as the governing document, the latest financial statements, policy documents and Charity Commission guidance.

Pay Policy for Staff

During this reporting period BTOG did not employ its own staff. From 1st April 2025 the post of Chief Operating Officer was employed directly by BTOG. An NHS Trust employed the staff and charged the associated salary costs to the charity in accordance with a service level agreement. Pay levels for posts supported by the charity but employed by the NHS Trust are determined through standard NHS procedures.

BRITISH THORACIC ONCOLOGY GROUP



TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

STRUCTURE GOVERNANCE AND MANAGEMENT (CONTINUED)

Organisational Structure and Decision Making

The trustees are responsible for BTOG; they safeguard the values and purpose of BTOG and check activities contribute to achieving the objects and ensure BTOG follows its legal obligations. Trustees are Non-Executive Directors of BTOG. The trustees during this reporting period comprised an emeritus consultant and honorary professor of respiratory medicine/specialist clinical advisor for Cancer Research UK; two lung cancer specialist nurses, a professor and consultant clinical oncologist, a retired professor/medical oncologist; a retired tax inspector, a retired lawyer and a retired senior pharmaceutical professional. The trustees and Steering Committee Chair decide the policies which provide the framework for the work of BTOG; decide overall aims and objectives, priorities and strategy; monitor and evaluate progress and delegate day-to-day work to the BTOG Chief Operating Officer (COO) and other appointed staff/agents. The trustees meet 4 times/year and communicate by email at all other times. One trustee also attends Steering Committee meetings as an observer (subject to availability).

The Steering Committee Chair is an Executive Officer of BTOG, accountable to the trustees. The Steering Committee supports BTOG's aims and objectives; take an active role in the delivery of the BTOG educational programme; comments and advises on thoracic oncology guidelines for care or treatment; represents BTOG on other thoracic oncology boards/committees/groups and recognises their affiliation to BTOG in their work. The Steering Committee are Executive Officers of BTOG, accountable to the SC Chair. The Steering Committee meet in person 4 times/year and communicate by email at all other times. The Steering Committee members represent the thoracic oncology multi-disciplinary team. In addition, BTOG recognises the importance of input from advocates in improving outcomes for lung cancer and mesothelioma patients and therefore the Steering Committee includes two advocate members. BTOG defines advocates as those who sit on clinical studies or trial management groups, advisory boards/groups or other related groups related to lung cancer or mesothelioma.

BTOG is a member of the National Council for Voluntary Organisations (NCVO) and trustees have access to online resources and information for charities. The trustees are required to update their trustee knowledge and training regularly to ensure they understand their role and responsibilities. Trustees periodically attend both theoretical and practical training courses organised by the NCVO covering a wide variety of charitable issues and they also complete online training.

The COO carries out the work of BTOG; reports regularly on achievements and progress; makes decisions (where the power to do this has been delegated); provides information on issues, problems and policy matters and makes recommendations; draws up plans for the future development of BTOG's work for the Trustees and Steering Committee to decide upon; advises and informs the trustee board so that it is able to carry out its governing role and recruits and appoints staff/agents. The COO is reportable to University Hospitals of Leicester NHS Trust (UHL) Line Manager and Steering Committee Chair and accountable to the trustees.

The relationship of the BTOG Executive is based on a shared vision for BTOG; a commitment to achieving the objectives of BTOG; clear and understood trustee roles to not interfere inappropriately with the day-to-day running of BTOG; confidence in the abilities of the COO and willingness to back the judgement of the COO in the event of problems (providing they have been kept informed); the provision of good information to enable informed decisions to be made and a clear management framework and lines of accountability.

The COO and Executive Officer (EO) are paid roles employed by UHL, who charge the associated salary costs to the charity in accordance with a formal service level agreement. Communications/website, conference and accountancy services were contracted out to external commercial providers. All other roles in the BTOG Executive are unpaid.

Following the pandemic, starting 1st February 2022, BTOG have leased an office from Mesothelioma UK in Mountsorrel, Leicester and there is a Memorandum of Understanding in place in this respect. BTOG staff do a combination of office and home working.

BTOG works collaboratively with many organisations including Mesothelioma UK (a related party) in the pursuit of its charitable activities.

BRITISH THORACIC ONCOLOGY GROUP



TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

STRUCTURE GOVERNANCE AND MANAGEMENT (CONTINUED)

Organisational Structure and Decision Making (continued)

BTOG recognised the need for appropriate governance to ensure transparent working and therefore has a comprehensive portfolio of policies covering charity structure, roles and responsibilities of trustees and the steering committee, conflict of interest, finance, procurement, reserves, endorsement, media and privacy, developed taking account of Charity Commission guidance. The policies are reviewed as per the review dates and new policies are developed as needed/identified and are available in the Governance section of the BTOG website.

The Trustees confirm that the major risks relating to BTOG have been reviewed and systems and procedures have been established to manage those risks, as detailed on page 19 under risk management.

Plans for Future Years

BTOG will continue to work towards its strategic outcomes, mission and vision as per pages 1 and 2.

During the 2025/26 year and beyond we plan to:

Education

- Continue to provide relevant CPD education and information via an annual conference, essential updates, webinars, podcasts and the website.
- Work collaboratively with Associate of Pulmonary Pathologists (APP) and Society for Cardiothoracic Surgery in Great Britain & Ireland (SCTS) and other societies
- Produce standard slide sets and a webinar on adoption of Version 9 of the TNM stage classification for lung cancer in the UK and any identified areas of interest.
- Provide networking, education and resources for trainees.
- Continue to update www.btog.org to improve visual design, navigation and content.

Research

- Continue to develop a Research Strategy to focus and support the thoracic oncology research agenda and advise trainees on research proposals to encourage and promote the development of research.

Representation

- Build relationships with existing and new national and international relevant groups and societies – e.g. in the following specialities/organisations Clinical Expert Group (CEG), Surgery, Pathology and Radiology.
- Recognise the future implementation of screening and ctDNA and the importance of BTOG representation in these areas.
- Liaise with NICE/NHS England for earlier notification of new decisions on NICE appraisals and announce "New NICE Approval" via separate BTOG E-news and Twitter.
- Communicate with the Association of the British Pharmaceutical Industry (ABPI) with reference to regulations for conference and events.

Governance and Operational

- Appoint a Chair-Elect/Vice-Chair of the Steering Committee.
- Work towards financial independence from the NHS by employing BTOG staff direct.

STATEMENT OF TRUSTEES' RESPONSIBILITIES

The trustees (who are also directors of BTOG for the purposes of company law) are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year, which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure of the charitable company for that period. In preparing these financial statements, the trustees are required to:



TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

STATEMENT OF TRUSTEES' RESPONSIBILITIES (CONTINUED)

- select suitable accounting policies and then apply them consistently; and
- observe the methods and principles in the Charities SORP 2019 (FRS 102); and
- make judgements and estimates that are reasonable and prudent; and
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the Trustees are aware:

- there is no relevant audit information of which the charitable company's auditor is unaware; and
- the trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

This report has been prepared in accordance with the special provisions relating to small companies within Part 15 of the Companies Act 2006.

Approved by the Board of Trustees on 16 December 2025 and signed on its behalf by:

Professor D Talbot
Chair of the Board of Trustees

BRITISH THORACIC ONCOLOGY GROUP

INDEPENDENT AUDITOR'S REPORT

TO THE TRUSTEES OF BRITISH THORACIC ONCOLOGY GROUP

Opinion

We have audited the financial statements of British Thoracic Oncology Group (the 'charitable company') for the year ended 31 March 2025 which comprise the statement of financial activities, the balance sheet, the statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 March 2025 and of its incoming resources and application of resources, for the year then ended; and
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the Trustee's Report other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained within the Trustee's Report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

BRITISH THORACIC ONCOLOGY GROUP

INDEPENDENT AUDITOR'S REPORT (CONTINUED)

TO THE TRUSTEES OF BRITISH THORACIC ONCOLOGY GROUP

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters in relation to which the Charities (Accounts and Reports) Regulations 2008 require us to report to you if, in our opinion:

- the information given in the financial statements is inconsistent in any material respect with the trustees' report; or
- the charity has not kept adequate accounting records; or
- the financial statements are not in agreement with the accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of trustees

As explained more fully in the statement of trustees' responsibilities set out on pages 31-32, the trustees (who are also the directors of the charitable company for the purpose of company law), are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under section 144 of the Charities Act 2011 and report in accordance with regulations made under section 154 of that Act.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

Extent to which the audit was considered capable of detecting irregularities

We identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and then design and perform audit procedures responsive to those risks, including obtaining audit evidence that is sufficient and appropriate to provide a basis for our opinion. However, responsibility for the prevention and detection of fraud ultimately rests with both those charged with governance and management of the charitable company.

In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, our procedures included the following:

- obtaining an understanding of the legal and regulatory framework applicable to the charitable company by considering the nature of the industry in which the charitable company operates and enquiring of management; and
- identifying the key laws and regulations considered to have a direct impact on the financial statements including the UK Companies Act 2006, UK Charities Act 2011, UK Generally Accepted Accounting Practice and UK tax legislation; and
- assessing how the charitable company is complying with the applicable legal and regulatory framework by making further enquiries of management and observing the company's control environment regarding compliance with regulations and fraud prevention; and

BRITISH THORACIC ONCOLOGY GROUP

INDEPENDENT AUDITOR'S REPORT (CONTINUED)

TO THE TRUSTEES OF BRITISH THORACIC ONCOLOGY GROUP

- assessing the susceptibility of the charitable company's financial statements to material misstatement, including how fraud might occur, by considering the effectiveness of the charitable company's accounting systems and controls and how these were monitored by management. Where the risk of material misstatement was considered to be higher in certain areas, further audit procedures were designed to address this increased risk; and
- discussing amongst the engagement team how and where fraud might occur in the financial statements and any potential indicators of fraud.

Audit response to risks of irregularities identified

Our procedures to respond to risks identified included the following:

- reviewing financial statement disclosures and testing to supporting documentation to assess compliance with applicable laws and regulations; and
- enquiry of charitable company staff responsible for compliance to identify any instances of non-compliance with laws and regulations; and
- enquiry of management, those charged with governance and other relevant parties around actual and potential litigation claims; and
- reviewing minutes of meetings of those charged with governance; and
- performing audit work over the risk of management override of controls, including testing of journal entries and other adjustments for appropriateness, evaluating the business rationale of significant transactions outside the normal course of business and reviewing accounting estimates for bias; and
- communicating identified laws and regulations and potential fraud risks to all engagement team members and assessing whether there are any indications of fraud or non-compliance with laws and regulations throughout the audit.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities is available on the Financial Reporting Council's website at: <https://www.frc.org.uk/auditorsresponsibilities>. This description forms part of our auditor's report.

Other matters

In the previous accounting period, the directors of the company took advantage of audit exemption under section 477 of the Companies Act 2006. Therefore, the comparative financial statements are unaudited.

Use of our report

This report is made solely to the charity's trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our audit work has been undertaken so that we might state to the charity's trustees those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Newby Castleman LLP

Chartered Accountants
Statutory Auditor
West Walk Building
110 Regent Road
Leicester
LE1 7LT

18 December 2025

Newby Castleman LLP is eligible to act as an auditor in terms of section 1212 of the Companies Act 2006.

BRITISH THORACIC ONCOLOGY GROUP

STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT FOR THE YEAR ENDED 31 MARCH 2025

	Notes	Unrestricted Funds Total 2025 £	Unrestricted Funds Total 2024 £
Income from:			
Charitable activities	3	602,272	281,073
Other trading activities	4	1,093,950	483,500
Total		1,696,222	764,573
Expenditure on:			
Raising funds	5	53,558	39,274
Charitable activities	6	1,470,452	740,453
Total		1,524,010	779,727
Net income/(expenditure) for the year/ Net movement in funds		172,212	(15,154)
Reconciliation of funds			
Total funds brought forward		545,677	560,831
Total funds carried forward		717,889	545,677

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

BRITISH THORACIC ONCOLOGY GROUP

BALANCE SHEET

AS AT 31 MARCH 2025

		2025		2024	
	Notes	£	£	£	£
Fixed assets					
Tangible assets	11		500		1,020
Current assets					
Debtors	12	243,220		445,838	
Cash at bank and in hand		547,903		622,660	
		<u>791,123</u>		<u>1,068,498</u>	
Liabilities					
Creditors: amounts falling due within one year	13	(73,734)		(523,841)	
		<u></u>		<u></u>	
Net current assets			717,389		544,657
Net assets			<u>717,889</u>		<u>545,677</u>
Total funds of the charity					
Designated funds		5,831		17,775	
General funds		<u>712,058</u>		<u>527,902</u>	
Total unrestricted funds	15		<u>717,889</u>		<u>545,677</u>
Total charity funds			<u>717,889</u>		<u>545,677</u>

The company is entitled to the exemption from the audit requirement contained in section 477 of the Companies Act 2006, for the year ended 31 March 2025, although an audit has been carried out under section 144 of the Charities Act 2011.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

Trustees' responsibilities:

- The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476 of the Companies Act 2006;
- The trustees acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of the accounts.

The financial statements were approved and authorised for issue by the Board of Trustees on 16 December 2025 and are signed on its behalf by:

Mr C Kerr
Trustee and Treasurer

Company Registration No. 9816385

BRITISH THORACIC ONCOLOGY GROUP

STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED 31 MARCH 2025

	Notes	2025 £	£	2024 £	£
Cash flows from operating activities					
Cash (absorbed by)/generated from operations	20		(74,757)		231,820
Investing activities					
Purchase of tangible fixed assets		-		(1,316)	
Net cash used in investing activities			-		(1,316)
Net cash used in financing activities			-		-
Net (decrease)/increase in cash and cash equivalents			(74,757)		230,504
Cash and cash equivalents at beginning of year			622,660		392,156
Cash and cash equivalents at end of year			547,903		622,660

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025

1 Accounting policies

Charity information

British Thoracic Oncology Group ("BTOG") is a private company limited by guarantee incorporated in England and Wales. The address of the registered office and place of business is given in the legal and administrative information page of these financial statements.

The members of the charity include the trustees named within the legal and administrative information. In the event of the trust being wound up, the liability in respect of the guarantee is limited to £1 per member of the charity.

1.1 Basis of preparation

The charitable company is a Public Benefit Entity as defined by FRS 102. The financial statements have been prepared in accordance with: the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102), Accounting and Reporting by Charities: the Statement of Recommended Practice for charities applying FRS 102 (2019), the Charities Act 2011, the Companies Act 2006 and UK Generally Accepted Accounting Practice.

The financial statements are prepared in sterling, which is the functional currency of the charitable company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below. These policies have been consistently applied to all years presented unless otherwise stated.

1.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charitable company has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives.

Designated funds are unrestricted funds of the charity which have been set aside at the discretion of the trustees for specific purposes. The purposes and uses of the designated funds are set out in the notes to the financial statements.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The aim and use of each restricted fund is set out in the notes to the financial statements.

1.4 Income recognition

Income is recognised when the charitable company is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Income from charitable activities primarily includes income received for conference and course registration fees. Such income is recognised at fair value when the event has occurred.

Income from trading activities includes income earned from sponsorship.

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025

1 Accounting policies

(Continued)

1.5 Expenditure recognition

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs relating to the category. Expenditure is recognised when there is legal or constructive obligation to make the payment to a third party, if it is probable that settlement will be required and the amount of the obligation can be measured reliably. It is recognised under the following headings:

- Expenditure on raising funds - this includes costs for advertising, marketing, direct mail and publicity.
- Expenditure on charitable activities - this includes services to further the delivery of the objectives of the charity.

Irrecoverable VAT is charged against the category of resources expensed for which it was incurred.

Support costs

Support costs are those that assist the work of the charity but do not directly represent charitable activities and costs of raising funds and include office costs and governance costs. They are incurred directly in support of expenditure on the objects of the charity. Support costs are allocated to costs of raising funds and expenditure on charitable activities on a basis consistent with use of the resources.

The analysis of these costs is included in note 8.

1.6 Tangible fixed assets

Tangible fixed assets are measured at cost, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost of assets less their residual values over their useful lives on the following bases:

Fixtures & fittings	15% of cost
Computer equipment	33.33% of cost

1.7 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less.

1.8 Financial instruments

Financial instruments are recognised in the charitable company's balance sheet when the charitable company becomes party to the contractual provisions of the instrument.

Debtors and creditors with no stated interest rate and receivable or payable within one year are measured at transaction price. Any losses arising from impairment are recognised in the SOFA.

1.9 Taxation

British Thoracic Oncology Group is a registered charity and no taxation provision is required as its income from charitable activities falls within the various exemptions available to registered charities.

1.10 Employee benefits

When employees have rendered service to the charity, short-term employee benefits to which the employees are entitled are recognised at the undiscounted amount expected to be paid in exchange for that service.

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025

1 Accounting policies

(Continued)

1.11 Leases

Rentals payable under operating leases, including any lease incentives received, are charged to the SOFA on a straight line basis over the term of the relevant lease.

2 Critical accounting estimates and judgements

In the application of the charitable company's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

The trustees do not consider there to be any key sources of estimation uncertainty that have a significant effect on the amounts recognised in the financial statements.

3 Charitable activities

	Unrestricted funds £	Restricted funds £	Total 2025 £	Total 2024 £
Conference and course registration fees	602,272	-	602,272	281,073
Unrestricted funds				281,073
Restricted funds				-
				281,073
			2025 £	2024 £
Conference and course registration fees breakdown:				
BTOG 2025			329,461	-
BTOG 2024			262,910	-
BTOG 2023			-	280,423
Essential Update Therapeutic Strategies for Stage 4			6,200	-
Mesothelioma Essential Update 2024			3,701	-
Essential Update 2023			-	650
			602,272	281,073

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025

4 Other trading activities

	Unrestricted funds 2025 £	Restricted funds 2025 £	Total 2025 £	Total 2024 £
Sponsorship	1,093,950	-	1,093,950	483,500
Unrestricted funds				483,500
Restricted funds				-
				483,500

5 Raising funds

	Unrestricted funds £	Restricted funds £	Total 2025 £	Total 2024 £
Advertising, marketing, direct mail and publicity	31,169	-	31,169	18,569
Support costs (see note 8)	22,389	-	22,389	20,705
	53,558	-	53,558	39,274
Unrestricted funds				39,274
Restricted funds				-
				39,274

6 Charitable activities

	Activities undertaken directly Note 7 £	Support Costs Note 8 £	Total 2025 £	Total 2024 £
Conference and courses	1,292,413	178,039	1,470,452	740,453
Unrestricted funds			1,470,452	740,453
Restricted funds			-	-
			1,470,452	740,453

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025

7 Expenditure on activities undertaken directly

	2025 £	2024 £
Conference and courses		
Venue and accommodation management	1,189,835	546,642
Abstract publication	42,213	16,754
Prizes and bursaries	3,050	1,650
Travel	33,612	39,208
Course accreditation	1,292	795
Bank and card charges	15,551	8,472
Webinar activities	6,860	5,022
	<u>1,292,413</u>	<u>618,543</u>
	2025 £	2024 £
Venue and accommodation management breakdown:		
BTOG 2025	604,566	-
BTOG 2024	554,204	-
BTOG 2023	-	514,097
Essential Update Therapeutic Strategies for Stage 4	12,220	-
Mesothelioma Essential Update 2024	18,845	-
Essential update 2023	-	25,370
New Consultants Study Day	-	4,791
Other	-	2,384
	<u>1,189,835</u>	<u>546,642</u>

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025

8 Expenditure on support costs

	Basis of allocation	2025 £	2024 £
Staff costs	Raising funds and charitable activities	111,944	103,529
Travel	Charitable activities	24	150
Training	Charitable activities	176	160
Subscriptions	Charitable activities	254	489
Rent	Charitable activities	4,260	4,260
Insurance	Charitable activities	13,608	6,814
Office costs	Charitable activities	980	1,108
Software costs	Charitable activities	2,125	2,729
Professional fees	Charitable activities	12,689	6,173
Sundry	Charitable activities	-	32
Irrecoverable VAT	Charitable activities	53,848	16,627
Depreciation	Charitable activities	520	544
		<u>200,428</u>	<u>142,615</u>
Analysed between:			
Raising funds		22,389	20,705
Charitable activities		<u>178,039</u>	<u>121,910</u>
		<u>200,428</u>	<u>142,615</u>

Support costs have been allocated to raising funds and charitable activities on a basis consistent with the use of the resource. Support costs include governance costs totalling £10,949 (2024: £6,173).

The amount charged to the SOFA in respect of governance costs includes the following:

Statutory audit £9,010 (2024: independent examination £4,775)

Other financial services £1,939 (2024: £1,398)

9 Trustees

The trustees neither received nor waived any emoluments during the year (2024: £Nil).

Travel and subsistence expenses were reimbursed to 1 trustees (2024: 1) in the sum of £24 (2024: £150) during the year.

10 Employees

The average monthly number of employees during the year was:

	2025 Number	2024 Number
Total	<u>2</u>	<u>2</u>

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025

10 Employees (Continued)

Employment costs	2025 £	2024 £
Wages and salaries	111,944	103,529

Staff working for the charity are employed directly by the University Hospitals of Leicester NHS Trust and their salary costs are charged to the charity in accordance with a service level agreement between BTOG and the Trust. The amount charged for the year was £111,944 (2024 - £103,529).

There were no employees whose annual remuneration was more than £60,000.

Remuneration of key management personnel

The remuneration of key management personnel is as follows.

	2025 £	2024 £
Aggregate compensation	66,435	62,942

11 Tangible fixed assets

	Fixtures & fittings £	Computer equipment £	Total £
Cost			
At 1 April 2024	692	1,821	2,513
At 31 March 2025	692	1,821	2,513
Depreciation and impairment			
At 1 April 2024	549	944	1,493
Depreciation charged in the year	81	439	520
At 31 March 2025	630	1,383	2,013
Carrying amount			
At 31 March 2025	62	438	500
At 31 March 2024	143	877	1,020

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025

12 Debtors

	2025 £	2024 £
Amounts falling due within one year:		
Trade debtors	88,180	283,267
Other debtors	5,832	17,776
Prepayments and accrued income	149,208	144,795
	<u>243,220</u>	<u>445,838</u>

13 Creditors: amounts falling due within one year

	2025 £	2024 £
Other taxation and social security	63,967	64,335
Deferred income (see note 14)	-	447,075
Other creditors	-	5,400
Accruals	9,767	7,031
	<u>73,734</u>	<u>523,841</u>

14 Deferred income

	2025 £	2024 £
Arising from advanced registration fees and sponsorships	-	447,075
	<u>-</u>	<u>447,075</u>

Deferred income is included in the financial statements as follows:

	2025 £	2024 £
Deferred income is included within:		
Current liabilities	-	447,075
	<u>-</u>	<u>447,075</u>
Movements in the year:		
Deferred income at 1 April 2024	447,075	510,467
Released from previous periods	(447,075)	(510,467)
Resources deferred in the year	-	447,075
	<u>-</u>	<u>447,075</u>
Deferred income at 31 March 2025	-	447,075

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

15 Unrestricted funds

The unrestricted funds of the charity include designated funds which have been set aside out of unrestricted funds by the trustees for a specific purpose:

	Balance at 1 April 2024 £	Movement in funds			Balance at 31 March 2025 £
		Income £	Expenditure £	Transfers £	
General funds	527,902	1,696,222	(1,412,066)	(100,000)	712,058
Designated funds - wages fund	17,775	-	(111,944)	100,000	5,831
	<u>545,677</u>	<u>1,696,222</u>	<u>(1,524,010)</u>	<u>-</u>	<u>717,889</u>

	Balance at 1 April 2023 £	Movement in funds			Balance at 31 March 2024 £
		Income £	Expenditure £	Transfers £	
General funds	559,527	764,573	(676,198)	(120,000)	527,902
Designated funds - wages fund	1,304	-	(103,529)	120,000	17,775
	<u>560,831</u>	<u>764,573</u>	<u>(779,727)</u>	<u>-</u>	<u>545,677</u>

The wages fund represents funds held by the University Hospitals of Leicester NHS Trust as Custodian Trustee on behalf of British Thoracic Oncology Group for primarily the payment of wages to staff working for the charity but who are employed by the NHS Trust.

16 Analysis of net assets between funds

	Unrestricted funds £	Designated funds £	Total £
Fund balances at 31 March 2025 are represented by:			
Tangible assets	500	-	500
Current assets/(liabilities)	711,558	5,831	717,389
	<u>712,058</u>	<u>5,831</u>	<u>717,889</u>

	Unrestricted funds £	Designated funds £	Total £
Fund balances at 31 March 2024 are represented by:			
Tangible assets	1,020	-	1,020
Current assets/(liabilities)	526,882	17,775	544,657
	<u>527,902</u>	<u>17,775</u>	<u>545,677</u>

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025

17 Related party transactions

During the year rent and office expenses in the sum of £4,260 (2024 - £4,260) were invoiced by Mesothelioma UK Charitable Incorporated Organisation (formerly Mesothelioma UK Charitable Trust) to the British Thoracic Oncology Group, to which Ms D E McKinley was a trustee of this organisation until 31-Dec-24. At the balance sheet date there was an outstanding balance of £nil (2024 - £nil) for these services.

There have been no further related party transactions in the reporting period that require disclosure in the financial statements, other than those noted in note 9 to the financial statements.

18 Operating lease commitments

At 31 March 2024 the charity had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

	2025 £	2024 £
Within one year	3,550	3,550

Lease payments totalling £4,260 (2024 - £4,260) have been recognised as an expense during the year.

19 Controlling party

British Thoracic Oncology Group is a company limited by guarantee and not having a share capital; it is incorporated under the Companies Act and governed by the Memorandum and Articles of Association of the charity. The trustees of the charity are elected members and act as directors of the charity who are deemed to be the controlling party of the charity.

20 Cash generated from operations	2025 £	2024 £
Surplus/(deficit) for the year	172,212	(15,154)
Adjustments for:		
Depreciation and impairment of tangible fixed assets	520	544
Movements in working capital:		
Decrease in debtors	202,618	305,966
(Decrease)/increase in creditors	(3,032)	3,856
(Decrease) in deferred income	(447,075)	(63,392)
Cash (absorbed by)/generated from operations	(74,757)	231,820

Accounts

Charity Registration No. 1166012

Company Registration No. 9816385 (England and Wales)

BRITISH THORACIC ONCOLOGY GROUP

**TRUSTEES' REPORT AND
FINANCIAL STATEMENTS**

**FOR THE YEAR ENDED
31 MARCH 2024**

BRITISH THORACIC ONCOLOGY GROUP

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees	Professor D Talbot (Chairman) Mr C Kerr (Treasurer) Professor M D Peake
Senior Executive Officer	Ms D E McKinley
Steering Committee Chair	Professor S Popat
Steering Committee Vice-Chair	Dr T Newsom-Davis
Charity number	1166012
Company number	9816385
Principal address	235 Loughborough Road Mountsorrel Loughborough Leicestershire LE12 7AS
Registered office	235 Loughborough Road Mountsorrel Loughborough Leicestershire LE12 7AS
Independent examiner	P T Barnett FCCA Newby Castleman LLP West Walk Building 110 Regent Road Leicester LE1 7LT
Bankers	Santander UK plc Bridle Road Bootle Merseyside L30 4GB

BRITISH THORACIC ONCOLOGY GROUP

CONTENTS

	Page
Trustees' report	1 - 22
Independent examiner's report	23
Statement of financial activities	24
Balance sheet	25
Statement of cash flows	26
Notes to the financial statements	27 - 37

BRITISH THORACIC ONCOLOGY GROUP



TRUSTEES' REPORT

FOR THE YEAR ENDED 31 MARCH 2024

The trustees, who are the directors of the charitable company, present their report and financial statements for the year ended 31 March 2024. The BTOG Board of Trustees ("trustees") are responsible for safeguarding the values and purpose of BTOG and ensuring that activities contribute to achieving the objects of the charity and that BTOG follows its legal obligations.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the charity's governing document, the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102), Accounting and Reporting by Charities: Statement of Recommended Practice for Charities applying FRS 102 (2019), the Charities Act 2011, the Companies Act 2006 and UK Generally Accepted Accounting Practice.

The legal and administrative information forms part of this report.

OBJECTIVES AND ACTIVITIES

The charitable objects are:

- (1) The promotion and advancement of health or the saving of lives by way of improving the care of patients with thoracic malignancies through multi-disciplinary education and clinical and scientific research for the benefit of the public;
- (2) To advance public education and research into lung cancer and mesothelioma, in particular but not exclusively by facilitation of exchange of information on thoracic oncology including disseminating results of research and other news related to lung cancer and mesothelioma;
- (3) Such other charitable purposes beneficial to the community consistent with the objects as above as the trustees shall in their absolute discretion determine.



The British Thoracic Oncology Group (BTOG) is the multi-disciplinary group for healthcare professionals involved with thoracic malignancies throughout the UK.

Our Vision

To contribute to achieving survival rates equal to the best in the world.

Our Mission

To support and educate thoracic oncology healthcare professionals, creating a professional community to exchange ideas, information and innovation and to foster the development of research. The overall aim is to represent the needs of people with thoracic malignancies in the UK and ensure they have equitable access to optimal care.

Our Values



Commitment

We are committed to achieving our mission and vision.



Pride

We are proud to be an important part of the thoracic oncology professional community.



Collaboration

We work collaboratively with other groups who in their own ways are also striving to improve outcomes for this group of patients.



Engagement

We engage with our stakeholders to ensure what we do is relevant and effective.



Professionalism

We maintain professional independence from commercial organisations.



Focussed

We hold patients at the centre of everything we do.

BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT

FOR THE YEAR ENDED 31 MARCH 2024



Strategic Outcomes

01

To reach all lung /mesothelioma MDTs in the UK to ensure all thoracic oncology healthcare professionals have access to relevant education and resources.

02

To be a leader in thoracic oncology research to focus and support the research agenda.

03

To represent thoracic oncology patients by making contributions and collaborating with others.

Strategic Activities	Make www.btog.org the one-stop resource shop for thoracic oncology healthcare professionals	Identify and communicate with lung and mesothelioma MDTs.	Develop education and resources for trainees e.g. trainee E-news and forum
Education	- Conference (Flagship Event) - Essential Updates - Workshops (ad hoc) - Annual updates from thoracic oncology international conferences - Produce a podcast series on hot topics and recent data releases - Essential Updates for New Consultants e.g. Oncology or Respiratory		- Produce standard slide sets in identified areas of interest e.g. The TNMv9 stage classification for lung cancer - Produce Breaking News/Alerts/Press - Releases for Changes in Practice - Trainee-specific resources including newsletters, Slack channel, dedicated Annual Conference session
Research	- Establish BTOG Special Interest Groups to complement other external subgroups - Ensure BTOG Special Interest Groups report regularly on the delivery of specific objectives		- Develop a Research Strategy to focus and support the thoracic oncology research agenda - Research Group to advise trainees on research proposals - Promote and support trainee research projects
Representation	- Make reactive contributions: NICE appraisals; Specialist Statement of Practice; Endorsements - Make proactive contributions: Guidelines; Position and Consensus Statements; Comment on Public Health England / Department of Health Policy - Support relevant campaigns for equitable access to optimal care and make proactive contributions by commenting on Public Health England and Department of Health Policy		- Partner with specialist societies / groups / organisations (e.g. Surgeons, Nurses, Pathologists, Radiologists) - Engage with advocates by ensuring advocate representation on the BTOG steering committee and making advocate places available at BTOG educational events - Recognise the future Implementation of Screening and ctDNA and the importance of BTOG representation - Represent all the UK including the devolved nations

For good practice BTOG regularly reviews its strategic outcomes and activities to ensure they are appropriate and feasible.

Activities for achieving objectives for the public benefit

The trustees have had regard to the Charity Commission's guidance on public benefit. The main activities undertaken to further the charitable purposes for the public benefit are set out above.

Criteria to measure success in the reporting period;

We measure our success in achieving our objectives in several of ways:

- By providing an annual CPD education programme of value to the whole multi-disciplinary team and receiving good feedback from attendees and consistent or increased attendance to the events.
- By keeping in touch with the professional community to encourage networking and collaboration virtually and in person.
- By listening to our stakeholders to ensure what we do is relevant and effective through feedback and surveys.
- By working collaboratively with other groups to improve patient outcomes.
- By ensuring that BTOG represents patients in relevant guideline and drug development.

The BTOG Steering Committee represents the multi-disciplinary team, supports the aims and objectives of BTOG and takes an active role in education and representation. During this year, the BTOG steering committee saw 5 steering committee members step-down and 5 new steering committee members join representing Medical Oncology and Respiratory Medicine specialities.

BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2024



ACHIEVEMENTS AND PERFORMANCE

Review of Activities - Education



Education

Events, podcasts, breaking news, eNews, trainee eNews, and a library of educational material.

During the 2023/24 year, BTOG has provided a relevant Continuing Professional Development (CPD) education programme for the thoracic oncology multi-disciplinary team.



226 healthcare professionals attended the **Screening Essential Update** on 6th October 2023 at the America Square Conference Centre in London chaired by Professor Matthew Callister (pictured below) from Leeds Teaching Hospitals NHS Trust and BTOG Steering Committee Member.



All participants responded that they agreed or strongly agreed with all the positive feedback statements included on the evaluation form. The main request was for more time for discussion.

TRUSTEES' REPORT (CONTINUED)


FOR THE YEAR ENDED 31 MARCH 2024

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities – Education (continued)

Feedback highlights:

- Very informative event and clearly offered more insights into national program and experience of different sectors providing the TLHC services.
- Enjoyable and informative sessions.
- This was my first time attending and I felt the information was relevant for my area of work. I really enjoyed the radiology part as I don't normally get involved and learnt a lot especially about the changing of positive to not positive through additional scanning or MDT review.
- Excellent Update meeting - focusing on the most important topics
- Fantastic event with some really excellent sessions- gave a great overview of current situation.



68 healthcare professionals attended the **New Consultants Study Day** on 13th December 2023 at the Wellcome Collection in London.

All participants responded that they agreed or strongly agreed with all the positive feedback statements included on the evaluation form. The main request was for more time for discussion.

Feedback highlights:

- It was a really great idea to have a forum for young consultants to discuss cases and common pitfalls.
- Really useful and interesting day. I learnt a lot and it was really useful to meet other consultants in the same area.
- Very useful and enjoyable day. Excellent speakers. Great opportunity to learn about challenging areas in the management of lung cancer patients and also to meet colleagues from other centres.
- Excellent study day covering topics relevant to oncologists managing lung cancer, and the grey areas relevant to clinical practice. I feel this would be good to make this regular event.



The annual conference is BTOG's flagship event. It is a 3-day educational event, CPD accredited and involves national and international experts. The programme includes presentations, panel discussions, specialist parallel sessions, poster oral presentations and collaborative sessions.




ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)

BTOG strives to create an environment at the annual conference that facilitates interaction between colleagues. BTOG 2023 saw BTOG move from a hotel setting to a conference centre and a change to Belfast.

Learning Objectives:

1. To update all attendees on state-of-the-art management of lung cancer and other thoracic malignancies; to develop new national research studies in lung cancer and mesothelioma.
2. To give knowledge of new procedures for the management of lung cancer and other thoracic malignancies.
3. To increase understanding of multi-disciplines on the nature of clinical practice and research and to learn from clinical experts about implication on UK practice now and in the future.



All participants responded that they agreed or strongly agreed with all the positive feedback statements included on the evaluation form. The main request was for more time for discussion.

Feedback highlights:

- Extremely well organised conference with appropriate sessions, keynote talk was amazing
- Excellent Conference - as per BTOG high standard. Amazing location. I have to say, Dublin - you set high standards and I wasn't sure how you would improve in Belfast, but boy you delivered. THANKYOU.
- The conference was fantastic for networking and I learnt loads. The lung cancer community is such a friendly and welcoming community and I'm proud to be part of an amazing network of professionals.
- Very much enjoyed the new venue, which was more spacious. Excellent selection of topics discussed.
- An excellent conference as always. Great talks applicable to the whole MDT.

BRITISH THORACIC ONCOLOGY GROUP




TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2024

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)

- It was an excellent conference covering all aspects of managing lung cancer.
- Excellent conference - very high quality and also very inclusive with a lovely and friendly atmosphere.



VJ Oncology Lung Cancer Sessions

We partnered with the Video Journal of Oncology (VJ Oncology), an independent, global, open-access video journal, to produce a series of pre-recorded webinars, called Lung Cancer Sessions/. BTOG Steering Committee Chair, Professor Sanjay Popat (far left) and BTOG Steering Committee Member, Dr Riyaz Shah (far right) participated as leading UK thoracic experts.

- How to interpret ctDNA reports (18th May 2023)
- CT Screening in the UK (29th June 2023)
- Drug treatment of operable NSCLC (12th October 2023)

Webinars



BTOG continued with its regular short (typically around 1-hour) webinars that were developed when in-person events were not possible. These webinars take account of the latest data released and include a panel of relevant experts in thoracic oncology. Registration at all BTOG webinars is free of charge for health care professionals.

We held three 1-hour webinars during this year and all events and webinars were accredited by the Federation of the Royal Colleges of Physicians of the UK for category 1 (external) CPD credits. CPD credits were available both live and up to 4 weeks post-event for on-demand and the stats provided below reflect this timeframe. Attendees were encouraged to give feedback on the content and organisation and any feedback was recorded and analysed to ensure continuous improvement.

All BTOG webinars are also available to view 'On Demand' in the BTOG Member Only Resources area and to download as a podcast. Video recordings of in-person events are available in the BTOG Member Only Resources within 2 weeks for attendees of the event and 6 months post-event for other members.

Live and on-demand

The 3 BTOG webinars during this year resulted in a total audience of 302 live and on demand (up to 4 weeks):

ASCO 2023 & AACR Update (12 th June 2023)	80
WCLC 2023 Update (25 th September 2023)	98
ESMO 2023 Update (8 th November 2023)	124

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2024

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)


Feedback for short webinars:

- I am so grateful to the presenters and to BTOG for this opportunity. The combination of having a large amount of data presented and also having the perspective of the experts presenting it is a truly valuable and beneficial experience. It's almost better than attending the full ASCO! I expect it is an awful lot of work preparing for this, because being concise and clear is always difficult. I want to say particular thanks to the presenters and also to Sanjay for providing the energy to keep these webinars going.
- Excellent all round, a very accessible meeting. It's great to get an update when one can't attend the actual event.
- Great summaries and overviews of the topics by clearly experienced and practiced Speakers who knew their remit and delivered the information well. An awful lot of information to take in at a fast pace, so maybe one suggestion is to allow just a little longer between topics, so we can take notes and reflect as we listen and not feel so pressured.
- Excellent summaries. I really appreciated all the hard work given I wasn't able to attend ESMO in person. Many thanks.
- Updates after big conferences very useful-please continue.
- Really useful presentation, thank you. Very useful to be able to watch recorded version as missed the live version.



Podcasts of all BTOG webinars are available to listen to or download. BTOG also publishes a series of podcasts called “BTOG does ...” where we discuss a variety of thoracic oncology topics with a different expert each time. You can subscribe to BTOG podcasts through the Apple App Store and the Google Play Store or listen on Spotify by searching BTOG (CPD points are not available for the podcasts).

During this year a total of 7,863 podcast downloads, compared to 3,024 in the previous year. 18,919 total downloads since podcasts were started in November 2021.



BRITISH THORACIC ONCOLOGY GROUP



TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2024

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)

BTOG does ...	Expert	Interviewer	
BTOG Does ... Mesothelioma and Surgery	Eric Lim & David Waller	Tom Newsom-Davis	445
BTOG does ... the BTS Pleural Guidelines	Najib M Rahman	Tom Newsom-Davis	435
BTOG Does ... ROS1	Meenali Chitnis	Tom Newsom-Davis	212
BTOG does ... RET	Nadza Tokaca	Tom Newsom-Davis	427
BTOG Does... GIRFT (Getting it Right First Time)	Paul Beckett & Victoria Anderson	Tom Newsom-Davis	371
BTOG Does... KRAS	Colin Lindsay	Tom Newsom-Davis	455
BTOG Does...BRAF	Jarushka Naidoo	Tom Newsom-Davis	386
BTOG Podcast Series: BTOG does...National Lung Cancer Audit (NLCA)	Neal Navani & John Conibear	Tom Newsom-Davis	289
BTOG Podcast Series: BTOG does...EGFR Mutated Lung Cancer	Shobit Baijal	Tom Newsom-Davis	627
			3873
PODCAST DOWNLOADS OF WEBINAR RECORDINGS			
BTOG Webinar – ESMO 2023 Update			640
BTOG Webinar: WCLC 2023 Update			631
BTOG webinar: ASCO 2023 and AACR 2023			563
			1834

BTOG Membership

During this year BTOG continued to provide relevant and up-to-date member services.

- Free CPD education (e.g. BTOG webinars, study days and essential updates)
- CPD education (annual conference)
- BTOG Resources member area including BTOG presentation/video library, trainee resources and podcasts
- Free access to the full digital edition of *Lung Cancer Journal*
- Bursaries/scholarships for BTOG meeting registration or travel (subject to application process)
- Weekly E-News including relevant information about education, research, research surveys
- BTOG networking and professional community
- Discounted membership rates for International Association for the Study of Lung Cancer (IASLC) membership



- 55 E-News were sent during this year
- 44% average open rate (Up from 41% in previous year and 38% the year before. Industry average is 20% for similar emails.)
- 6.16% click rate (Industry average is 2-4% for similar emails.)

BRITISH THORACIC ONCOLOGY GROUP



TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2024

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)



- In October 2023, our trainee representatives on the steering committee produced the first E-News specifically intended to educate and inform their fellow trainee members. We identified over 450 trainees on our membership list and will send a this new E-News to them quarterly.
- October 2023: 45% open rate, 5.71% click rate
- January 2024: 40% open rate, 4.18% click rate

The informal feedback has been very positive, and we will continue this initiative.

BTOG Membership Stats

March 2024

- 2,740 members (2,317 last year) (2429 HCP, 311 Network)
- Full renewals planned for later in 2024 – after new website launch
- Ongoing data cleansing based on:
 - E-news unsubscribes and 'never-opens'
 - 'never logged in' + registered before 2022

To ensure compliance to General Data Protection Regulation (GDPR), BTOG contacts its members regularly to renew and opt-in to receive information from BTOG. The next renewal is due later in 2024 following the April launch of a new website.

Health Care Professionals Members by Speciality

	Mar24	Mar23	Mar22	2021	2020
Respiratory	26%	26%	26%	26%	26%
Nursing	21%	21%	22%	22%	22%
Medical Oncology	13%	13%	14%	14%	15%
Clinical Oncology	13%	14%	14%	14%	14%
Oncology	6%	5%	5%	5%	6%
Science/research/clinical trials	3%	3%	4%	4%	4%
Surgery	4%	5%	4%	4%	3%
Radiology	3%	3%	3%	3%	3%
Pathology	1%	2%	2%	2%	2%
Allied HCP	3%	2%	2%	2%	2%
Pharmacy	1%	1%	2%	2%	1%
Palliative Care	1%	1%	1%	1%	1%
Academic	0.6%	0.6%	0.5%	0.5%	1%
Student	0.9%	0.9%	0.8%	0.8%	0%

Based on the sample of 2,418 members with this field completed. (Percentages are rounded)

BRITISH THORACIC ONCOLOGY GROUP



TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2024

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)

Membership (continued)

Health Care Professionals Members by Geography

	Mar 24	Mar 23	Mar22	2021	2020	2019
Yorkshire and the Humber	233	189	187	182	80	86
North West	193	184	178	179	79	107
East Midlands	325	250	222	213	58	102
North West London	136	119	118	116	50	24
South London	132	110	102	100	47	48
South West	140	130	126	123	42	73
West Midlands	142	113	104	105	41	67
Scotland	130	105	101	93	39	NA
East of England	122	106	101	96	36	57
Kent, Surrey and Sussex	182	134	119	114	34	37
North Central and East London	152	111	100	92	33	33
Thames Valley	70	58	56	54	25	24
Wales	66	45	37	36	21	NA
Northern Ireland	36	19	18	18	NA	NA
Republic of Ireland	42	36	36	35	NA	NA

Based on the sample of 2,226 members with this field completed.

Network Members by Area of Interest

	Mar24	Mar23	Mar22	2021	2020
Industry	64%	64%	64%	66%	57.1%
Patient advocate	13%	12%	12%	10%	17.6%
Charity/non-profit	6%	7%	6%	6%	5.5%
Other non-HCP	17%	18%	18%	18%	19.8%

Based on the sample of 298 members with this field completed.

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2024

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)



3,816 followers (3,420 last year, 12% increase)


	New Followers					
	2023-2024	2022-2023	2021-2022	2020-2021	2019-2020	2018-2019
NEW	396	224	467	479	510	602
INCREASE	12%	7%	18%	21%	29%	29%

	Mentions					
	2023-2024	2022-2023	2021-2022	2020-2021	2019-2020	2018-2019
TOTALS	1314	706	1118	902	926	706

	Impressions					
	2023-2024	2022-2023	2021-2022	2020-2021	2019-2020	2018-2019
TOTALS	330,975	154,557	437,459	274,800	283,600	184,400

3.15% engagement rate (average across healthcare is 0.98%).

X (formally Twitter) is event-driven, with 25,000 post impressions on April 26th, the first day of the Annual Conference, 50,000 post impressions on the 27th and 45,000 on the 28th when the average for BTOG is 900 post impressions per day. The Annual Conference therefore accounts for 36% of the total post impressions for the year.



BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2024



ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)

Highest Engagement	Most Impressions	Most Retweets


Website – www.btog.org

	Users	Page views	Avg. session duration	Pages per session
18-19	13,818	86,157	02:24	3.29
19-20	19,679	116,303	01:55	3.56
20-21	18,191	82,029	01:35	3.15
21-22	20,648	155,999	01:50	4.56
22-23	20,508	143,117	01:46	4.01
23-24	11,118	63,565	01:56 (engagement time)	N/A

Google stopped tracking data on its Universal Analytics platform in July 2023 and the new GA4 analytics platform tracks and presents data slightly differently.

74% of traffic is from the UK, 5% from the US, 2% Ireland then India, Spain, China, Germany, Australia, France and Japan.

Website traffic over time



TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2024

Spike in traffic on Wednesday 28th June 2023 may be linked to E-news of that day promoting the screening event within days of the national screening programme announcement (26th June) and a few days after the E-news that BTOG sent about NICE approval for selipercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer (sent 22nd June).

	23-24	22-23	21-22
Desktop	53%	61%	72%
Mobile	46%	38%	27%
Tablet	1%	1%	1%

Mobile continues to grow in popularity for accessing the website so the new site (launched April 2024) will prioritise mobile viewers to ensure a good experience for all visitors.

Top Referrers

Google / organic Top search terms: BTOG, BTOG 2024 and BTOG 2023	43%
Direct	38%
Social (96% = X)	5%
Other/unassigned	14%

NOTE: The balance between search and direct remains consistent from 2022-2023, suggesting that slightly more people are finding the website through a search rather than bookmarking or typing in the web address directly.

TOP PAGES

1. 2024 Annual Conference
2. Home
3. 2023 Annual Conference
4. LC Screening Essential Update
5. Events
6. Meet the team
7. Podcasts
8. Join BTOG
9. Login/members area
10. 2023 Annual Conference archive



ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Research



Research

Special Interest Groups and a research strategy to focus on and support the thoracic oncology agenda.

During this year a Supplement to Lung Cancer was published at BTOG 2023. The supplement showcased important work in 208 abstracts from colleagues in the UK and beyond – research or audit relevant to thoracic oncology including Basic Science, Diagnosis and Staging, Radiotherapy, Screening, Supportive Care, Surgery and more.

[Lung Cancer - Vol.178, Suppl.1 - April 2023 \(elsevierdigitalaedition.com\)](https://elsevierdigitalaedition.com)



A BTOG Special Interest Group (SIG) is a sub-group of the BTOG steering committee with a shared interest in advancing a specific area of thoracic oncology. Members co-operate to affect change or improvement within that speciality. They may communicate, meet, and organise further training or education and resources for the purpose of advancement. They can use the BTOG logo in relation to the SIG. The aim of the BTOG SIGs is to promote the highest standards of knowledge and facilitate research and representation in that specific area of thoracic oncology.



The BTOG Thymic Malignancies SIG, chaired by Dr David Gilligan, met 4 times during this year. Tumours of the thymus gland constitute a rare but significant part of thoracic oncology. Management of these tumours can be complex and is often poorly understood. The BTOG Thymic Malignancies SIG is a multi-disciplinary group of interested health care professionals, including the patient advocacy group Thymic UK. The aims of this group are to promote understanding, improve knowledge of thymic tumours and to work co-operatively to improve the management pathways for thymic tumours.

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2024

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities – Research (continued)

During this year the group met regularly on-line and once in person at the annual meeting in Belfast in April 2023. At that meeting we were joined by Prof. Nicolas Girard, Medical Oncologist & Pneumologist at the Institut Curie, Paris and lead for the French RYTHMIC network. Prof Girard shared his experience of setting up and running a multi-disciplinary group for thymic tumours in France with the group. The Thymic SIG produced the Anterior Mediastinal Pathway, a new diagnostic algorithm for anterior mediastinal lesions (Leads Dr Stephen Robinson & Prof Matt Evison). We also uploaded information on thymic tumours to a dedicated section on the BTOG website. Continuing workstreams during 2023-24 include a radiotherapy working group looking at a consensus for target volume delineation for post-operative radiotherapy (Lead Dr Maggie Harris), establishing a specialist nurse network (Leads Marrika Colvin and Marie Eaton) and improving recognition of associated medical conditions (Lead David Gilligan).



The BTOG Large Cell Neuroendocrine Carcinoma (LCNEC) SIG, chaired by Dr Colin Lindsay, met 4 times during this year. Members will work together to share knowledge and cases to establish a standard of care for Lung LCNECs including but not limited to:

- Evaluating the pathology of high-grade neuroendocrine carcinomas of lung origin
- Understanding biological basis of high-grade neuroendocrine carcinomas of lung origin
- Developing clinical consensus around optimal management of high-grade neuroendocrine carcinomas of lung origin
- Communicating/circulating information via the LCNEC SIG, BTOG online education resources and BTOG relevant education events

During this year the group has shifted focus towards generating output, having now established clear foundations with consistent engagement from UK leaders in pathology, respiratory medicine and oncology. Our ambition is to leverage the potential of the SIG as the largest international LCNEC network, reaching a national consensus on LCNEC diagnosis and care. To summarise our recent progress:

- 1) We have successfully obtained MacMillan funding to hire the first ever dedicated LCNEC position in the UK, a project manager (Karen Shackcloth) to help co-ordinate the myriad contracts, MTAs, applications and meetings involved with driving progress in this work.
- 2) We conduct regular 2-weekly 'LCNEC pathology panel' meetings, where we i) share anonymised images of retrospective cases for knowledge transfer and education; ii) have developed a Clinical Report Form to standardise diagnostic assessment between pathologists, aiming now to perform blinded assessment of a cohort of 20-30 cases with suspected LCNEC; and iii) scrutinise digital and data sharing platforms which could be used for research/education. Our line of sight with this work is a national LCNEC MDT and pathology support for a LCNEC clinical trial.
- 3) We are engaged in promising discussions with two pharma companies and a UK CTU about conducting the first ever UK LCNEC clinical trial. Provisionally this would be a phase II 'pick the winner' design comparing SCLC and NSCLC chemo backbones, in combination with immunotherapy. This design is based on the premise that i) it is very unlikely that immunotherapy doesn't have efficacy on advanced LCNEC (given its benefits in the NSCLC and SCLC settings), and ii) there currently exists no standard-of-care systemic therapy for LCNEC.
- 4) We are in advanced discussions with another pharma company about supporting our foundation work – collecting data and reporting output from our pathology panel, UK treatment patterns, clinical outcomes, etc. This is intended to employ our first ever UK LCNEC clinical fellow in Q4.

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities – Research (continued)



The [BTOG Research Group](#), chaired by Professor Sanjay Popat, met 3 times during this year and formally launched in April 2024. It is an invited group of health care professionals recognised for their leadership in clinical trials and research aiming to develop and foster clinical research in thoracic oncology, to take over some of the functions of the defunct NCRI Lung CSG.

The purpose of the BTOG Research Group is to:

- Meet regularly to brainstorm and generate ideas for clinical trial research;
- Contribute to and peer review trial design and assist investigators to develop clinical trial protocols;
- Develop Investigator Initiated trials (IITs) – in particular phase 1B-3 randomised clinical trials;
- Develop translational protocols and proof of principle studies;
- To foster and develop relationships with academic trials groups from outside the UK;
- To engage with and work alongside established other UK organisations/research charities;
- Engage and build relationships with industry.



During this period BTOG were one of three stakeholder organisations invited to consult on the Standards and datasets for reporting cancers - Dataset for the histopathological reporting of mesothelioma. Published March 2024.

Surveys:

In September 2023, BTOG circulated a survey from IC-OS International Cardio-Oncology Society entitled Reducing Cardiotoxicity from Lung Cancer Radiation Therapy: A Survey of Opinions & Current Practice.

In October 2023, BTOG circulated the OPTIMA Lung Cancer Research Question Prioritisation Survey to determine the most important and critical research questions that still need to be answered within lung cancer research.

In November 2023, BTOG circulated for opinions on a proposed study design for a randomised placebo-controlled study of an oral anticoagulant (the DOAC, Apixaban) from the Hull and Warwick team.

In December 2023, BTOG circulated a survey from colleagues in Newcastle regarding the ANTLE trial to assess the potential of direct oral anti-coagulants to reduce blood clots in patients with NSCLC receiving systemic therapy.

In December 2023, BTOG circulated a survey from Asthma + Lung UK who were conducting a research priority setting partnership with the James Lind Alliance. The survey asked people who have experience of breathlessness (including people living with malignant pleural mesothelioma), and the healthcare professionals that care for them, to help identify the top 10 questions that research should address.

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2024

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities – Representation



Representation

Proactive and reactive contributions to guidelines, policies, appraisals, statements of practice

Advocates

BTOG recognises the importance of input from advocates in improving outcomes for lung cancer and mesothelioma patients. BTOG defines advocates as those who sit on clinical studies or trial management groups, advisory boards/groups or other related groups related to lung cancer or mesothelioma. BTOG ensures that ...

- Advocate representatives are included on the BTOG steering committee and BTOG Special Interest Groups.
- Advocates have access to relevant BTOG educational events held for health care professionals and limited funding is available to facilitate this (where possible in line with pharmaceutical industry regulations).
- A BTOG Advocate Meeting is held at the Annual Conference with representation from the BTOG Steering Committee and relevant thoracic oncology patient organisations. The remit of the meeting is to provide an informal educational opportunity for advocates; give insight into BTOG, the annual conference and current issues in thoracic oncology and the opportunity to share experiences and feedback.

Collaboration

BTOG continues to work collaboratively with many organisations, societies, and groups and to build close and enduring relationships and to have mutual memberships to ensure representation. Steering Committee members undertake this work on behalf of BTOG and these include the following examples:

- British Thoracic Society
- Cancer Chemotherapy Interest Group
- European Association for Cardio-Thoracic Surgery (EACTS)
- European Organisation for Research and Treatment of Cancer (EORTC)
- European Thoracic Oncology Platform (ETOP)-IBCSG Partners
- International Association for the Study of Lung Cancer (IASLC)
- Mesothelioma UK
- National Lung Cancer Audit
- Lung Cancer Nursing UK
- Public Health England Implementation Board for Tobacco
- Roy Castle Lung Cancer Foundation
- Royal College of Physicians Tobacco Advisory Board
- Society for Cardiothoracic Surgery (SCTS)
- Taskforce for Lung Health
- UK Lung Cancer Coalition

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2024

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities – Representation (continued)



NICE Representation

NICE appraisals review and make recommendations on the clinical and cost-effectiveness of medicines and treatments in the NHS.

During this period BTOG provided expertise and representation on 58 NICE Scoping and Full Appraisals to improve access to treatment for patients affected by thoracic malignancies. There were 19 negative/suspended trials not included in the above total.

Participating in a NICE appraisal involves a significant time and effort commitment by the representatives involved including:

- Attending in-person and online appraisal meetings,
- Reviewing lengthy and detailed documents on the efficacy and cost effectiveness of medicines and treatments under review and
- Making comment and recommendations.

During this period 3 NICE appraisals resulted in positive recommendations for treatment options.

ID Number	Title
4056	Lung cancer (non-small-cell, advanced, RET fusion, untreated) - Selpercatinib
3984	Mobocertinib for treating EGFR Exon 20 insertion-positive advanced non-small-cell lung cancer after platinum-based chemotherapy (Not recommend (Appeal) now recommended Jan 2023. Withdrawn March 24
TA898	Dabrafenib-trametinib for BRAF V600E mutant advanced NSCLC and given a positive recommendation for the submitted indication: 1st line BRAF V600E advanced NSCLC

Steering Committee Representative	58 Appraisals
Sanjay Popat	12
Samreen Ahmed	7 (1 joint)
Shobhit Bajjal	6
Riyaz Shah	5
James Spicer	4
Tom Newsom-Davis	3
Alastair Greystoke	2
Yvonne Summers	2
Matthew Callister, David Gilligan, Adam Januszewski and Clive Peedell	1 each
Co-Opted Steering Committee Members: Sanjay Agrawal, Martin Forster, Matthew Hatton, Matthew Krebs, Mary O'Brien and Robin Young	8
No representation	5

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2024

FINANCIAL REVIEW

Going Concern

After making appropriate enquiries, the trustees have a reasonable expectation that BTOG has adequate resources to continue in operational existence for the foreseeable future. For this reason, they continue to adopt the going concern basis in preparing the financial statements.


Finance Overview

Our Annual Conferences over the last few years were held in April 2021, January 2022, April 2023 and April 2024, therefore two annual conferences were in the financial year ending 2022, none in financial year ending 2023 and one in financial year ending 2024. This has had a large impact in both income for sponsorship and registration fees. Total income for the year increased from £137,691 in 2023 to £764,573 in 2024.

The investment in online learning and webinars brought in as our face-to-face educational programme was set aside due to COVID-19 restrictions, has been hugely successful and has been continued.

Total expenditure for the year ended 31 March 2024 increased this year amounting to £779,727 (2023 - £316,575). The expenditure was split between charitable activities costs in the sum of £740,453 and costs of raising funds in the sum of £39,274.

Net income (expenditure) for the year ended 31 March 2024 amounted to £(15,154) compared to £(178,884) in the previous year.



Risk Management

A risk policy and a detailed risk register have been produced. The risk register covers governance, external, financial, operational and regulatory risk and a review of the risk register is a standing item at every trustee meeting. The trustees are satisfied that systems and procedures are in place to mitigate exposure to the major risks. A major risk to BTOG is the reliance on registration fees and external sponsorship income to provide enough funding for BTOG to deliver its aims and objectives. This is particularly relevant given the COVID-19 pandemic. Mitigating actions include strategic planning, operating a reserves policy and ongoing engagement with our key sponsors.

Reserves Policy

BTOG is committed to demonstrate good stewardship and active financial management and to identifying through risk assessment and budgeting any uncertainty in future income streams. A major risk to BTOG is the reliance on registration fees and external sponsorship to provide enough funding for BTOG to deliver its aims and objectives. Therefore, the trustees have agreed that at any one time the charity can hold a maximum of 2 years' normal operating expenditure in reserve (at the time of writing the charity has not yet reached this level of reserve). Normal operating expenditure is identified in annual budgets which are approved by the trustees. This reserve level will ensure that the current service provided by BTOG is secure in times when income to the charity may be reduced.

In March 2024, a financial stress test exercise was conducted by the BTOG treasurer, to consider the financial risks which attach to BTOG in its current format and the extent to which those risks provide any danger to the continued existence and operations of the charity, thereby assessing the resilience of BTOG.

BRITISH THORACIC ONCOLOGY GROUP



TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2024

FINANCIAL REVIEW (CONTINUED)

Reserves Policy (continued)

The conclusion was that BTOG is in a stable and satisfactory financial position, and that there were no immediate concerns that need to be brought to the attention of the trustees.

Total reserves as at 31 March 2024 amounted to £545,677 of which £nil are restricted. As at 31 March 2024 free reserves (total unrestricted reserves less unrestricted tangible fixed assets) amounted to £544,657 which is significantly below the trustees' long term target level of reserves. At current levels of normal activity, the maximum level of reserves would be in the range of £1.2m to £1.5m.

The trustees are considering measures to try and build up free reserves going forward and they will monitor the level of reserves as part of BTOG's financial processes. If reserves were to exceed the agreed level (2 years' normal operating expenditure) BTOG will take immediate steps to reduce the level of those reserves either by increasing expenditure on charitable activities or by reducing its income (or a combination of both). The time frame for this reduction will be within 2 years of discovery of the excess and during that time the trustees will consider whether some or all the reserves can be invested to obtain a financial return for the charity.

STRUCTURE GOVERNANCE AND MANAGEMENT

Constitution

British Thoracic Oncology Group registered as a company (9816385) on 8th October 2015 and as a charity (1166012) on 11th March 2016. The company is limited by guarantee and has no share capital. Every member of the company undertakes to contribute to the assets of the company, in the event of winding up, such an amount as may be required not exceeding £1. The governing document is the Memorandum of Association.

Trustees

The following trustees have served since 1 April 2023:

Professor D Talbot (Chairman from 7-Oct-24)
Mr AM Grange (Chairman until resigned 7-Oct-24)
Mr C Kerr (Treasurer)
Professor MD Peake
Ms S Hiom (resigned 30-Jun-23)
Professor D Talbot
Mr G Bland (appointed 31-Dec-23 and resigned 5-Jul-24)

Method of Appointment or Election of Trustees

The management of the charity is the responsibility of the trustees elected under the Memorandum of Association of BTOG. Trustees set the policies for the recruitment, induction and training of new trustees. In selecting individuals for appointment as new trustees, the trustees will consider the skills, knowledge and experience needed for the effective running of the charity. Upon appointment, trustees are provided with an induction pack which includes various items such as the governing document, the latest financial statements, policy documents and Charity Commission guidance.

Pay Policy for Staff

BTOG does not employ its own staff. An NHS Trust employs the staff and charges the associated salary costs to the charity in accordance with a service level agreement. Pay levels for posts supported by the charity are determined through standard NHS procedures.

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2024

STRUCTURE GOVERNANCE AND MANAGEMENT (CONTINUED)

Organisational Structure and Decision Making

The trustees are responsible for BTOG; they safeguard the values and purpose of BTOG and check activities contribute to achieving the objects and ensure BTOG follows its legal obligations. Trustees are Non-Executive Directors of BTOG. The trustees during this reporting period comprise a Consultant and Honorary Professor of respiratory medicine who is also Clinical Co-Director of the Centre for Cancer Outcomes at UCLH, Honorary Clinical Lead for NHS Digital and a Specialist Clinical Advisor at Cancer Research UK; a former senior policy figure from Cancer Research UK of 20 years' standing who is now Director of Cancer Intelligence at GRAIL Europe; a retired professor/medical oncologist; a retired tax inspector and a retired senior pharmaceutical professional. The trustees and Steering Committee Chair decide the policies which provide the framework for the work of BTOG; decide overall aims and objectives, priorities and strategy; monitor and evaluate progress and delegate day-to-day work to the BTOG Senior Executive Officer and other appointed staff/agents. The trustees meet 4 times/year and communicate by email at all other times. One trustee also attends Steering Committee meetings as an observer (subject to availability).

The Steering Committee Chair is an Executive Officer of BTOG, accountable to the trustees. The Steering Committee supports BTOG's aims and objectives; take an active role in the delivery of the BTOG educational programme; comments and advises on thoracic oncology guidelines for care or treatment; represents BTOG on other thoracic oncology boards/committees/groups and recognises their affiliation to BTOG in their work. The Steering Committee are Executive Officers of BTOG, accountable to the SC Chair. The Steering Committee meet in person 4 times/year and communicate by email at all other times. The Steering Committee members represent the thoracic oncology multi-disciplinary team. In addition, BTOG recognises the importance of input from advocates in improving outcomes for lung cancer and mesothelioma patients and therefore the Steering Committee includes two advocate members. BTOG defines advocates as those who sit on clinical studies or trial management groups, advisory boards/groups or other related groups related to lung cancer or mesothelioma.

BTOG is a member of the National Council for Voluntary Organisations (NCVO) and trustees have access to online resources and information for charities. The trustees are required to update their trustee knowledge and training regularly to ensure they understand their role and responsibilities. Trustees periodically attend both theoretical and practical training courses organised by the NCVO covering a wide variety of charitable issues and they also complete online training.

The Senior Executive Officer (SEO) carries out the work of BTOG; reports regularly on achievements and progress; makes decisions (where the power to do this has been delegated); provides information on issues, problems and policy matters and makes recommendations; draws up plans for the future development of BTOG's work for the Trustees and Steering Committee to decide upon; advises and informs the trustee board so that it is able to carry out its governing role and recruits and appoints staff/agents. The SEO is reportable to University Hospitals of Leicester NHS Trust (UHL) Line Manager and Steering Committee Chair and accountable to the trustees.

The relationship of the BTOG Executive is based on a shared vision for BTOG; a commitment to achieving the objectives of BTOG; clear and understood trustee roles to not interfere inappropriately with the day-to-day running of BTOG; confidence in the abilities of the SEO and willingness to back the judgement of the SEO in the event of problems (providing they have been kept informed); the provision of good information to enable informed decisions to be made and a clear management framework and lines of accountability.

The SEO and Executive Officer (EO) are paid roles employed by UHL, who charge the associated salary costs to the charity in accordance with a formal service level agreement. Communications/website, conference and accountancy services were contracted out to external commercial providers. All other roles in the BTOG Executive are unpaid.

Following the pandemic, starting 1st February 2022, BTOG have leased an office from Mesothelioma UK in Mountsorrel, Leicester and there is a Memorandum of Understanding in place in this respect. BTOG staff do a combination of office and home working.

BTOG works collaboratively with many organisations including Mesothelioma UK (a related party) in the pursuit of its charitable activities.

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2024

STRUCTURE GOVERNANCE AND MANAGEMENT (CONTINUED)

Organisational Structure and Decision Making (continued)

BTOG recognised the need for appropriate governance to ensure transparent working and therefore has a comprehensive portfolio of policies covering charity structure, roles and responsibilities of trustees and the steering committee, conflict of interest, finance, procurement, reserves, endorsement, media and privacy, developed taking account of Charity Commission guidance. The policies are reviewed as per the review dates and new policies are developed as needed/identified and are available in the Governance section of the BTOG website.

The Trustees confirm that the major risks relating to BTOG have been reviewed and systems and procedures have been established to manage those risks, as detailed on page 19 under risk management.

Plans for Future Years

BTOG will continue to work towards its strategic outcomes, mission and vision as per pages 1 and 2.

During the 2024/25 year and beyond we plan to:

Education

- Continue to provide relevant CPD education and information via an annual conference, essential updates, webinars, podcasts and the website.
- Produce standard slide sets and a webinar on release of Version 9 of the TNM stage classification for lung cancer and any identified areas of interest.
- Provide networking, education and resources for trainees.
- Complete the major refurbishment of www.btog.org to improve visual design, navigation and content.
- Complete work on the BTOG One-Stop Resource Hub on www.btog.org for trainees and all thoracic oncology health care professionals and develop a structured review plan to ensure that content is current and relevant. The BTOG One-Stop Resource Hub is a comprehensive, searchable database of presentations and videos from BTOG education events (annual conferences, essential updates, study days, webinars, and podcasts). Also included are Useful Core Resources: educational resources, guidelines, and other materials relevant to UK thoracic oncology professionals from organisations worldwide.

Research

- Launch the BTOG Research Group, develop a Research Strategy to focus and support the thoracic oncology research agenda and advise trainees on research proposals to encourage and promote the development of research.

Representation

- Build relationships with existing and new national and international relevant groups and societies – e.g. in the following specialities/organisations Clinical Expert Group (CEG), Surgery, Pathology and Radiology.
- Recognise the future implementation of screening and ctDNA and the importance of BTOG representation in these areas.
- Liaise with NICE/NHS England for earlier notification of new decisions on NICE appraisals and announce “New NICE Approval” via separate BTOG E-news and X (formally Twitter).

Governance and Operational

- Continue with the current plan for succession in the Steering Committee to ensure transition of the Chair-Elect to take over the Steering Committee Chair role from April 2025 and develop a clear plan for a new Chair-Elect to be in place during the new Chair's term.
- Work towards financial independence from the NHS by employing BTOG staff direct.

This report has been prepared in accordance with the special provisions relating to small companies within Part 15 of the Companies Act 2006.

Approved by the Board of Trustees on 16 December 2024 and signed on its behalf by:

Professor D Talbot
Chair of the Board of Trustees

BRITISH THORACIC ONCOLOGY GROUP

INDEPENDENT EXAMINER'S REPORT

TO THE TRUSTEES OF BRITISH THORACIC ONCOLOGY GROUP

I report to the trustees on my examination of the financial statements of British Thoracic Oncology Group (the charity) for the year ended 31 March 2024.

Responsibilities and basis of report

As the trustees of the charity (and also its directors for the purposes of company law) you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006 (the 2006 Act).

Having satisfied myself that the accounts of the company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your company's accounts carried out under section 145 of the Charities Act 2011 (the 2011 Act). In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145 (5)(b) of the 2011 Act.

Independent examiner's statement

Since the charity's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of the Association of Chartered Certified Accountants, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

- 1 accounting records were not kept in respect of the charity as required by section 386 of the 2006 Act; or
- 2 the financial statements do not accord with those records; or
- 3 the financial statements do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
- 4 the financial statements have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

P T Barnett FCCA (Independent Examiner)

Newby Castleman LLP
West Walk Building
110 Regent Road
Leicester
LE1 7LT

17 December 2024

BRITISH THORACIC ONCOLOGY GROUP

STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT FOR THE YEAR ENDED 31 MARCH 2024

		Unrestricted Funds Total 2024 £	Unrestricted Funds Total 2023 £
	Notes		
Income from:			
Charitable activities	3	281,073	34,488
Other trading activities	4	483,500	103,203
Total		764,573	137,691
Expenditure on:			
Raising funds	5	39,274	38,029
Charitable activities	6	740,453	280,014
Other	9	-	(1,468)
Total		779,727	316,575
Net expenditure for the year/ Net movement in funds		(15,154)	(178,884)
Reconciliation of funds			
Total funds brought forward		560,831	739,715
Total funds carried forward		545,677	560,831

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

BRITISH THORACIC ONCOLOGY GROUP

BALANCE SHEET

AS AT 31 MARCH 2024

		2024		2023	
	Notes	£	£	£	£
Fixed assets					
Tangible assets	12		1,020		248
Current assets					
Debtors	13	445,838		751,804	
Cash at bank and in hand		622,660		392,156	
		1,068,498		1,143,960	
Liabilities					
Creditors: amounts falling due within one year	14	(523,841)		(583,377)	
Net current assets			544,657		560,583
Net assets			545,677		560,831
Total funds of the charity					
Designated funds		17,775		1,304	
General funds		527,902		559,527	
Total unrestricted funds	16		545,677		560,831
Total charity funds			545,677		560,831

The company is entitled to the exemption from the audit requirement contained in section 477 of the Companies Act 2006, for the year ended 31 March 2024.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

Trustees' responsibilities:

- The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476 of the Companies Act 2006;
- The trustees acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of the accounts.

The financial statements were approved and authorised for issue by the Board of Trustees on 5 December 2024 and are signed on its behalf by:

Mr C Kerr
Trustee and Treasurer

Company Registration No. 9816385

BRITISH THORACIC ONCOLOGY GROUP

STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED 31 MARCH 2024

	Notes	2024 £	£	2023 £	£
Cash flows from operating activities					
Cash generated from/(absorbed by) operations	21		231,820		(279,326)
Investing activities					
Purchase of tangible fixed assets		(1,316)		-	
Net cash used in investing activities			(1,316)		-
Net cash used in financing activities			-		-
Net increase/(decrease) in cash and cash equivalents			230,504		(279,326)
Cash and cash equivalents at beginning of year			392,156		671,482
Cash and cash equivalents at end of year			622,660		392,156

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2024

1 Accounting policies

Charity information

British Thoracic Oncology Group ("BTOG") is a private company limited by guarantee incorporated in England and Wales. The address of the registered office and place of business is given in the legal and administrative information page of these financial statements.

The members of the charity include the trustees named within the legal and administrative information. In the event of the trust being wound up, the liability in respect of the guarantee is limited to £1 per member of the charity.

1.1 Basis of preparation

The charity is a Public Benefit Entity as defined by FRS 102. The financial statements have been prepared in accordance with: the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102), Accounting and Reporting by Charities: the Statement of Recommended Practice for charities applying FRS 102 (2019), the Charities Act 2011, the Companies Act 2006 and UK Generally Accepted Accounting Practice.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below. These policies have been consistently applied to all years presented unless otherwise stated.

1.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives.

Designated funds are unrestricted funds of the charity which have been set aside at the discretion of the trustees for specific purposes. The purposes and uses of the designated funds are set out in the notes to the financial statements.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The aim and use of each restricted fund is set out in the notes to the financial statements.

1.4 Income recognition

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Income from charitable activities primarily includes income received for conference and course registration fees. Such income is recognised at fair value when the event has occurred.

Income from trading activities includes income earned from sponsorship.

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2024

1 Accounting policies

(Continued)

1.5 Expenditure recognition

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs relating to the category. Expenditure is recognised when there is legal or constructive obligation to make the payment to a third party, if it is probable that settlement will be required and the amount of the obligation can be measured reliably. It is recognised under the following headings:

- Expenditure on raising funds - this includes costs for advertising, marketing, direct mail and publicity.
- Expenditure on charitable activities - this includes services to further the delivery of the objectives of the charity.

Irrecoverable VAT is charged against the category of resources expensed for which it was incurred.

Support costs

Support costs are those that assist the work of the charity but do not directly represent charitable activities and costs of raising funds and include office costs and governance costs. They are incurred directly in support of expenditure on the objects of the charity. Support costs are allocated to costs of raising funds and expenditure on charitable activities on a basis consistent with use of the resources.

The analysis of these costs is included in note 8.

1.6 Tangible fixed assets

Tangible fixed assets are measured at cost, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost of assets less their residual values over their useful lives on the following bases:

Fixtures & fittings	15% of cost
Computer equipment	33.33% of cost

1.7 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less.

1.8 Financial instruments

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Debtors and creditors with no stated interest rate and receivable or payable within one year are measured at transaction price. Any losses arising from impairment are recognised in the SOFA.

1.9 Taxation

British Thoracic Oncology Group is a registered charity and no taxation provision is required as its income from charitable activities falls within the various exemptions available to registered charities.

1.10 Employee benefits

When employees have rendered service to the charity, short-term employee benefits to which the employees are entitled are recognised at the undiscounted amount expected to be paid in exchange for that service.

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2024

1 Accounting policies (Continued)

1.11 Leases

Rentals payable under operating leases, including any lease incentives received, are charged to the SOFA on a straight line basis over the term of the relevant lease.

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

The trustees do not consider there to be any key sources of estimation uncertainty that have a significant effect on the amounts recognised in the financial statements.

3 Charitable activities

	Unrestricted funds £	Restricted funds £	Total 2024 £	Total 2023 £
Conference and course registration fees	281,073	-	281,073	34,488
Unrestricted funds				34,488
Restricted funds				-
				34,488
			2024 £	2023 £
Conference and course registration fees breakdown:				
BTOG 2023			280,423	-
Summer Event 2022			-	32,688
Essential Update 2023 / 2022			650	1,800
			281,073	34,488

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2024

4 Other trading activities

	Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £	Total 2023 £
Sponsorship	483,500	-	483,500	103,203
Unrestricted funds				103,203
Restricted funds				-
				103,203

5 Raising funds

	Unrestricted funds £	Restricted funds £	Total 2024 £	Total 2023 £
Advertising, marketing, direct mail and publicity	18,569	-	18,569	18,744
Support costs (see note 8)	20,705	-	20,705	19,285
	39,274	-	39,274	38,029
Unrestricted funds				38,029
Restricted funds				-
				38,029

6 Charitable activities

	Activities undertaken directly Note 7 £	Support Costs Note 8 £	Total 2024 £	Total 2023 £
Conference and courses	618,543	121,910	740,453	280,014
Unrestricted funds			740,453	280,014
Restricted funds			-	-
			740,453	280,014

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2024

7 Expenditure on activities undertaken directly

	2024 £	2023 £
Conference and courses		
Venue and accommodation management	546,642	111,595
Abstract publication	16,754	-
Prizes and bursaries	1,650	100
Travel	39,208	15,237
Course accreditation	795	350
Bank and card charges	8,472	384
Webinar activities	5,022	24,062
	<u>618,543</u>	<u>151,728</u>
	2024 £	2023 £
Venue and accommodation management breakdown:		
BTOG 2023	514,097	-
Summer Event 2022	-	83,941
Essential update 2023 / 2022	25,370	27,144
New Consultants Study Day	4,791	-
Other	2,384	510
	<u>546,642</u>	<u>111,595</u>

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2024

8 Expenditure on support costs

	Basis of allocation	2024 £	2023 £
Staff costs	Raising funds and charitable activities	103,529	96,426
Travel	Charitable activities	150	452
Training	Charitable activities	160	277
Subscriptions	Charitable activities	489	450
Rent	Charitable activities	4,260	4,170
Insurance	Charitable activities	6,814	1,618
Office costs	Charitable activities	1,108	1,035
Software costs	Charitable activities	2,729	1,991
Professional fees	Charitable activities	6,173	5,868
Sundry	Charitable activities	32	40
Irrecoverable VAT	Charitable activities	16,627	35,028
Depreciation	Charitable activities	544	216
		<u>142,615</u>	<u>147,571</u>
Analysed between:			
Raising funds		20,705	19,285
Charitable activities		<u>121,910</u>	<u>128,286</u>
		<u>142,615</u>	<u>147,571</u>

Support costs have been allocated to raising funds and charitable activities on a basis consistent with the use of the resource. Support costs include governance costs totalling £6,173 (2023: £5,868).

The amount charged to the SOFA in respect of governance costs includes the following:

Independent examination £4,775 (2023 - £4,550)

Other financial services £1,398 (2023 - £1,318)

9 Other expenditure

	Unrestricted funds 2024 £	Total 2024 £	Unrestricted funds 2023 £	Total 2023 £
Interest	-	-	(1,468)	(1,468)

The company classifies certain one-off charges and credits which have a material impact on the company's financial results as 'exceptional items'. These are disclosed separately to provide further understanding of the financial performance of the company.

In July 2020 the charity paid £50,005 to HM Revenue and Customs for input VAT disallowed in respect of the four years ended 31 March 2020, following a review of the charity's VAT affairs. Interest was estimated in the sum of £3,000 on late payment of the total VAT liability which was classified as an exceptional item in the accounts to 31 March 2021 and included within accruals. The figure was confirmed by HM Revenue and Customs as £1,532 therefore there a credit amounting to £1,468 occurred in the financial year ending 31 March 2023.

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2024

10 Trustees

The trustees neither received nor waived any emoluments during the year (2023: £Nil).

Travel and subsistence expenses were reimbursed to 1 trustees (2023: 2) in the sum of £150 (2023: £452) during the year.

11 Employees

The average monthly number of employees during the year was:

	2024 Number	2023 Number
Total	2	2
	<u> </u>	<u> </u>
Employment costs	2024	2023
	£	£
Wages and salaries	103,529	96,426
	<u> </u>	<u> </u>

Staff working for the charity are employed directly by the University Hospitals of Leicester NHS Trust and their salary costs are charged to the charity in accordance with a service level agreement between BTOG and the Trust. The amount charged for the year was £103,529 (2023 - £96,426).

There were no employees whose annual remuneration was more than £60,000.

Remuneration of key management personnel

The remuneration of key management personnel is as follows.

	2024 £	2023 £
Aggregate compensation	62,942	60,132
	<u> </u>	<u> </u>

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2024

12 Tangible fixed assets

	Fixtures & fittings £	Computer equipment £	Total £
Cost			
At 1 April 2023	692	1,689	2,381
Additions	-	1,316	1,316
Disposals	-	(1,184)	(1,184)
At 31 March 2024	692	1,821	2,513
Depreciation and impairment			
At 1 April 2023	444	1,689	2,133
Depreciation charged in the year	105	439	544
Eliminated in respect of disposals	-	(1,184)	(1,184)
At 31 March 2024	549	944	1,493
Carrying amount			
At 31 March 2024	143	877	1,020
At 31 March 2023	248	-	248

13 Debtors

	2024 £	2023 £
Amounts falling due within one year:		
Trade debtors	283,267	288,908
Other debtors	17,776	1,304
Prepayments and accrued income	144,795	461,592
	445,838	751,804

14 Creditors: amounts falling due within one year

	2024 £	2023 £
Other taxation and social security	64,335	64,699
Deferred income (see note 15)	447,075	510,467
Other creditors	5,400	-
Accruals	7,031	8,211
	523,841	583,377

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2024

15 Deferred income

	2024 £	2023 £
Arising from advanced registration fees and sponsorships	447,075	510,467
	<u>447,075</u>	<u>510,467</u>

Deferred income is included in the financial statements as follows:

	2024 £	2023 £
Deferred income is included within:		
Current liabilities	447,075	510,467
	<u>447,075</u>	<u>510,467</u>
Movements in the year:		
Deferred income at 1 April 2023	510,467	74,866
Released from previous periods	(510,467)	(74,866)
Resources deferred in the year	447,075	510,467
	<u>447,075</u>	<u>510,467</u>
Deferred income at 31 March 2024	447,075	510,467
	<u>447,075</u>	<u>510,467</u>

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2024

16 Unrestricted funds

The unrestricted funds of the charity include designated funds which have been set aside out of unrestricted funds by the trustees for a specific purpose:

	Balance at 1 April 2023 £	Movement in funds			Balance at 31 March 2024 £
		Income £	Expenditure £	Transfers £	
General funds	559,527	764,573	(676,198)	(120,000)	527,902
Designated funds - wages fund	1,304	-	(103,529)	120,000	17,775
	<u>560,831</u>	<u>764,573</u>	<u>(779,727)</u>	<u>-</u>	<u>545,677</u>

	Balance at 1 April 2022 £	Movement in funds			Balance at 31 March 2023 £
		Income £	Expenditure £	Transfers £	
General funds	731,985	137,691	(220,149)	(90,000)	559,527
Designated funds - wages fund	7,730	-	(96,426)	90,000	1,304
	<u>739,715</u>	<u>137,691</u>	<u>(316,575)</u>	<u>-</u>	<u>560,831</u>

The wages fund represents funds held by the University Hospitals of Leicester NHS Trust as Custodian Trustee on behalf of British Thoracic Oncology Group for primarily the payment of wages to staff working for the charity but who are employed by the NHS Trust.

17 Analysis of net assets between funds

	Unrestricted funds £	Designated funds £	Total £
Fund balances at 31 March 2024 are represented by:			
Tangible assets	1,020	-	1,020
Current assets/(liabilities)	526,882	17,775	544,657
	<u>527,902</u>	<u>17,775</u>	<u>545,677</u>

	Unrestricted funds £	Designated funds £	Total £
Fund balances at 31 March 2023 are represented by:			
Tangible assets	248	-	248
Current assets/(liabilities)	559,279	1,304	560,583
	<u>559,527</u>	<u>1,304</u>	<u>560,831</u>

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2024

18 Related party transactions

During the year rent and office expenses in the sum of £4,260 (2023 - £5,363) were invoiced by Mesothelioma UK Charitable Incorporated Organisation (formerly Mesothelioma UK Charitable Trust) to the British Thoracic Oncology Group, to which Ms D E McKinley is a trustee of this organisation. At the balance sheet date there was an outstanding balance of £nil (2023 - £nil) for these services.

There have been no further related party transactions in the reporting period that require disclosure in the financial statements, other than those noted in note 11 to the financial statements.

19 Operating lease commitments

At 31 March 2024 the charity had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

	2024 £	2023 £
Within one year	3,550	3,550

Lease payments totalling £4,260 (2023 - £4,170) have been recognised as an expense during the year.

20 Controlling party

British Thoracic Oncology Group is a company limited by guarantee and not having a share capital; it is incorporated under the Companies Act and governed by the Memorandum and Articles of Association of the charity. The trustees of the charity are elected members and act as directors of the charity who are deemed to be the controlling party of the charity.

21 Cash generated from operations

	2024 £	2023 £
Deficit for the year	(15,154)	(178,884)
Adjustments for:		
Depreciation and impairment of tangible fixed assets	544	216
Movements in working capital:		
Decrease/(increase) in debtors	305,966	(556,594)
Increase in creditors	3,856	20,335
(Decrease)/increase in deferred income	(63,392)	435,601
Cash generated from/(absorbed by) operations	231,820	(279,326)

Accounts

Charity Registration No. 1166012

Company Registration No. 9816385 (England and Wales)

BRITISH THORACIC ONCOLOGY GROUP

**TRUSTEES' REPORT AND
FINANCIAL STATEMENTS**

**FOR THE YEAR ENDED
31 MARCH 2023**

BRITISH THORACIC ONCOLOGY GROUP

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees	Mr A M Grange (Chairman) Mr C Kerr (Treasurer) Professor M D Peake Ms S Hiom Professor D Talbot
Senior Executive Officer	Ms D E McKinley
Steering Committee Chair	Professor S Popat
Steering Committee Vice-Chair	Dr T Newsom-Davis
Charity number	1166012
Company number	9816385
Principal address	235 Loughborough Road Mountsorrel Loughborough Leicestershire LE12 7AS
Registered office	235 Loughborough Road Mountsorrel Loughborough Leicestershire LE12 7AS
Independent examiner	P T Barnett FCCA Newby Castleman LLP West Walk Building 110 Regent Road Leicester LE1 7LT
Bankers	Santander UK plc Bridle Road Bootle Merseyside L30 4GB

BRITISH THORACIC ONCOLOGY GROUP

CONTENTS

	Page
Trustees' report	1 - 21
Independent examiner's report	22
Statement of financial activities	23
Balance sheet	24
Notes to the financial statements	25 - 34

BRITISH THORACIC ONCOLOGY GROUP



TRUSTEES' REPORT

FOR THE YEAR ENDED 31 MARCH 2023

The trustees, who are the directors of the charitable company, present their report and financial statements for the year ended 31 March 2023.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the charity's governing document, the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102), Accounting and Reporting by Charities: Statement of Recommended Practice for Charities applying FRS 102 (2019), the Charities Act 2011, the Companies Act 2006 and UK Generally Accepted Accounting Practice.

The legal and administrative information forms part of this report.

OBJECTIVES AND ACTIVITIES

The charitable objects are:

- (1) The promotion and advancement of health or the saving of lives by way of improving the care of patients with thoracic malignancies through multi-disciplinary education and clinical and scientific research for the benefit of the public;
- (2) To advance public education and research into lung cancer and mesothelioma, in particular but not exclusively by facilitation of exchange of information on thoracic oncology including disseminating results of research and other news related to lung cancer and mesothelioma;
- (3) Such other charitable purposes beneficial to the community consistent with the objects as above as the trustees shall in their absolute discretion determine.

Vision and Mission

The vision of British Thoracic Oncology Group ("BTOG") is to contribute to achieving survival rates equal to the best in the world.

The mission of BTOG is to support and educate thoracic oncology health care professionals, creating a professional community to exchange ideas, information and innovation and to foster the development of research. The overall aim is to represent the needs of people with thoracic malignancies in the UK and ensure they have equitable access to optimal care.

BTOG's Values

- We are committed to achieving our vision and mission.
- We are proud to be an important part of the thoracic oncology professional community.
- We work collaboratively with other groups who in their own ways are also striving to improve outcomes for this group of patients or reduce the prevalence of lung cancer e.g. relating to smoking cessation.
- We engage with our stakeholders to ensure what we do is relevant and effective.
- We maintain professional independence from commercial organisations.
- We hold patients at the centre of everything we do.

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2023

OBJECTIVES AND ACTIVITIES (CONTINUED)

Activities for achieving objectives for the public benefit

The Board of Trustees ("trustees") has had regard to the Charity Commission's guidance on public benefit. The main activities undertaken to further the charitable purposes for the public benefit are set out below:

Education:

- Provides an annual CPD education programme of value to the whole multi-disciplinary team (MDT).
- Provides access to events for advocates who sit on thoracic oncology clinical studies or trial management groups, advisory boards/groups or other related groups.
- Ensures registration fees are accessible to members of the MDT.
- Provides an education bursary for the annual conference and other events where possible.
- Provides a membership for thoracic oncology health care professionals including access to useful resources (regular BTOG E-News; a website member only on-line resource including films and presentations from BTOG educational events and access to an online lung cancer journal; opportunity to participate in relevant research studies/questionnaires and provide an up-to-date calendar of thoracic oncology events).

Research:

- Provides networking opportunities at educational events and foster a professional community through its membership for the research community to develop clinical trials and other research.
- Provides workshops or stand-alone events for the sole purpose of research development.
- Circulates research surveys and questionnaires that support relevant research.
- Is a member of relevant research groups (e.g. European Thoracic Oncology Platform (ETOP), IBCSG Partners Foundation and International Association for the Study of Lung Cancer).

Representation:

- Reviews NICE appraisals for new drug therapies/technologies.
- Reviews appropriate guidelines/policy documents.
- Reviews and participates in the development of relevant guidelines/position documents.
- Participates in other groups, sub-groups, committees and boards.
- Represents patients in any capacity it deems appropriate with the overall aim to improve outcomes or reduce the prevalence of lung cancer e.g. relating to smoking cessation.

Criteria to measure success in the reporting period;

We measure our success in achieving our objectives in several of ways:

- By providing an annual CPD education programme of value to the whole multi-disciplinary team and receiving good feedback from attendees and consistent or increased attendance to the events.
- By keeping in touch with the professional community to encourage networking and collaboration virtually.
- By listening to our stakeholders to ensure what we do is relevant and effective through feedback and surveys.
- By working collaboratively with other groups to improve patient outcomes.
- By ensuring that BTOG represents patients in relevant guideline and drug development.

Longer term aims and objectives

In 2020, the BTOG's Trustees and Steering Committee worked together to produce the Strategic Plan 2020-2025 taking account of stakeholder needs. During this year COVID-19 continued to have some impact on the timeline for some of our strategic activities although some activities returned to in-person. The Plan remains relevant but for good practice the Strategic Activities within the BTOG Strategy Plan will be reviewed during the 2023/24 year to ensure they are still appropriate and feasible as recover continues post-COVID-19.



OBJECTIVES AND ACTIVITIES (CONTINUED)

STRATEGIC PLAN 2020 – 2025

MISSION

To support and educate thoracic oncology healthcare professionals, creating a professional community to exchange ideas, information and innovation and to foster the development of research.

The overall aim is to represent the needs of people with thoracic malignancies in the UK and ensure they have equitable access to optimal care.

STRATEGIC ACTIVITIES

- Make www.btog.org the one-stop resource shop for thoracic oncology healthcare professionals
- Identify and communicate with lung and mesothelioma MDTs.
- Engage with Juniors through trainee representation on the steering committee
- Establish a BTOG Regional Champion Scheme to engage with existing members and attract new ones

VISION

To contribute to achieving survival rates equal to the best in the world.

OUR VALUES

We are committed to achieving our mission and vision.

We are proud to be an important part of the thoracic oncology professional community.

We work collaboratively with other groups who in their own ways are also striving to improve outcomes for this group of patients.

We engage with our stakeholders to ensure what we do is relevant and effective.

We maintain professional independence from commercial organisations.

We hold patients at the centre of everything we do.

STRATEGIC OUTCOMES

- To reach all lung/mesothelioma MDTs in the UK to ensure all thoracic oncology healthcare professionals have access to relevant education and resources
- To be a leader in thoracic oncology research to focus and support the research agenda
- To represent thoracic oncology patients by making contributions and collaborating with others

EDUCATION

- Conference (Flagship Event)
- Essential Updates
- Workshops (ad hoc)
- Annual updates from thoracic oncology international conferences
- Postgraduate Course (Biennial)
- Produce standard slide sets for Changes in Practice / What's New series – included in regional updates
- Produce Breaking News/Alerts/Press Releases for Changes in Practice

RESEARCH

- Facilitate a Think Tank Workshop to identify gaps for development of research with UK, European and other research organisations
- Establish BTOG research specialist subgroups to complement other external subgroups
- Ensure subgroups report regularly on the delivery of specific objectives

REPRESENTATION

- Make reactive contributions: NICE appraisals; Specialist Statement of Practice; Endorsements
- Make proactive contributions: Guidelines; Position and Consensus Statements; Comment on Public Health England / Department of Health Policy
- Campaign with relevant organisations for equitable access to optimal care
- Partner with specialist societies / groups / organisations (e.g. Surgeons, Nurses, Pathologists, Radiologists)
- Engage with advocates by ensuring advocate representation on the BTOG steering committee and making advocate places available at BTOG educational events
- Represent all the UK including the devolved nations

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2023

ACHIEVEMENTS AND PERFORMANCE

Review of Activities - Education

During the year April 2022 to March 2023 BTOG was able to restart in-person educational activity again and continued with some virtual events.

During the 2022/23 year, BTOG has worked hard to provide a relevant Continuing Professional Development (CPD) education programme for the thoracic oncology multi-disciplinary team. Advocates who sit on thoracic oncology clinical studies or trial management groups, advisory boards/groups or other related groups are welcome to register for BTOG education.

During this year, BTOG returned to in-person events with a Summer Meeting in July and Essential Updates in October and December.



This meeting was held in-person and was also available as a live-stream on-line.

Attendees: 300 in-person and 33 virtual


Bursaries: BTOG awarded 45 bursaries to concessionary rate attendees that covered registration fee and a contribution towards travel/accommodation.

Feedback:

- Really great to have a face-to-face BTOG event again!
- Excellent meeting made more enjoyable as it was face to face. Interesting to hear about the most recent developments in the management of lung cancer.
- Efficient and well-run conference. Effectively managed for virtual attendees. Informative and useful educationally for registrar attendees.
- Well organised as usual. Very relevant presentations from great speakers.
- Fantastic event, each individual session was well thought and presented.
- Excellent selection of topics, this is my first BTOG meeting - excellent experience, learned a lot.

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)




This meeting was held in-person in collaboration with Ruth Strauss Foundation and registration was free of charge for health care professionals.

Attendees: 93

Bursaries: Health care professionals were able to apply for a travel bursary (100 available) and this was funded and accessed via the Ruth Strauss Foundation

Feedback:

- Excellent day with great input from the multidisciplinary team.
- It was an excellent meeting, venue and number of delegates allowing discussion over coffee/lunch.
- It was great to see a multidisciplinary approach to the day and it was very brave of the patients to speak.
- Nice venue; well-organised. Good meeting.



This meeting was a joint event with Mesothelioma UK.

Attendees: 150

Feedback:

- Gave me updated knowledge on Meso to pass onto our Meso patients.
- Fantastic session with top notch speakers. Thanks for organising.
- A very enjoyable and informative face to face meeting. Particularly enjoyed the updates from the surgical perspective and emerging/ expected data and its potential impact.
- Excellent venue and pre joining instructions were great. I thought the day was well structured and the presentations were excellent.

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2023

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)



BTOG continued with its regular 1-hour webinars that were developed when in-person events were not possible. These webinars take account of the latest data released and include a panel of relevant experts in thoracic oncology. Registration at all BTOG webinars is free of charge for health care professionals.

We held 4, 1-hour webinars and 1, full-day webinar during this year and all webinars were accredited by the Federation of the Royal Colleges of Physicians of the UK for category 1 (external) CPD credits. CPD credits were available both live and up to 4 weeks post-event for on-demand and the stats provided below reflect this timeframe. Attendees were encouraged to give feedback on the content and organisation and any feedback was recorded and analysed to ensure continuous improvement.

All BTOG webinars are also available to view 'On Demand' in the BTOG Member Resources area and to download as a podcast.

Live and on-demand

The 5 BTOG webinars during this year resulted in a total audience of 577 live and on demand (up to 4 weeks).

393 attendees to the following in an Hour webinars:

Mesothelioma Essential Update (28 th April 2022)	106
Surgical Essential Update (26 th May 2022)	51
ASCO in an Hour (23 rd June 2022)	126
WCLC and ESMO Update (19 th September 2022)	110

Feedback for 1-hour webinars:

- Grateful for the webinar virtual option as this makes it easier to participate in events when face to face attendance is not an option.
- An excellent, succinct summary of ground-breaking information.
- This was excellent. The speakers spoke clearly and presented very helpful information. Really enjoyed the session.
- These are fantastic sessions. They must be a lot of work to produce but they are so valuable. Really appreciate the expertise of the presenters.
- Good coverage particularly of the fast-changing landscape in systemic treatments which has been static for so long.
- I find all of the BTOG series immensely helpful and very grateful for the time and effort put into delivery.

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2023

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)

184 attendees to the full-day webinar:

Thymic Malignancies Essential Update (19th May 2022)

Feedback:

- It was the best education on thymoma that I have received. The first session reviewing current practice was a great way of setting the agenda. Highly recommended to others.
- An outstandingly useful session which will definitely influence my practice.
- Excellent update very relevant to my practice.

Webinar attendance by speciality/category:

Speciality/Category	%
Nursing	7.5%
Medical Oncology	21.2%
Clinical Oncology	22.4%
Oncology	3.3%
Respiratory	25.3%
Surgery	3.3%
Palliative Care	0.0%
Radiology	2.5%
Science/research/clinical trials	2.1%
Pharmacy	1.7%
Academic	0.0%
Student	0.0%
Pathology	1.7%
Allied HCP	0.8%
Other HCP	1.7%
Industry	5.0%
Patient advocate	0.8%
Charity/non-profit	0.4%
Other non-HCP	0.3%

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2023

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)


Review of Activities - Education (continued)



Podcasts of all BTOG webinars are available to listen to or download. BTOG introduced a series of podcasts called “*BTOG does ...*” where we discussed a variety of thoracic oncology topics with a different expert each time. You can subscribe to BTOG podcasts through the Apple App Store and the Google Play Store or listen on Spotify by searching BTOG (CPD points are not available for the podcasts).

During this year a total of 3,024 podcast downloads.

10,600 total downloads since podcasts were started in November 2021.



TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2023

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)

BTOG does ...	Expert	Interviewer	
Update on LC Specialist Nursing	Karen Clayton	Tom Newsom-Davis	234
Palliative Thoracic Radiotherapy	David Woolf	Stephen Harrow	243
Trainees	Helen McDill and Adam Januszewski		212
NOLCP/Diagnostic Pathway	Sanjay Agrawal	Helen McDill	238
ESTRO 2022	Fiona McDonald	Tom Newsom-Davis	262
Surgery	Sofina Begum	Tom Newsom-Davis	242
Metastatic Advanced Stage Neuroendocrine Tumours	Debashis Sarker	Tom Newsom-Davis and Lianne Castle	376
Thymic malignancies	David Gilligan	Tom Newsom-Davis and Lianne Castle	449
Management of thymic lesions	Henrietta Wilson	Tom Newsom-Davis and Lianne Castle	306
Lung cancer prehab	Zoe Merchant	Tom Newsom-Davis and Lianne Castle	462
			3,024
PODCAST DOWNLOADS OF WEBINAR RECORDINGS (NOT ALL WERE AVAILABLE DUE TO TECHNICAL ISSUES WITH UPLOADS)			
Masterclass: Diagnostics (March 24 th)			387
ASCO 2022 in an Hour (June 23 rd)			482
WCLC and ESMO 2022 (September 26 th)			381
			1,250

BTOG Trainees Network Launched in January 2022

One of BTOG's key aims is to bring the thoracic oncology community closer together and foster collaboration and education. In BTOG's trainee survey in 2021 we heard that trainees wanted to be connected with other like-minded trainees and therefore we launched the '**BTOG Trainees Network**'. The Slack platform (QR code to join) is designed to bring trainees together from across disciplines and the UK to foster collaborations, open opportunities and foster a community of like-minded trainees. The platform is also used to highlight educational events and opportunities.



Following an application process, in May 2022 BTOG was delighted to announce the appointment of Dr Anand Sundaralingam and Dr Gerard Walls as BTOG's new trainee representatives. BTOG's existing trainee representatives, Helen McDill and Adam Januszewski will stay on the steering committee for a cross-over period so that they can pass on anything in progress, their knowledge and experience of being a steering committee trainee representative.

Online resources at www.btog.org

BTOG Trainee Representatives have continued to work on a major upgrade to our online resource library, where members can access all the videos and presentations from our education events. A new search function will enable all members to find relevant resources by various categories, by event or by the type of resource. The goal is to create a kind of 'one-stop-shop' and include many other resources beyond those from our events. The new library will go live during the 2023/24 year.

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2023

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)

BTOG Membership

During this year BTOG continued to provide relevant and up-to-date member services.

- Free CPD education (e.g. BTOG webinars and essential updates)
- CPD education (annual conference)
- BTOG Resources member area including BTOG presentation/video library, trainee resources and podcasts
- Free access to the full digital edition of *Lung Cancer Journal*
- Bursaries/scholarships for BTOG meeting registration or travel (subject to application process)
- Weekly E-News including relevant information about education, research, research surveys
- BTOG networking and professional community



- 50 E-News were sent during this year
- 41% average open rate (Up from 38% in previous year. Industry average is 20% for similar emails.)
- 9% click rate (Up from 5.69% in previous year. Industry average is 2-4% for similar emails.)

BTOG Membership Stats

March 2023

- 2,317 members (2062 HCP, 255 Network)
- Full renewals planned to align with new website in 2024
- Interim data cleansing based on:
 - e-news unsubscribes and 'never-opens'
 - 'never logged in' + registered before 2022
- 10 have never logged in (excluding admin and tech support accounts) – these have now been removed as members (and are not counted in the total number above)
- 2,014 have logged in once
- 174 twice
- 231 three or more times

To ensure compliance to General Data Protection Regulation (GDPR), BTOG contacts its members regularly to renew and opt-in to receive information from BTOG. In August 2022 and September 2022 BTOG emailed members via BTOG E-news to remind that members can unsubscribe or update their preferences at any time. The next renewal is due at the launch of the new website in 2024.

BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2023



ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)

Membership (continued)

Health Care Professionals Members by Speciality

	2023	2022	2021	2020
Respiratory	26%	26%	26%	26%
Nursing	21%	22%	22%	22%
Medical Oncology	13%	14%	14%	15%
Clinical Oncology	14%	14%	14%	14%
Oncology	5%	5%	5%	6%
Science/research/clinical trials	3%	4%	4%	4%
Surgery	5%	4%	4%	3%
Radiology	3%	3%	3%	3%
Pathology	2%	2%	2%	2%
Allied HCP	2%	2%	2%	2%
Pharmacy	1%	2%	2%	1%
Palliative Care	1%	1%	1%	1%
Academic	0.6%	0.5%	0.5%	1%
Student	0.9%	0.8%	0.8%	0%

(Percentages are rounded up)

Health Care Professionals Members by Geography

	2023	2022	2021	2020	2019
Yorkshire and the Humber	189	187	182	80	86
North West	184	178	179	79	107
East Midlands	250	222	213	58	102
North West London	119	118	116	50	24
South London	110	102	100	47	48
South West	130	126	123	42	73
West Midlands	113	104	105	41	67
Scotland	105	101	93	39	NA
East of England	106	101	96	36	57
Kent, Surrey and Sussex	134	119	114	34	37
North Central and East London	111	100	92	33	33
Thames Valley	58	56	54	25	24
Wales	45	37	36	21	NA
Northern Ireland	19	18	18	NA	NA
Republic of Ireland	36	36	35	NA	NA

Based on the sample of 1,817 members with this field completed.

BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2023



ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)

Membership (continued)

Network Members by Area of Interest

	2023	2022	2021	2020
Industry	64%	64%	66%	57.1%
Patient advocate	12%	12%	10%	17.6%
Charity/non-profit	7%	6%	6%	5.5%
Other non-HCP	18	18%	18%	19.8%

Twitter, journal and website



3,420 followers

New Followers					
	2022-2023	2021-2022	2020-2021	2019-2020	2018-2019
NEW	224	467	479	510	602
INCREASE	7%	18%	21%	29%	29%

Mentions					
	2022-2023	2021-2022	2020-2021	2019-2020	2018-2019
TOTALS	706	1118	902	926	706

Impressions					
	2022-2023	2021-2022	2020-2021	2019-2020	2018-2019
TOTALS	154,557	437,459	274,800	283,600	184,400

Twitter is event-driven, with significant jumps in April 2021 and January 2022 from the Annual Conferences (therefore, two annual conferences are in the 2021-2022 figures, and none are in 2022-2023). BTOG 2023 was held in April 2023.

Lung Cancer Journal

@LungCaJournal

International peer-reviewed journal on clinical, translational & basic science of lung & chest malignancies [#LCSM](#).
Affiliated with [@BTOGORG](#), [@ETOP_eu](#) and ILCCO

In February 2021, BTOG joined forces with European Thoracic Oncology Platform (ETOP) and International Lung Cancer Consortium (ILCCO) to highlight via twitter significant articles of interest published in the *Lung Cancer Journal*.

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2023

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)

Twitter, journal and website (continued)

Website – www.btog.org

	Users	Page views	Avg. session duration	Pages per session
18-19	13,818	86,157	02:24	3.29
19-20	19,679	116,303	01:55	3.56
20-21	18,191	82,029	01:35	3.15
21-22	20,648	155,999	01:50	4.56
22-23	20,508	143,117	01:46	4.01

65% of traffic is from the UK, 11% from the US, 3% Ireland then India, Germany, China, Netherlands, France, and Canada

49% Windows, 23% iOS, 12% Mac, 11% Android (61% desktop, down from 72% last year; 44% mobile, up from 32% last year).

Top Referrers

Google / organic Top search terms: BTOG 2023 and BTOG	44%
(direct) / (none)	40%
Bing	6%
Social (96% = Twitter)	3%
Other	7%

NOTE: Slightly more search traffic than direct traffic, than in 21-22, indicates more people are finding the website through a search rather than bookmarking or typing in the web address directly.

Top (non-Twitter) referrers are Eventscloud, Veeva, bsti.org.uk, Facebook, Yahoo Search

TOP PAGES

1. Home
2. 2023 Annual Conference
3. 2022 Annual Conference
4. Summer meeting & Dinner
5. News: NOLCP Sep 2020
6. Meet the team
7. Events
8. Non-smoking LC Essential Update
9. Mesothelioma Essential Update
10. Podcasts

Typically
78%
New Users

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2023

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Research

During this year BTOG opened submission for poster abstracts at BTOG 2023 being held 26th to 28th April 2023. BTOG will publish the poster abstracts from this annual conference in a supplement to *Lung Cancer*. This is reportable next year.

A BTOG Special Interest Group (SIG) is a sub-group of the BTOG steering committee with a shared interest in advancing a specific area of thoracic oncology. Members co-operate to affect change or improvement within that speciality. They may communicate, meet, and organise further training or education and resources for the purpose of advancement. They can use the BTOG logo in relation to the SIG. The aim of the BTOG SIGs is to promote the highest standards of knowledge and facilitate research and representation in that specific area of thoracic oncology.

The **BTOG Thymic Malignancies SIG**, chaired by Dr David Gilligan, met 4 times during this year. Tumours of the thymus gland constitute a rare but significant part of thoracic oncology. Management of these tumours can be complex and is often poorly understood. The BTOG Thymic Malignancies SIG is a multi-disciplinary group of interested health care professionals, including the patient advocacy group Thymic UK. The aims of this group are to promote understanding, improve knowledge of thymic tumours and to work co-operatively to improve the management pathways for thymic tumours.

During this year this group discussed various areas for development and action including updating the BTOG website with details of the group, the development of an inferior mediastinal (suspected thymic) lesion diagnostic pathway and collaboration and learning from international thymic and pathology networks. The group also organised a Thymic Malignancies Essential Update in May 2022 which attracted 184 attendees (on-line on the day and on-demand post-event).

The **BTOG Large Cell Neuroendocrine Carcinoma (LCNEC) SIG**, chaired by Dr Colin Lindsay met for the 1st time in June 2022 and a further 2 times during this year. Members will work together to share knowledge and cases to establish a standard of care for Lung LCNECs including but not limited to:

- Evaluating the pathology of high-grade neuroendocrine carcinomas of lung origin
- Understanding biological basis of high-grade neuroendocrine carcinomas of lung origin
- Developing clinical consensus around optimal management of high-grade neuroendocrine carcinomas of lung origin
- Communicating/circulating information via the LCNEC SIG, BTOG online education resources and BTOG relevant education events

During this year the group discussed and formalised the terms of reference including the aims and objectives and stakeholders of the group, discussed priorities and actions including focussing on high-grade neuroendocrine tumours of lung origin and developing a consensus on LCNEC pathology. An application for external funding to support a project manager towards delivering a co-ordinated UK network approach has been successful – the post-holder will be recruited in the next month.



In January 2022, contributed to Health and Social Care Committee's Expert Panel evaluation of the progress the Government has made against its commitments in cancer services in England.

BRITISH THORACIC ONCOLOGY GROUP


TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2023



ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities – Research (continued)



BTOG Endorsed the Final Report published in April 2022

Endorsements



www.neuroendocrinecancer.org.uk

During this year BTOG reviewed and endorsed a document “Neuroendocrine Cancer – an Ideal Pathway” – publication date to be confirmed.



<https://www.brit-thoracic.org.uk/>

During this year BTOG reviewed and endorsed a guideline document from the British Thoracic Society, the BTS Guideline for Pleural Disease due to be published in 2023.

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2023

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities – Research (continued)

Surveys

In April 2022, BTOG circulated a Survey for Thoracic Clinical Oncologists from The National Oncology Trainee Collaborative for Healthcare Research (NOTCH). NOTCH wanted to hear views on current radiotherapy practice for Thymic Epithelial Tumours (TET).

In November 2022, BTOG circulated an NCRI Lung Group strategic priorities survey.

In December 2022, BTOG circulated a Survey “Optima lung cancer guidelines identification survey”. [OPTIMA](#) is an EU funded project that aims to improve cancer care through real-world data and artificial intelligence. This survey aims to understand which guidelines health care professionals use for the screening, diagnosis and treatment of lung cancer patients across Europe.

In January 2023, BTOG circulated a chance to participate in the Nodule surveillance in screening interview study. Invited to share insights to inform best practice and contribute to a novel study funded by Barts Charity. Researchers at Queen Mary University of London wanted to hear experiences of communicating with patients under surveillance for pulmonary nodules following lung cancer screening.

Review of Activities – Representation

BTOG continues to work collaboratively with many organisations, societies, and groups and to build close and enduring relationships and to have mutual memberships to ensure representation. Steering Committee members undertake this work on behalf of BTOG and these include the following examples:

- British Thoracic Society
- Cancer Chemotherapy Interest Group
- European Association for Cardio-Thoracic Surgery (EACTS)
- European Organisation for Research and Treatment of Cancer (EORTC)
- European Thoracic Oncology Platform (ETOP)-IBCSG Partners
- International Association for the Study of Lung Cancer (IASLC)
- Mesothelioma UK
- National Cancer Research Institute (NCRI)
- National Lung Cancer Audit
- Lung Cancer Nursing UK
- Public Health England Implementation Board for Tobacco
- Roy Castle Lung Cancer Foundation
- Royal College of Physicians Tobacco Advisory Board
- Society for Cardiothoracic Surgery (SCTS)
- Taskforce for Lung Health
- UK Mesothelioma Alliance
- UK Lung Cancer Coalition

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2023

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities – Representation (continued)



NICE Representation

NICE appraisals review and make recommendations on the clinical and cost-effectiveness of medicines and treatments in the NHS.

Participation in the NICE appraisal process involves a significant time commitment by representatives and includes attending appraisal meetings, reviewing lengthy and detailed documents and making comment and recommendations to improve access to treatment for patients.

During this year Steering Committee members have represented BTOG on

- **55** NICE appraisals (scoping and full)

During this year Non-Steering Committee members were co-opted to represent BTOG on

- **10** NICE appraisals

Samreen Ahmed	11 (1 joint)	Sanjay Agrawal	3	Riyaz Shah	4
Sanjay Popat	10	Clive Peedel	2	David Gilligan	1
Tom Newsom-Davis	6	James Spicer	2	Shobit Bajjal	5
Matt Callister	1				
Co-opted (non-SC)					
Alastair Greystoke	2	Mary O'Brien	2	Robin Young	1
Matthew Hatton	1	Yvonne Summers	3	Matthew Krebs	1
Mark Forster	1 (joint)				

During this period 3 NICE appraisals resulted in recommendations.

ID Number	Title
3757	Lung cancer (non-small-cell, early, neoadjuvant) - nivolumab (with chemotherapy)
3852	Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer
3885	Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation

Exhibition

BTOG exhibited at the following meetings to showcase BTOG and to encourage health care professional membership:

- Society for Cardiothoracic Surgery Annual Meeting on 9th and 10th May 2022 in Belfast
- British Thoracic Society (BTS) Summer Meeting 2022 on 23rd and 24th June in Manchester
- Cancer Research UK's Lung Cancer Conference 2022 on 15th-17th November 2022 in Manchester

BRITISH THORACIC ONCOLOGY GROUP



TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2023

FINANCIAL REVIEW

Going Concern

After making appropriate enquiries, the trustees have a reasonable expectation that BTOG has adequate resources to continue in operational existence for the foreseeable future. For this reason, they continue to adopt the going concern basis in preparing the financial statements.


Finance Overview

Our Annual Conferences over the last few years were held in April 2021, January 2022 and April 2023, therefore two annual conferences are in the year ending 2022, and none are in year ending 2023. This has had a large impact in both income for sponsorship and registration fees. Total income for the year decreased from £526,534 in 2022 to £137,691 in 2023.

The investment in online learning and webinars brought in as our face-to-face educational programme was set aside due to COVID-19 restrictions, has been hugely successful and has been continued.

Total expenditure for the year ended 31 March 2023 amounted to £316,575 (2022 - £286,940). The expenditure was split between charitable activities costs in the sum of £280,014, costs of raising funds in the sum of £38,029 and other £(1,468).

Net income (expenditure) for the year ended 31 March 2023 amounted to £(178,884) compared to £239,594 in the previous year.



Risk Management

A risk policy and a detailed risk register have been produced. The risk register covers governance, external, financial, operational and regulatory risk and a review of the risk register is a standing item at every trustee meeting. The trustees are satisfied that systems and procedures are in place to mitigate exposure to the major risks. A major risk to BTOG is the reliance on registration fees and external sponsorship income to provide enough funding for BTOG to deliver its aims and objectives. This is particularly relevant given the COVID-19 pandemic. Mitigating actions include strategic planning, operating a reserves policy and ongoing engagement with our key sponsors.

Reserves Policy

BTOG is committed to demonstrate good stewardship and active financial management and to identifying through risk assessment and budgeting any uncertainty in future income streams. A major risk to BTOG is the reliance on registration fees and external sponsorship to provide enough funding for BTOG to deliver its aims and objectives. Therefore, the trustees have agreed that at any one time the charity can hold a maximum of 2 years' normal operating expenditure in reserve (at the time of writing the charity has not yet reached this level of reserve). Normal operating expenditure is identified in annual budgets which are approved by the trustees. This reserve level will ensure that the current service provided by BTOG is secure in times when income to the charity may be reduced.

BRITISH THORACIC ONCOLOGY GROUP



TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2023

FINANCIAL REVIEW (CONTINUED)

Reserves Policy (continued)

Total reserves as at 31 March 2023 amounted to £560,831 of which £nil are restricted. As at 31 March 2023 free reserves (total unrestricted reserves less unrestricted tangible fixed assets) amounted to £560,583 which is significantly below the trustees' long term target level of reserves. At current levels of normal activity, the maximum level of reserves would be in the range of £1m to £1.2m. The trustees are considering measures to try and build up free reserves going forward and they will monitor the level of reserves as part of BTOG's financial processes.

If reserves were to exceed the agreed level (2 years' normal operating expenditure) BTOG will take immediate steps to reduce the level of those reserves either by increasing expenditure on charitable activities or by reducing its income (or a combination of both). The time frame for this reduction will be within 2 years of discovery of the excess and during that time the trustees will consider whether some or all the reserves can be invested to obtain a financial return for the charity.

STRUCTURE GOVERNANCE AND MANAGEMENT

Constitution

British Thoracic Oncology Group registered as a company (9816385) on 8th October 2015 and as a charity (1166012) on 11th March 2016. The company is limited by guarantee and has no share capital. Every member of the company undertakes to contribute to the assets of the company, in the event of winding up, such an amount as may be required not exceeding £1. The governing document is the Memorandum of Association.

Trustees

The following trustees have served since 1 April 2022:

Mr AM Grange (Chairman)
Mr C Kerr (Treasurer)
Professor MD Peake
Ms S Hiom
Professor D Talbot

Method of Appointment or Election of Trustees

The management of the charity is the responsibility of the trustees elected under the Memorandum of Association of BTOG. Trustees set the policies for the recruitment, induction and training of new trustees. In selecting individuals for appointment as new trustees, the trustees will consider the skills, knowledge and experience needed for the effective running of the charity. Upon appointment, trustees are provided with an induction pack which includes various items such as the governing document, the latest financial statements, policy documents and Charity Commission guidance.

Pay Policy for Staff

BTOG does not employ its own staff. An NHS Trust employs the staff and charges the associated salary costs to the charity in accordance with a service level agreement. Pay levels for posts supported by the charity are determined through standard NHS procedures.



TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2023

STRUCTURE GOVERNANCE AND MANAGEMENT (CONTINUED)

Organisational Structure and Decision Making

The trustees are responsible for BTOG; they safeguard the values and purpose of BTOG and check activities contribute to achieving the objects and ensure BTOG follows its legal obligations. Trustees are Non-Executive Directors of BTOG. The current trustees comprise a Consultant and Honorary Professor of respiratory medicine who is also Clinical Co-Director of the Centre for Cancer Outcomes at UCLH, Honorary Clinical Lead for NHS Digital and a Specialist Clinical Advisor at Cancer Research UK; a former senior policy figure from Cancer Research UK of 20 years' standing who is now Director of Cancer Intelligence at GRAIL Europe; a retired professor/medical oncologist; a retired tax inspector and a retired senior pharmaceutical professional. The trustees and Steering Committee Chair decide the policies which provide the framework for the work of BTOG; decide overall aims and objectives, priorities and strategy; monitor and evaluate progress and delegate day-to-day work to the BTOG Senior Executive Officer and other appointed staff/agents. The trustees meet 4 times/year and communicate by email at all other times. One trustee also attends Steering Committee meetings as an observer (subject to availability).

The Steering Committee Chair is an Executive Officer of BTOG, accountable to the trustees. The Steering Committee supports BTOG's aims and objectives; take an active role in the delivery of the BTOG educational programme; comments and advises on thoracic oncology guidelines for care or treatment; represents BTOG on other thoracic oncology boards/committees/groups and recognises their affiliation to BTOG in their work. The Steering Committee are Executive Officers of BTOG, accountable to the SC Chair. The Steering Committee meet in person 4 times/year and communicate by email at all other times. The Steering Committee members represent the thoracic oncology multi-disciplinary team. In addition, BTOG recognises the importance of input from advocates in improving outcomes for lung cancer and mesothelioma patients and therefore the Steering Committee includes two advocate members. BTOG defines advocates as those who sit on clinical studies or trial management groups, advisory boards/groups or other related groups related to lung cancer or mesothelioma.

BTOG is a member of the National Council for Voluntary Organisations (NCVO) and trustees have access to online resources and information for charities. The trustees are required to update their trustee knowledge and training regularly to ensure they understand their role and responsibilities. Trustees periodically attend both theoretical and practical training courses organised by the NCVO covering a wide variety of charitable issues and they also complete online training.

The Senior Executive Officer (SEO) carries out the work of BTOG; reports regularly on achievements and progress; makes decisions (where the power to do this has been delegated); provides information on issues, problems and policy matters and makes recommendations; draws up plans for the future development of BTOG's work for the Trustees and Steering Committee to decide upon; advises and informs the trustee board so that it is able to carry out its governing role and recruits and appoints staff/agents. The SEO is reportable to University Hospitals of Leicester NHS Trust (UHL) Line Manager and Steering Committee Chair and accountable to the trustees.

The relationship of the BTOG Executive is based on a shared vision for BTOG; a commitment to achieving the objectives of BTOG; clear and understood trustee roles to not interfere inappropriately with the day-to-day running of BTOG; confidence in the abilities of the SEO and willingness to back the judgement of the SEO in the event of problems (providing they have been kept informed); the provision of good information to enable informed decisions to be made and a clear management framework and lines of accountability.

The SEO and Executive Officer (EO) are paid roles employed by UHL, who charge the associated salary costs to the charity in accordance with a formal service level agreement. Communications/website, conference and accountancy services were contracted out to external commercial providers. All other roles in the BTOG Executive are unpaid.

Following the pandemic, starting 1st February 2022, BTOG have leased an office from Mesothelioma UK in Mountsorrel, Leicester and there is a Memorandum of Understanding in place in this respect. BTOG staff do a combination of office and home working.

BTOG works collaboratively with many organisations including Mesothelioma UK (a related party) in the pursuit of its charitable activities.

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2023

STRUCTURE GOVERNANCE AND MANAGEMENT (CONTINUED)

Organisational Structure and Decision Making (continued)

BTOG recognised the need for appropriate governance to ensure transparent working and therefore has a comprehensive portfolio of policies covering charity structure, roles and responsibilities of trustees and the steering committee, conflict of interest, finance, procurement, reserves, endorsement, media and privacy, developed taking account of Charity Commission guidance. The policies are reviewed as per the review dates and new policies are developed as needed/identified and are available in the Governance section of the BTOG website.

The Trustees confirm that the major risks relating to BTOG have been reviewed and systems and procedures have been established to manage those risks, as detailed on page 26 under risk management.

Plans for future periods

Following the start of the COVID-19 recovery phase BTOG re-introduced in-person education during 2022/23. BTOG will continue to work towards its strategic outcomes, mission and vision within the Strategic Plan 2020-2025 (on page 3). The Strategic Plan remains relevant but for good practice the Strategic Activities within the BTOG Strategy Plan will be reviewed during the 2023/24 year to ensure they are still appropriate and feasible as we move into the endemic phase of COVID-19.

During the 2023/24 year and beyond we plan to:

- Continue to provide relevant CPD education (virtual and in-person). In-person will include an annual conference and essential updates;
- Produce a standard slide set and webinar for Version 9 of the TNM stage classification for lung cancer and any identified areas of interest;
- Liaise with NICE/NHS England for earlier notification of new decisions on NICE appraisals and announce "New NICE Approval" via separate BTOG E-news and Twitter;
- Continue to provide "BTOG does ..." Podcasts;
- Provide networking, education and resources for trainees;
- Complete work on the one-stop resource shop on www.btog.org for trainees and all thoracic oncology health care professionals and develop a structured review plan to ensure that content is current and relevant;
- Undertake a major refurbishment of www.btog.org to improve visual design, navigation and content;
- Formalise the BTOG Research Group to develop a Research Strategy to focus and support the thoracic oncology research agenda;
- Recognise the future implementation of screening and ctDNA and the importance of BTOG representation in these areas;
- Formulate a clear plan for succession to include a set term of office for the Chair Elect of the Steering Committee. The current Steering Committee Chair's term has been extended until 2025 under special resolution.

This report has been prepared in accordance with the special provisions relating to small companies within Part 15 of the Companies Act 2006.

Approved by the Board of Trustees on 13 November 2023 and signed on its behalf by:

Mr AM Grange
Chair of the Board of Trustees

BRITISH THORACIC ONCOLOGY GROUP

INDEPENDENT EXAMINER'S REPORT

TO THE TRUSTEES OF BRITISH THORACIC ONCOLOGY GROUP

I report to the trustees on my examination of the accounts of the company for the year ended 31 March 2023.

Responsibilities and basis of report

As the trustees of the charity (and also its directors for the purposes of company law) you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006 (the 2006 Act).

Having satisfied myself that the accounts of the company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your company's accounts carried out under section 145 of the Charities Act 2011 (the 2011 Act). In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145 (5)(b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

- 1 accounting records were not kept in respect of the charity as required by section 386 of the 2006 Act; or
- 2 the financial statements do not accord with those records; or
- 3 the financial statements do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
- 4 the financial statements have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

P T Barnett FCCA (Independent Examiner)

Newby Castleman LLP

West Walk Building

110 Regent Road

Leicester

LE1 7LT

14 November 2023

BRITISH THORACIC ONCOLOGY GROUP

STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT FOR THE YEAR ENDED 31 MARCH 2023

		Unrestricted Funds Total 2023 £	Unrestricted Funds Total 2022 £
	Notes		
Income from:			
Charitable activities	3	34,488	58,736
Other trading activities	4	103,203	467,798
Total		137,691	526,534
Expenditure on:			
Raising funds	5	38,029	32,475
Charitable activities	6	280,014	254,155
Other	9	(1,468)	310
Total		316,575	286,940
Net (expenditure)/income for the year/ Net movement in funds		(178,884)	239,594
Reconciliation of funds			
Total funds brought forward		739,715	500,121
Total funds carried forward		560,831	739,715

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

BRITISH THORACIC ONCOLOGY GROUP

BALANCE SHEET

AS AT 31 MARCH 2023

		2023		2022	
	Notes	£	£	£	£
Fixed assets					
Tangible assets	12		248		464
Current assets					
Debtors	13	751,804		195,210	
Cash at bank and in hand		392,156		671,482	
		<u>1,143,960</u>		<u>866,692</u>	
Liabilities					
Creditors: amounts falling due within one year	14	(583,377)		(127,441)	
Net current assets			560,583		739,251
Net assets			<u>560,831</u>		<u>739,715</u>
Total funds of the charity					
Designated funds		1,304		7,730	
General funds		<u>559,527</u>		<u>731,985</u>	
Total unrestricted funds	16		560,831		739,715
Total charity funds			<u>560,831</u>		<u>739,715</u>

The company is entitled to the exemption from the audit requirement contained in section 477 of the Companies Act 2006, for the year ended 31 March 2023.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

Trustees' responsibilities:

- The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476 of the Companies Act 2006;
- The trustees acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of the accounts.

The financial statements were approved and authorised for issue by the Board of Trustees on 13 November 2023 and are signed on its behalf by:

Mr C Kerr
Trustee and Treasurer

Company Registration No. 9816385

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2023

1 Accounting policies

Charity information

British Thoracic Oncology Group ("BTOG") is a private company limited by guarantee incorporated in England and Wales. The address of the registered office and place of business is given in the legal and administrative information page of these financial statements.

The members of the charity include the trustees named within the legal and administrative information. In the event of the trust being wound up, the liability in respect of the guarantee is limited to £1 per member of the charity.

1.1 Basis of preparation

The charity is a Public Benefit Entity as defined by FRS 102. The financial statements have been prepared in accordance with: the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102), Accounting and Reporting by Charities: the Statement of Recommended Practice for charities applying FRS 102 (2019), the Charities Act 2011, the Companies Act 2006 and UK Generally Accepted Accounting Practice.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below. These policies have been consistently applied to all years presented unless otherwise stated.

1.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives.

Designated funds are unrestricted funds of the charity which have been set aside at the discretion of the trustees for specific purposes. The purposes and uses of the designated funds are set out in the notes to the financial statements.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The aim and use of each restricted fund is set out in the notes to the financial statements.

1.4 Income recognition

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Income from charitable activities primarily includes income received for conference and course registration fees. Such income is recognised at fair value when the event has occurred.

Income from trading activities includes income earned from sponsorship.

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2023

1 Accounting policies

(Continued)

1.5 Expenditure recognition

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs relating to the category. Expenditure is recognised when there is legal or constructive obligation to make the payment to a third party, if it is probable that settlement will be required and the amount of the obligation can be measured reliably. It is recognised under the following headings:

- Expenditure on raising funds - this includes costs for advertising, marketing, direct mail and publicity.
- Expenditure on charitable activities - this includes services to further the delivery of the objectives of the charity.

Irrecoverable VAT is charged against the category of resources expensed for which it was incurred.

Support costs

Support costs are those that assist the work of the charity but do not directly represent charitable activities and costs of raising funds and include office costs and governance costs. They are incurred directly in support of expenditure on the objects of the charity. Support costs are allocated to costs of raising funds and expenditure on charitable activities on a basis consistent with use of the resources.

The analysis of these costs is included in note 8.

1.6 Tangible fixed assets

Tangible fixed assets are measured at cost, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost of assets less their residual values over their useful lives on the following bases:

Fixtures & fittings	15% of cost
Computer equipment	33.33% of cost

1.7 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less.

1.8 Financial instruments

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Debtors and creditors with no stated interest rate and receivable or payable within one year are measured at transaction price. Any losses arising from impairment are recognised in the SOFA.

1.9 Taxation

British Thoracic Oncology Group is a registered charity and no taxation provision is required as its income from charitable activities falls within the various exemptions available to registered charities.

1.10 Employee benefits

When employees have rendered service to the charity, short-term employee benefits to which the employees are entitled are recognised at the undiscounted amount expected to be paid in exchange for that service.

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2023

1 Accounting policies (Continued)

1.11 Leases

Rentals payable under operating leases, including any lease incentives received, are charged as an expense on a straight line basis over the term of the relevant lease.

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

The trustees do not consider there to be any key sources of estimation uncertainty that have a significant effect on the amounts recognised in the financial statements.

3 Charitable activities

	Unrestricted funds £	Restricted funds £	Total 2023 £	Total 2022 £
Conference and course registration fees	34,488	-	34,488	58,736
Unrestricted funds				58,736
Restricted funds				-
				58,736

4 Other trading activities

	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £	Total 2022 £
Sponsorship	103,203	-	103,203	467,798
Unrestricted funds				467,798
Restricted funds				-
				467,798

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2023

5 Raising funds

	Unrestricted funds £	Restricted funds £	Total 2023 £	Total 2022 £
Advertising, marketing, direct mail and publicity	18,744	-	18,744	14,363
Support costs (see note 8)	19,285	-	19,285	18,112
	<u>38,029</u>	<u>-</u>	<u>38,029</u>	<u>32,475</u>
Unrestricted funds				32,475
Restricted funds				-
				<u>32,475</u>

6 Charitable activities

	Activities undertaken directly Note 7 £	Support Costs Note 8 £	Total 2023 £	Total 2022 £
Conference and courses	151,728	128,286	280,014	254,155
Unrestricted funds			280,014	254,155
Restricted funds			-	-
			<u>280,014</u>	<u>254,155</u>

7 Expenditure on activities undertaken directly

	2023 £	2022 £
Conference and courses		
Venue and accommodation management	111,595	29,499
Abstract publication	-	26,630
Prizes and bursaries	100	3,300
Travel	15,237	-
Course accreditation	350	695
Bank and card charges	384	1,714
Webinar activities	24,062	108,074
	<u>151,728</u>	<u>169,912</u>

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2023

8 Expenditure on support costs

	Basis of allocation	2023 £	2022 £
Staff costs	Raising funds and charitable activities	96,426	90,562
Travel	Charitable activities	452	665
Training	Charitable activities	277	-
Subscriptions	Charitable activities	450	486
Rent	Charitable activities	4,170	650
Insurance	Charitable activities	1,618	1,677
Office costs	Charitable activities	1,035	1,318
Software costs	Charitable activities	1,991	1,291
Professional fees	Charitable activities	5,868	5,120
Sundry	Charitable activities	40	177
Irrecoverable VAT	Charitable activities	35,028	-
Depreciation	Charitable activities	216	409
		<u>147,571</u>	<u>102,355</u>
Analysed between:			
Raising funds		19,285	18,112
Charitable activities		<u>128,286</u>	<u>84,243</u>
		<u>147,571</u>	<u>102,355</u>

Support costs have been allocated to raising funds and charitable activities on a basis consistent with the use of the resource. Support costs include governance costs totalling £5,768 (2022: £5,120).

The amount charged to the SOFA in respect of governance costs includes the following:

Independent examination £4,450 (2022 - £4,000)

Other financial services £1,318 (2022 - £1,120)

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2023

9 Other expenditure

	Unrestricted funds 2023 £	Total 2023 £	Unrestricted funds 2022 £	Total 2022 £
Net loss on disposal of tangible fixed assets	-	-	310	310
Interest	(1,468)	(1,468)	-	-
	<u>(1,468)</u>	<u>(1,468)</u>	<u>310</u>	<u>310</u>

The company classifies certain one-off charges and credits which have a material impact on the company's financial results as 'exceptional items'. These are disclosed separately to provide further understanding of the financial performance of the company.

In July 2020 the charity paid £50,005 to HM Revenue and Customs for input VAT disallowed in respect of the four years ended 31 March 2020, following a review of the charity's VAT affairs.

Interest was estimated in the sum of £3,000 on late payment of the total VAT liability which was classified as an exceptional item in the accounts to 31 March 2021 and included within accruals. The figure has been confirmed by HM Revenue and Customs as £1,532 therefore there is a credit amounting to £1,468.

10 Trustees

The trustees neither received nor waived any emoluments during the year (2022: £Nil).

Travel and subsistence expenses were reimbursed to 2 trustees (2022: 0) in the sum of £452 (2022: £nil) during the year.

11 Employees

Number of employees

The average monthly number of employees during the year was:

	2023 Number	2022 Number
Total	<u>2</u>	<u>2</u>
Employment costs	2023 £	2022 £
Wages and salaries	<u>96,426</u>	<u>90,562</u>

Staff working for the charity are employed directly by the University Hospitals of Leicester NHS Trust and their salary costs are charged to the charity in accordance with a service level agreement between BTOG and the Trust. The amount charged for the year was £96,426 (2022 - £90,562).

There were no employees whose annual remuneration was £60,000 or more.

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2023

12 Tangible fixed assets

	Fixtures & fittings £	Computer equipment £	Total £
Cost			
At 1 April 2022	692	1,689	2,381
At 31 March 2023	692	1,689	2,381
Depreciation and impairment			
At 1 April 2022	339	1,578	1,917
Depreciation charged in the year	105	111	216
At 31 March 2023	444	1,689	2,133
Carrying amount			
At 31 March 2023	248	-	248
At 31 March 2022	353	111	464

13 Debtors

	2023 £	2022 £
Amounts falling due within one year:		
Trade debtors	288,908	155,590
Other debtors	1,304	7,730
Prepayments and accrued income	461,592	31,890
	751,804	195,210

14 Creditors: amounts falling due within one year

	2023 £	2022 £
Other taxation and social security	64,699	43,565
Deferred income (see note 16)	510,467	74,866
Accruals	8,211	9,010
	583,377	127,441

15 Deferred income

	2023 £	2022 £
Arising from advanced registration fees and sponsorships	510,467	74,866

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2023

15 Deferred income

(Continued)

Deferred income is included in the financial statements as follows:

	2023 £	2022 £
Deferred income is included within:		
Current liabilities	510,467	74,866
Movements in the year:		
Deferred income at 1 April 2022	74,866	190,000
Released from previous periods	(74,866)	(190,000)
Resources deferred in the year	510,467	74,866
Deferred income at 31 March 2023	510,467	74,866

16 Unrestricted funds

The unrestricted funds of the charity include designated funds which have been set aside out of unrestricted funds by the trustees for a specific purpose:

	Balance at 1 April 2022 £	Movement in funds			Balance at 31 March 2023 £
		Income £	Expenditure £	Transfers £	
General funds	731,985	137,691	(220,149)	(90,000)	559,527
Designated funds - wages fund	7,730	-	(96,426)	90,000	1,304
	739,715	137,691	(316,575)	-	560,831

	Balance at 1 April 2021 £	Movement in funds			Balance at 31 March 2022 £
		Income £	Expenditure £	Transfers £	
General funds	491,805	526,534	(166,040)	(90,000)	731,985
Designated funds - wages fund	8,316	-	(90,586)	90,000	7,730
	500,121	526,534	(256,626)	-	739,715

The wages fund represents funds held by the University Hospitals of Leicester NHS Trust as Custodian Trustee on behalf of British Thoracic Oncology Group for primarily the payment of wages to staff working for the charity but who are employed by the NHS Trust.

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2023

17 Analysis of net assets between funds

	Unrestricted funds £	Designated funds £	Total £
Fund balances at 31 March 2023 are represented by:			
Tangible assets	248	-	248
Current assets/(liabilities)	559,279	1,304	560,583
	<u>559,527</u>	<u>1,304</u>	<u>560,831</u>
	Unrestricted funds £	Designated funds £	Total £
Fund balances at 31 March 2022 are represented by:			
Tangible assets	464	-	464
Current assets/(liabilities)	731,521	7,730	739,251
	<u>731,985</u>	<u>7,730</u>	<u>739,715</u>

18 Related party transactions

Remuneration of key management personnel

The remuneration of key management personnel is as follows.

	2023 £	2022 £
Aggregate compensation	<u>60,132</u>	<u>57,356</u>

During the year rent and office expenses in the sum of £5,363 (2022 - £1,478) were invoiced by Mesothelioma UK Charitable Incorporated Organisation (formerly Mesothelioma UK Charitable Trust) to the British Thoracic Oncology Group. Professor M D Peake and Ms D E McKinley are both trustees of these organisations. At the balance sheet date there was an outstanding balance of £nil (2022 - £nil) for these services.

There have been no further related party transactions in the reporting period that require disclosure in the financial statements, other than those noted in note 10 to the financial statements.

19 Operating lease commitments

At 31 March 2023 the charity had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

	2023 £	2022 £
Within one year	<u>3,550</u>	<u>3,250</u>

Lease payments totalling £4,170 (2022 - £650) have been recognised as an expense during the year.

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2023

20 Controlling party

British Thoracic Oncology Group is a company limited by guarantee and not having a share capital; it is incorporated under the Companies Act and governed by the Memorandum and Articles of Association of the charity. The trustees of the charity are elected members and act as directors of the charity who are deemed to be the controlling party of the charity.

Accounts

Charity Registration No. 1166012

Company Registration No. 9816385 (England and Wales)

BRITISH THORACIC ONCOLOGY GROUP

**TRUSTEES' REPORT AND
FINANCIAL STATEMENTS**

**FOR THE YEAR ENDED
31 MARCH 2022**

BRITISH THORACIC ONCOLOGY GROUP

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees	Mr A M Grange (Chairman) Mr C Kerr (Treasurer) Professor M D Peake Ms S Hiom Professor D Talbot
-----------------	---

Senior Executive Officer	Ms D E McKinley
---------------------------------	-----------------

Steering Committee Chair	Professor S Popat
---------------------------------	-------------------

Steering Committee Vice-Chair	Dr T Newsom-Davis
--------------------------------------	-------------------

Charity number	1166012
-----------------------	---------

Company number	9816385
-----------------------	---------

Principal address	235 Loughborough Road Mountsorrel Loughborough Leicestershire LE12 7AS
--------------------------	--

Registered office	West Walk Building 110 Regent Road Leicester LE1 7LT
--------------------------	---

Independent examiner	P T Barnett FCCA Newby Castleman LLP West Walk Building 110 Regent Road Leicester LE1 7LT
-----------------------------	--

Bankers	Santander UK plc Bridle Road Bootle Merseyside L30 4GB
----------------	--

BRITISH THORACIC ONCOLOGY GROUP

CONTENTS

	Page
Trustees' report	1 - 29
Independent examiner's report	30
Statement of financial activities	31
Balance sheet	32
Statement of cash flows	33
Notes to the financial statements	34 - 43

BRITISH THORACIC ONCOLOGY GROUP



TRUSTEES' REPORT

FOR THE YEAR ENDED 31 MARCH 2022

The trustees, who are the directors of the charitable company, present their report and financial statements for the year ended 31 March 2022.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the charity's governing document, the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102), Accounting and Reporting by Charities: Statement of Recommended Practice for Charities applying FRS 102 (2019), the Charities Act 2011, the Companies Act 2006 and UK Generally Accepted Accounting Practice.

The legal and administrative information forms part of this report.

OBJECTIVES AND ACTIVITIES

The charitable objects are:

- (1) The promotion and advancement of health or the saving of lives by way of improving the care of patients with thoracic malignancies through multi-disciplinary education and clinical and scientific research for the benefit of the public;
- (2) To advance public education and research into lung cancer and mesothelioma, in particular but not exclusively by facilitation of exchange of information on thoracic oncology including disseminating results of research and other news related to lung cancer and mesothelioma;
- (3) Such other charitable purposes beneficial to the community consistent with the objects as above as the trustees shall in their absolute discretion determine.

Vision and Mission

The vision of British Thoracic Oncology Group ("BTOG") is to contribute to achieving survival rates equal to the best in the world.

The mission of BTOG is to support and educate thoracic oncology health care professionals, creating a professional community to exchange ideas, information and innovation and to foster the development of research. The overall aim is to represent the needs of people with thoracic malignancies in the UK and ensure they have equitable access to optimal care.

BTOG's Values

- We are committed to achieving our vision and mission.
- We are proud to be an important part of the thoracic oncology professional community.
- We work collaboratively with other groups who in their own ways are also striving to improve outcomes for this group of patients or reduce the prevalence of lung cancer e.g. relating to smoking cessation.
- We engage with our stakeholders to ensure what we do is relevant and effective.
- We maintain professional independence from commercial organisations.
- We hold patients at the centre of everything we do.

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

OBJECTIVES AND ACTIVITIES (CONTINUED)

Activities for achieving objectives for the public benefit

The Board of Trustees ("trustees") has had regard to the Charity Commission's guidance on public benefit. The main activities undertaken to further the charitable purposes for the public benefit are set out below:

Education:

- Provides an annual CPD education programme of value to the whole multi-disciplinary team (MDT).
- Provides access to events for advocates who sit on thoracic oncology clinical studies or trial management groups, advisory boards/groups or other related groups.
- Ensures registration fees are accessible to members of the MDT.
- Provides an education bursary for the annual conference and other events where possible.
- Provides a membership for thoracic oncology health care professionals including access to useful resources (regular BTOG E-News; a website member only on-line resource including films and presentations from BTOG educational events and access to an online lung cancer journal; opportunity to participate in relevant research studies/questionnaires and provide an up-to-date calendar of thoracic oncology events).

Research:

- Provides networking opportunities at educational events and foster a professional community through its membership for the research community to develop clinical trials and other research.
- Provides workshops or stand-alone events for the sole purpose of research development.
- Circulates research surveys and questionnaires that support relevant research.
- Is a member of relevant research groups (e.g. European Thoracic Oncology Platform, International Association for the Study of Lung Cancer).

Representation:

- Reviews NICE appraisals for new drug therapies/technologies.
- Reviews appropriate guidelines/policy documents.
- Develops BTOG-own guidelines/position documents.
- Participates in other groups, sub-groups, committees and boards.
- Represents patients in any capacity it deems appropriate with the overall aim to improve outcomes or reduce the prevalence of lung cancer e.g. relating to smoking cessation.

Criteria to measure success in the reporting period;

We measure our success in achieving our objectives in several of ways:

- By providing an annual CPD education programme of value to the whole multi-disciplinary team and receiving good feedback from attendees and consistent or increased attendance to the events.
- By keeping in touch with the professional community to encourage networking and collaboration virtually.
- By listening to our stakeholders to ensure what we do is relevant and effective through feedback and surveys.
- By working collaboratively with other groups to improve patient outcomes.
- By ensuring that BTOG represents patients in relevant guideline and drug development.

Longer term aims and objectives

In 2020, the BTOG's trustees and Steering Committee worked together to produce the Strategic Plan 2020-2025 taking account of stakeholder needs. Although COVID-19 has impacted the timeline for some of our strategic activities, BTOG is committed to adapting and fulfilling its longer term aims and objectives. Therefore, the Strategic Plan remains a relevant working document.



OBJECTIVES AND ACTIVITIES (CONTINUED)

STRATEGIC PLAN 2020 – 2025

MISSION

To support and educate thoracic oncology healthcare professionals, creating a professional community to exchange ideas, information and innovation and to foster the development of research.

The overall aim is to represent the needs of people with thoracic malignancies in the UK and ensure they have equitable access to optimal care.

STRATEGIC ACTIVITIES

- Make www.btog.org the one-stop resource shop for thoracic oncology healthcare professionals
- Identify and communicate with lung and mesothelioma MDTs.
- Engage with Juniors through trainee representation on the steering committee
- Establish a BTOG Regional Champion Scheme to engage with existing members and attract new ones

VISION

To contribute to achieving survival rates equal to the best in the world.

OUR VALUES

We are committed to achieving our mission and vision.

We are proud to be an important part of the thoracic oncology professional community.

We work collaboratively with other groups who in their own ways are also striving to improve outcomes for this group of patients.

We engage with our stakeholders to ensure what we do is relevant and effective.

We maintain professional independence from commercial organisations.

We hold patients at the centre of everything we do.

EDUCATION

- Conference (Flagship Event)
- Essential Updates
- Workshops (ad hoc)
- Annual updates from thoracic oncology international conferences
- Postgraduate Course (Biennial)
- Produce standard slide sets for Changes in Practice / What's New series – included in regional updates
- Produce Breaking News/Alerts/Press Releases for Changes in Practice

RESEARCH

- Facilitate a Think Tank Workshop to identify gaps for development of research with UK, European and other research organisations
- Establish BTOG research specialist subgroups to complement other external subgroups
- Ensure subgroups report regularly on the delivery of specific objectives

REPRESENTATION

- Make reactive contributions: NICE appraisals; Specialist Statement of Practice; Endorsements
- Make proactive contributions: Guidelines; Position and Consensus Statements; Comment on Public Health England / Department of Health Policy
- Campaign with relevant organisations for equitable access to optimal care
- Partner with specialist societies / groups / organisations (e.g. Surgeons, Nurses, Pathologists, Radiologists)
- Engage with advocates by ensuring advocate representation on the BTOG steering committee and making advocate places available at BTOG educational events
- Represent all the UK including the devolved nations

STRATEGIC OUTCOMES

- To reach all lung/mesothelioma MDTs in the UK to ensure all thoracic oncology healthcare professionals have access to relevant education and resources
- To be a leader in thoracic oncology research to focus and support the research agenda
- To represent thoracic oncology patients by making contributions and collaborating with others

BRITISH THORACIC ONCOLOGY GROUP



TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

ACHIEVEMENTS AND PERFORMANCE

Review of Activities - Education

In common with all organisations, the COVID-19 pandemic has had a significant impact on the in-person events and networking of BTOG. During the period April 2021 to March 2022 due to continued COVID-19 restrictions and the risk involved for in-person events our educational activities remained on-line.

During the 2021/22 year, BTOG has worked hard to provide a relevant Continuing Professional Development (CPD) education programme for the thoracic oncology multi-disciplinary team. Advocates who sit on thoracic oncology clinical studies or trial management groups, advisory boards/groups or other related groups are welcome to register for BTOG education (except for the BTOG Journal Club which is for trainees).

Annual Conference

During this period BTOG held two virtual annual conferences, one in April 2021 (delayed from January 2021) and one in January 2022. For BTOG 2021, in recognition of challenging times, BTOG registration fees were waived for all health care professionals.

BRITISH THORACIC ONCOLOGY GROUP


TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022



ACHIEVEMENTS AND PERFORMANCE (CONTINUED)


Review of Activities - Education (continued)





ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)



TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)

Some Feedback from our Annual Conference in 2021

- Brilliantly organised! A credit to all involved. It was very good and informative.
- Well-structured and sessions ran very well.
- Excellent presentations. Very well organised meeting.
- Excellent programme and well organised. Interactive - Q and A sessions livened up the “virtual” world. Hoping next year returns to normal face to face meetings but this is a good 2nd best.
- Greatly appreciated the conference being available online. I found it extremely helpful.
- Great conference. Whilst missed the face-to-face interaction of conference it was helpful being able to view the difference streams- sometimes it can be hard to decide which stream to attend.

Some Feedback from our Annual Conference in 2022

- BTOG is incredibly useful for clinicians who work in smaller centres, to maintain up to date NHS relevant knowledge, to learn from other centres who share expertise in systems and services that have adapted well to the NHS pressures/pandemic pressures. It provides us with up-to-date information on the latest availability of treatments that are not yet fully NICE approved/funded etc.... I think it should be mandatory to attend as a lung oncologist!!
- Good balance of content across key specialties, but mostly aimed at general audience which was good.
- I have been to BTOG many times and usually always come back with lots of information to pass onto my colleagues.
- As always, an excellent conference with the live platform functioning well.
- I found the virtual platform very impressive - it was easy to navigate, and the hotel lobby design was a nice touch.
- The variety of topics and involvement of all types of Specialists in Oncology Care, including those in allied services such as dietician and physio and psychology was great to see at a major Conference.

Webinars



BTOG continued with its regular 1-hour webinars that were developed last year taking account of the latest data released and included a panel of relevant experts in thoracic oncology. Registration at all BTOG webinars is free of charge for health care professionals.

We held nine 1-hour webinars and two full-day webinars during this period and all webinars were accredited by the Federation of the Royal Colleges of Physicians of the UK for category 1 (external) CPD credits. CPD credits were available both live and up to 4 weeks post-event for on-demand and the stats provided below reflect this timeframe. Attendees were encouraged to give feedback on the content and organisation and any feedback was recorded and analysed to ensure continuous improvement. All BTOG webinars are also available to view 'On Demand' in the BTOG Member Resources area.

BRITISH THORACIC ONCOLOGY GROUP



TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)

Live and on-demand

The 11 BTOG webinars during this period resulted in a total audience of 1,029 live and on demand (up to 4 weeks).

813 attendees to the following 9 webinars:

#BTOGWebinars #BTOGMesoWebinar
BTOG Webinar: Mesothelioma Essential Update
Monday 17th May 2021 • 17:30 – 18:30 GMT

#BTOGWebinars #BTOGWebinar #BTOGASCO21
BTOG Webinar: 'ASCO 2021 in an Hour'
Thursday 10th June 2021 • 17:30 – 18:30 BST

Dr. David Gilligan, BTOG Steering Committee Vice Chair and Consultant Oncologist
Dr. David Gilligan, Consultant Medical Oncologist
Dr. David Gilligan, Consultant Medical Oncologist
Dr. David Gilligan, Consultant Medical Oncologist

#BTOGWebinars #BTOGMasterclass #BTOGperiOp
BTOG Masterclass: Peri-Operative Therapies
Thursday 29th July 2021 • 17:30 – 18:30 BST

Professor Dennis Saker, Professor of Experimental Cancer Medicine and Consultant in Medical Oncology, Royal College of Surgeons in Ireland
Dr. David Gilligan, Consultant Medical Oncologist, University Hospitals of Leicester NHS Trust
Professor Barbara Ahmed, Consultant Medical Oncologist, University Hospitals of Leicester NHS Trust

#BTOGWebinars #WCLCandESMOinAnHour
WCLC & ESMO 2021 in an Hour
Monday 21st September 2021 • 17:30 – 18:30 BST

Tom Newman-Davis, BTOG Steering Committee Vice Chair
Dr. David Gilligan, Consultant Oncologist
Samreen Ahmed, Consultant in Medical Oncology
Riyaz Shah, Consultant Medical Oncologist

#BTOGwebinars #BTOGwebinarRTtechniques
Advanced RT techniques: Tips and tricks for challenging cases
Thursday 7th October 2021 • 7:30 – 18:30 BST

Professor Matthew Horton, Weston Park Cancer Centre and Chair of the National Cancer Research Institute Lung Cancer Study Group
Dr. David Gilligan, Consultant Medical Oncologist at the Royal Marsden Hospital
Corinne Fothergill, Honorary Consultant Oncologist and a Member of the National Cancer Research Institute Lung Cancer Study Group
Liam Walsh, Consultant Clinical Oncologist, Neurosurgery Unit at the Royal Marsden

#BTOGEssentialUpdate #BTOGsupportingpatients
BTOG Essential Update: Supporting Patients with Thoracic Malignancies
Wednesday 10th November 2021 • 7:30 – 18:30 GMT

Tom Newman-Davis, BTOG Steering Committee Vice Chair
Nehal English, Clinical Nurse Specialist, Honorary Medical Oncologist, Consultant, West of Scotland Cancer Centre
Professor Maria Salter, M. D., Honorary Professor of Palliative Medicine and Honorary Consultant in Palliative Care, University of Edinburgh
Barry Lavelle, Senior Clinical Lecturer in Palliative Medicine and Honorary Consultant in Palliative Care, University of Edinburgh

#BTOGmasterclass #BTOGimmunotherapy
BTOG Masterclass: Immunotherapy Tips and Tricks
Thursday 9th December 2021 • 17:30 – 18:30 BST

Professor Sergio Hogg, Chief of the Medical Oncology Department, Royal Marsden Hospital, Honorary Consultant in Medical Oncology, University of Cambridge
Shashank Bagal, Consultant Medical Oncologist, Royal Marsden Hospital
Dr. David Gilligan, Consultant Medical Oncologist, University Hospitals of Leicester NHS Trust
Dr. David Gilligan, Consultant Medical Oncologist, University Hospitals of Leicester NHS Trust

#BTOGwebinars #BTOGImagingWebinar
How do we harness functional imaging information in Radiotherapy?
Thursday 24th February 2022 • 7:30 – 18:30 BST

Dr. David Gilligan, BTOG Steering Committee Vice Chair and Consultant Oncologist
Dr. David Gilligan, Consultant Medical Oncologist
Dr. David Gilligan, Consultant Medical Oncologist
Dr. David Gilligan, Consultant Medical Oncologist

BRITISH THORACIC ONCOLOGY GROUP



TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022



216 attendees to the following 2 webinars:



Speciality/Category	%
Nursing	9.4%
Medical Oncology	19.7%
Clinical Oncology	25.4%
Oncology	3.7%
Respiratory	21.7%
Surgery	0.4%
Palliative Care	0.4%
Radiology	2.0%
Science/research/clinical trials	2.5%
Pharmacy	1.6%
Academic	0.8%
Student	0.0%
Pathology	1.6%
Allied HCP	1.6%
Other HCP	1.6%
Industry	5.3%
Patient advocate	1.2%
Charity/non-profit	0.4%
Other non-HCP	0.4%

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)



BTOG held the Second BTOG Lung Cancer Screening Essential Update on Friday 11th June 2021 – this full day online event brought together national experts to discuss existing Lung Cancer Screening Projects in the UK and future plans and potential impact on their clinical practice. Parallel tracks provided detailed information and increased understanding on the screening roll out and knowledge relevant to professionals involved in thoracic oncology. A combination of short presentations from currently active screening/lung health check programmes and questions and debate gave attendees in depth knowledge to be related to their practice.



BTOG held a BTOG Masterclass: Leading your lung cancer pathway on Friday 8th October 2021 – this full day online event brought together national experts to discuss how to develop a lung cancer service and how to lead a lung cancer service, to learn about new developments related to running a lung cancer service and understanding unwarranted variation, to learn about managing the governance arrangements in a lung cancer service and horizon scanning for new challenges and opportunities.

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)

Feedback for Webinars

- Really enjoyed the meeting.
- Perfectly organised webinar on actual topics.
- A very informative session.
- Brilliant session- best yet! (Though may be biased as a clinical oncologist). Found session on brain mets particularly interesting.
- Excellent session, very helpful, nothing to improve. Thanks.
- Excellent as always.
- Very good overview of ESMO and WCLC 2021.
- Super informative session! Really enjoyed this update and great speakers - no improvements needed!
- Useful update.
- Well done; thank you.
- Just to say that I really enjoy the 'head-to-head' format on some of them. It helps air thorny issues.
- V good clear answers to questions, nice non-combative styles, congenial tone set by Chair.
- Another well organised and very useful BTOG webinar!
- Excellent up to date summary of current situation re meso treatment.



Impressions: The number of impressions on a tweet sent in the selected date range. An impression is the number of times a tweet appears to users in either their timeline or search results.

Engagements: The total number of times a user interacted with the tweets you sent during the selected date range.

A total of 837,137 impressions on event hashtags:

#BTOGsupportingpatients	124,808 impressions
#BTOGimmunotherapy	101,685 impressions
#BTOGPeriOp	100,086 impressions
#WCLCandESMOinAnHour	91,374 impressions
#BTOGscreeningupdate	85,895 impressions
#BTOGmasterclass	82,389 impressions
#BTOGwebinarRTtechniques	80,218 impressions
#BTOGLCpathway	73,806 impressions
#BTOGimagingwebinar	35,575 impressions
#BTOGASCO21 / #BTOGASCO2021	33,733 impressions
#BTOGmesoWebinar	24,556 impressions
#BTOGlungcancerdiagnostics	3,012 impressions

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)




Podcasts of all BTOG webinars are available to listen to or download. BTOG introduced a series of podcasts called “*BTOG does ...*” where we discussed a variety of thoracic oncology topics with a different expert each time. BTOG podcasts can be subscribed to through the Apple App Store and the Google Play Store or be listened to on Spotify by searching BTOG (CPD points are not available for the podcasts).

During this period a total of 2,614 podcast downloads.

	Downloads					
	Jan-Mar22	Oct-Dec21	Jul-Sep21	Apr-Jun21	Jan-Mar21	Oct-Dec20
TOTALS	1,500	806	348	478	373	233
CHANGE	↑86%	↑132%	↓27%	↑28%	↑60%	

Dedicated podcast series started November 2021



BRITISH THORACIC ONCOLOGY GROUP



TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)

Total podcasts downloads:

BTOG does ...	Expert	Interviewer	
EGFR Mutated lung cancer	Samreen Ahmed	Tom Newsom-Davis	209
Diagnosis and Staging	Neal Navani	Tom Newsom-Davis	191
CURE Project & Tobacco Addiction	Matt Evison	Helen McDill	186
Lung cancer screening	Emma O' Dowd	Helen McDill	181
Lung Histopathology	Angeles Montero-Fernandez	Tom Newsom-Davis	151
BTOG 20th Anniversary	Sanjay Popat	Tom Newsom-Davis	114
Oligometastatic disease and SABR	David Palma	Stephen Harrow	195
Management of Pleural Disease	Nick Maskell	Helen McDill	199
Management of Cancer Cachexia	Barry Laird	Stephen Harrow	187
			1613
WEBINARS – available data at time of reporting			
BTOG Webinar: Mesothelioma Essential Update			225
BTOG Masterclass: Peri-Operative Therapies			145
WCLC 2021 & ESMO 2021 in an Hour			126
BTOG Webinar: Advanced Radiotherapy Techniques			117
BTOG Essential Update on Supporting Patients with Thoracic Malignancies			127
BTOG Masterclass: Immunotherapy Tips & Tricks			261
			1001

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)



BTOG introduced a regular virtual journal club on the latest trials in thoracic oncology facilitated by experts and discussing all things from trial design to results interpretation and their implications for clinical practice. The target audience for the Journal Club is medical trainees of all grades including medical students and allied health professionals and attendee numbers are restricted to allow for and encourage interaction and discussion.

Moderator: Professor Allan Hackshaw, Professor of Epidemiology & Medical Statistics, Deputy Director, Cancer Research UK & UCL Cancer Trials Centre

BTOG Trainee Representatives: Adam Januszewski, Higher Specialty Trainee in Medical Oncology and Honorary Clinical Fellow, Imperial College London and Helen McDill, Respiratory Registrar, Gloucestershire Royal Hospital

Thursday 24th June 2021

Paper: CheckMate 743 investigating the use of first line ipilimumab and nivolumab in mesothelioma

Expert: Dr Riyaz Shah, Consultant Medical Oncologist, Kent Oncology Centre, Maidstone and Tunbridge Wells NHS Trust

Wednesday 21st July 2021

Paper: Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial Slotman et al

Expert: Dr Clive Peedell, Consultant Clinical Oncologist, James Cook University Hospital, South Tees Hospitals NHS Foundation Trust

Wednesday 29th September 2021

Paper: Nelson Trial 'Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomised Trial' Koning et al

Expert: Dr Anna Sharman, Consultant Thoracic Radiologist, Wythenshawe Hospital

Wednesday 8th December 2021

Paper: Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial – Albain et al (Intergroup Trial 0139)

Expert: Dr Matthew Evison, Consultant Physician in Respiratory Medicine (Thoracic Oncology), North West Lung Centre and University of Manchester

Friday 28th January 2022

Paper: Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study – Gomez et al

Expert: Dr Fiona McDonald, Consultant Thoracic Clinical Oncologist, The Royal Marsden NHSFT

BRITISH THORACIC ONCOLOGY GROUP



TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)

BTOG Trainees Network Launched in January 2022

One of BTOG's key aims is to bring the thoracic oncology community closer together and foster collaboration and education. In BTOG's trainee survey in 2021 we heard that trainees wanted to be connected with other like-minded trainees and therefore we launched the '**BTOG Trainees Network**'. The Slack platform (QR code to join) is designed to bring trainees together from across disciplines and the UK to foster collaborations, open opportunities and foster a community of like-minded trainees. The platform is also used to highlight educational events and opportunities.



Online resources at www.btog.org

BTOG Trainee Representatives have been working on a major upgrade to our online resource library, where members can access all the videos and presentations from our education events. A new search function will enable all members to find relevant resources by various categories, by event or by the type of resource. The goal is to create a kind of 'one-stop-shop' and include many other resources beyond those from our events. The new library will go live during the 2022/23 period.

BTOG Membership

During this period BTOG continued to provide relevant and up-to-date member services.

- Free CPD education (e.g. BTOG webinars and essential updates)
- CPD education (annual conference)
- BTOG Resources member area including BTOG presentation/video library, trainee resources and podcasts
- Full digital edition of Lung Cancer Journal
- Bursaries/scholarships for BTOG meeting registration or travel (subject to application process)
- Weekly E-News including relevant information about education, research, research surveys
- BTOG networking and professional community



- 56 E-News were sent during this period
- 38% average open rate (industry average is 20% for similar emails)
- 5.69% click rate (industry average is 2-4% for similar emails)

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)

Membership (continued)

March 2022

- 2,023 members (1785 HCP, 238 Network)
- Renewals planned for Autumn 2022
- Only 8 have never logged in
- 1,602 have logged in once
- 176 twice
- 101 three times

March 2021

- 1745 members (1528 HCP, 217 Network)
- 2021 member renewals postponed to 2022
- Only 14 have never logged in
- 1344 have logged in once
- 176 have logged in twice
- 109 have logged in three times

March 2020

- 754 members (668 HCP, 86 Network)
- 2020 member renewals postponed to March 2021

March 2019

- 1059 members (925 HCP, 134 Network)
- March to July 2019 renewals

To ensure compliance to General Data Protection Regulation (GDPR), BTOG contacts its members regularly to renew and opt-in to receive information from BTOG. The next renewal is due Autumn 2022.

Health Care Professionals Members by Speciality

	Mar22	2021	2020	2019
Respiratory	26%	26%	26%	27%
Nursing	22%	22%	22%	27%
Medical Oncology	14%	14%	15%	12%
Clinical Oncology	14%	14%	14%	14%
Oncology	5%	5%	6%	3%
Science/research/clinical trials	4%	4%	4%	3%
Surgery	4%	4%	3%	4%
Radiology	3%	3%	3%	3%
Pathology	2%	2%	2%	3%
Allied HCP	2%	2%	2%	2%
Pharmacy	2%	2%	1%	1%
Palliative Care	1%	1%	1%	1%
Academic	0.5%	0.5%	1%	0.5%
Student	0.8%	0.8%	0%	0%

(Percentages are rounded up)

BRITISH THORACIC ONCOLOGY GROUP



TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)

Membership (continued)

Health Care Professionals Members' Geography

	2022	2021	2020	2019
Yorkshire and the Humber	187	182	80	86
North West	178	179	79	107
East Midlands	222	213	58	102
North West London	118	116	50	24
South London	102	100	47	48
South West	126	123	42	73
West Midlands	104	105	41	67
Scotland	101	93	39	NA
East of England	101	96	36	57
Kent, Surrey and Sussex	119	114	34	37
North Central and East London	100	92	33	33
Thames Valley	56	54	25	24
Wales	37	36	21	NA
Northern Ireland	18	18	NA	NA
Republic of Ireland	36	35	NA	NA

Based on the sample of 1706 members with the HEE field completed

Network Members by Area of Interest

	2022	2021	2020	2019
Industry	64%	66%	57.1%	62.2%
Patient advocate	12%	10%	17.6%	8.3%
Charity/non-profit	6%	6%	5.5%	6.8%
Other non-HCP	18%	18%	19.8%	19.7%

BRITISH THORACIC ONCOLOGY GROUP



TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)

Twitter, journal and website



3,047 followers - 18% increase

	New Followers			
	2021-2022	2020-2021	2019-2020	2018-2019
New	467	479	510	602
Increase	18%	21%	29%	29%

	Mentions ↑ 24%			
	2021-2022	2020-2021	2019-2020	2018-2019
TOTALS	1118	902	926	706

	Impressions ↑ 59%			
	2021-2022	2020-2021	2019-2020	2018-2019
TOTALS	437,459	274,800	283,600	184,400

Lung Cancer Journal

@LungCaJournal

International peer-reviewed journal on clinical, translational & basic science of lung & chest malignancies [#LCSM](#).
Affiliated with [@BTOGORG](#) [@ETOP_eu](#) and ILCCO

In February 2021, BTOG joined forces with European Thoracic Oncology Platform (ETOP) and International Lung Cancer Consortium (ILCCO) to highlight via twitter significant articles of interest published in the *Lung Cancer Journal*.

Website – www.btog.org

	Users	Pageviews	Avg. session duration	Pages per session
18-19	13,818	86,157	02:14	3.29
19-20	19,679	116,303	01:55	3.56
20-21	18,181	82,029	01:35	3.15
21-22	20,648	155,999	01:50	4.56

70% of traffic is from the UK, 11% from the US, 3% China, 3% Ireland then India, Netherlands, Finland, Germany and France

Devices - 72% is desktop, 26% mobile and 1% tablet

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)

Twitter, journal and website

Top Referrers


NOTE: Slightly more direct traffic vs search than in 20-21, indicates more people are bookmarking or typing in the web address directly than finding the website through a search.

Top referrers are Eventscloud / btogconference.org, Baidu, Veeva, bsti.org.uk

Google / organic Top search terms: BTOG 2021 and BTOG	34%
(direct) / (none)	46%
Referral	8%
Social (96% Twitter)	5%
Other	7%

Top Pages


1. Home
2. 2022 Annual Conference
3. 2021 Annual Conference
4. Events
5. Webinar listing page
6. Join
7. Podcasts
8. Meet the team
9. Screening Essential Update
10. News




ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Research

The poster abstracts from the two BTOG virtual annual conferences were published in a supplement to *Lung Cancer*.



[https://www.lungcancerjournal.info/issue/S0169-5002\(21\)X0006-2](https://www.lungcancerjournal.info/issue/S0169-5002(21)X0006-2)



[https://www.lungcancerjournal.info/issue/S0169-5002\(22\)X0003-2](https://www.lungcancerjournal.info/issue/S0169-5002(22)X0003-2)

A BTOG Special Interest Group (SIG) is a sub-group of the BTOG steering committee with a shared interest in advancing a specific area of thoracic oncology. Members co-operate to affect change or improvement within that speciality. They may communicate, meet, and organise further training or education and resources for the purpose of advancement. They can use the BTOG logo in relation to the SIG. The aim of the BTOG SIGs is to promote the highest standards of knowledge and facilitate research and representation in that specific area of thoracic oncology.

The BTOG Thymic Malignancies SIG, chaired by Dr David Gilligan, met for the first time in January 2020 and following disruption due to the pandemic, reconvened in January 2022. Tumours of the thymus gland constitute a rare but significant part of thoracic oncology. Management of these tumours can be complex and is often poorly understood. The BTOG Thymic Malignancies SIG is a multi-disciplinary group of interested health care professionals, including the patient advocacy group ThymicUK. The aims of this group are to promote understanding, improve knowledge of thymic tumours and to work co-operatively to improve the management pathways for thymic tumours.

During this period, BTOG has also set up a BTOG Large Cell Neuroendocrine Carcinoma (LCNEC) SIG, chaired by Dr Colin Lindsay. The BTOG LCNEC SIG will be meeting in June 2022 for the first time.

BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022




ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities – Research (continued)

Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists published September 2021

Lindsay, C.R., Shaw, E.C., Moore, D.A. *et al.* Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists. *Br J Cancer* 125, 1210–1216 (2021). <https://doi.org/10.1038/s41416-021-01407-9>

In September 2021, BTOG submitted a supporting Letter to the NIHR an application relating to Prehabilitation for Lung Cancer Surgery.




The NLCA board is constituted by the Society for Cardiothoracic Surgery (SCTS), the Roy Castle Lung Cancer Foundation (representing lung cancer patients), Wales Cancer Network Lung Cancer Group, Lung Cancer Nursing UK (formerly the National Lung Cancer Forum for Nurses) and the **British Thoracic Oncology Group**.

<https://nlca.rcp.ac.uk/content/misc/NLCA%20annual%20report%202022.pdf>


The NLCA board is constituted by the Society for Cardiothoracic Surgery (SCTS), the Roy Castle Lung Cancer Foundation (representing lung cancer patients), Wales Cancer Network Lung Cancer Group, Lung Cancer Nursing UK (formerly the National Lung Cancer Forum for Nurses) and the **British Thoracic Oncology Group**.

[https://nlca.rcp.ac.uk/content/misc/LCCOP%202021\(2018\).pdf](https://nlca.rcp.ac.uk/content/misc/LCCOP%202021(2018).pdf)



ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities – Research (continued)



BTOG Endorsed the Final Report during this period which was released in April 2022

Endorsements



RCR Radical Thoracic Re-irradiation Guidance – BTOG Endorsed

BTOG endorsed this draft guidance during this period. As the time of this report the guidance is not yet published and it will form part of a wider guidance document in development.

Surveys

BTOG circulated a Pembrolizumab Survey led by Professor Innominato and Dr Ghosal, a team of clinical oncologists, based at the North Wales Cancer Treatment Centre. The survey aims to establish the practice and opinions of oncologists around the country regarding patients with metastatic NSCLC (with no actionable driver mutations), who had to stop 1st line palliative Pembrolizumab after completing two years of treatment in accordance with NICE guidance. The survey objectives are to assist to steer the practice guidance in the future.

BTOG circulated a Survey for Thoracic Clinical Oncologists from National Oncology Trainee Collaborative for Health care Research (NOTCH) regarding the current radiotherapy practice for Thymic Epithelial Tumours (TET). The aim is for at least one response from each radiotherapy centre in the UK to help NOTCH to provide a comprehensive review of UK practice.

TRUSTEES' REPORT (CONTINUED)


FOR THE YEAR ENDED 31 MARCH 2022

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities – Research (continued)

Consultations and Inquiries

In August 2021, BTOG contributed to The All Party Parliamentary Group for Respiratory Health inquiry into lung cancer. The inquiry invited expert opinion to inform the group's thinking and to recommend policy solutions for the NHS for implementation to help support the government's policy initiatives on lung cancer.



BTOG submitted evidence to this inquiry. The report was released in November 2021.

<https://www.appg-respiratory.co.uk/>

In January 2022, BTOG contributed to The Health and Social Care Committee's Expert Panel evaluation of the progress the Government has made against its commitments in cancer services in England.

Review of Activities – Representation

BTOG continues to work collaboratively with many organisations, societies, and groups and to build close and enduring relationships and to have mutual memberships to ensure representation. Steering Committee members undertake this work on behalf of BTOG and these include the following examples:

- British Thoracic Society
- Cancer Chemotherapy Interest Group
- European Association for Cardio-Thoracic Surgery (EACTS)
- European Organisation for Research and Treatment of Cancer (EORTC)
- European Thoracic Oncology Platform (ETOP)
- International Association for the Study of Lung Cancer (IASLC)
- Mesothelioma UK
- National Cancer Research Institute (NCRI)
- National Lung Cancer Audit
- Lung Cancer Nursing UK
- Public Health England Implementation Board for Tobacco
- Roy Castle Lung Cancer Foundation
- Royal College of Physicians Tobacco Advisory Board
- Society for Cardiothoracic Surgery (SCTS)
- Taskforce for Lung Health
- UK Mesothelioma Alliance
- UK Lung Cancer Coalition

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities – Representation (continued)



NICE Representation

NICE appraisals review and make recommendations on the clinical and cost-effectiveness of medicines and treatments in the NHS.

During this period Steering Committee members have represented BTOG on **51** NICE appraisals (scoping and full) to review the use of new and existing medicines and treatments within the NHS to ensure clinical and cost effectiveness. **8** NICE appraisals were represented by non-steering committee members – co-opted to represent BTOG.

Participation in the NICE appraisal process involves a significant time commitment by representatives and includes attending appraisal meetings, reviewing lengthy and detailed documents and making comment and recommendations to improve access to treatment for patients.

Samreen Ahmed	11 (1 joint)	Sanjay Agrawal	3	Riyaz Shah	3
Sanjay Popat	9	Clive Peedel	1	David Gilligan	1
Tom Newsom-Davis	6	James Spicer	2	Shobit Baijal	4
Matt Callister	1				
Co-opted (non-SC)					
Alastair Greystoke	2	Mary O'Brien	1	Robin Young	1
Matthew Hatton	1	Yvonne Summers (joint)	1	Matthew Krebs	1
Mark Forster	1 (joint)				

During this period 3 NICE appraisals resulted in recommendations:

- Pembrolizumab with carboplatin and paclitaxel is recommended as an option for untreated metastatic squamous non-small-cell lung cancer (NSCLC) in adults, only if:
 - their tumours express PD-L1 with a tumour proportion score of 0% to 49%;
 - their tumours express PD-L1 with a tumour proportion score of 50% or more and they need urgent clinical intervention;
 - it is stopped at 2 years of uninterrupted treatment or earlier if their disease progresses. Recommended February 2022 (ID1683)
- Lung cancer (non-small-cell, advanced, MET gene) - tepotinib [ID3761]. Recommended March 2022 (ID3761)
- Sotorasib (Lumykras) for previously treated KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults. Recommended March 2022 (ID3780)

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Campaigns



BTOG supports lung cancer campaign

BTOG is proud to have worked in collaboration with Ruth Strauss Foundation, ALK Positive UK and EGFR+UK to develop its [See Through The Symptoms](https://www.lungcancerseethroughthesymptoms.uk/) campaign which raises awareness of lung cancer and the importance of early investigation and referral.

Page 10 of 10
DATE: 20
AUTHOR: BTOG
REVIEWER: BTOG
STATUS: DRAFT
REASON FOR LUNG CANCER

Page 10 of 10
DATE: 20
AUTHOR: BTOG
REVIEWER: BTOG
STATUS: DRAFT
REASON FOR LUNG CANCER

Lung Cancer Early Diagnosis Campaign – Launched in May 2021

<https://www.lungcancerseethroughthesymptoms.uk/>



Cancer screening

How can cancer screening programmes be improved throughout the EU?

In August 2021, BTOG wrote to the Federation of European Academies of Medicine (FEAM) regarding the development of a report on cancer screening for the Scientific Advice Mechanism (SAM). BTOG wholeheartedly endorsed the adoption of low-dose computed tomography (LDCT) screening for individuals at high risk of lung cancer.

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

FINANCIAL REVIEW

Going Concern

After making appropriate enquiries, the trustees have a reasonable expectation that BTOG has adequate resources to continue in operational existence for the foreseeable future. For this reason, they continue to adopt the going concern basis in preparing the financial statements.


Finance Overview

Last year, the impact of the COVID-19 pandemic was significant, forcing us to cancel our flagship Annual Conference scheduled for January 2021 and replace it with a virtual conference in April 2021. This led to a dramatic downturn in income for the prior year. This year, with the Annual Virtual Conference being in April 2021 and the Annual Conference for this financial year being in January 2022 there has been a large increase in income for sponsorship and registration fees. Total income for the year rose from £19,500 in 2021 to £526,534 in 2022.

The investment in online learning and webinars brought in as our face-to-face educational programme was set aside due to COVID-19 restrictions, has been hugely successful and has been continued.

Total expenditure for the year ended 31 March 2022 amounted to £286,940 (2021 - £143,766). Expenditure has increased this year after the large fall in the prior year due to revised operating conditions during the pandemic. The expenditure was split between charitable activities costs in the sum of £254,155, costs of raising funds in the sum of £32,475 and other expenditure in the sum of £310.

Net income (expenditure) for the year ended 31 March 2022 amounted to £239,594 compared to £(124,266) in the previous year.



Risk Management

A risk policy and a detailed risk register have been produced. The risk register covers governance, external, financial, operational and regulatory risk and a review of the risk register is a standing item at every trustee meeting. The trustees are satisfied that systems and procedures are in place to mitigate exposure to the major risks. A major risk to BTOG is the reliance on registration fees and external sponsorship income to provide enough funding for BTOG to deliver its aims and objectives. This is particularly relevant given the ongoing COVID-19 pandemic. Mitigating actions include strategic planning, operating a reserves policy and ongoing engagement with our key sponsors.

Reserves Policy

BTOG is committed to demonstrate good stewardship and active financial management and to identifying through risk assessment and budgeting any uncertainty in future income streams. A major risk to BTOG is the reliance on registration fees and external sponsorship to provide enough funding for BTOG to deliver its aims and objectives. Therefore, the trustees have agreed that at any one time the charity can hold a maximum of 2 years' normal operating expenditure in reserve (at the time of writing the charity has not yet reached this level of reserve). Normal operating expenditure is identified in annual budgets which are approved by the trustees. This reserve level will ensure that the current service provided by BTOG is secure in times when income to the charity may be reduced.

BRITISH THORACIC ONCOLOGY GROUP



TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

FINANCIAL REVIEW (CONTINUED)

Reserves Policy (continued)

Total reserves as at 31 March 2022 amounted to £739,715 of which £nil are restricted. As at 31 March 2022 free reserves (total unrestricted reserves less unrestricted tangible fixed assets) amounted to £739,251 which is significantly below the trustees' long term target level of reserves. At current levels of normal activity, the maximum level of reserves would be in the range of £1m to £1.2m. The trustees are considering measures to try and build up free reserves going forward and they will monitor the level of reserves as part of BTOG's financial processes.

If reserves were to exceed the agreed level (2 years' normal operating expenditure) BTOG will take immediate steps to reduce the level of those reserves either by increasing expenditure on charitable activities or by reducing its income (or a combination of both). The time frame for this reduction will be within 2 years of discovery of the excess and during that time the trustees will consider whether some or all the reserves can be invested to obtain a financial return for the charity.

STRUCTURE GOVERNANCE AND MANAGEMENT

Constitution

British Thoracic Oncology Group registered as a company (9816385) on 8th October 2015 and as a charity (1166012) on 11th March 2016. The company is limited by guarantee and has no share capital. Every member of the company undertakes to contribute to the assets of the company, in the event of winding up, such an amount as may be required not exceeding £1. The governing document is the Memorandum of Association.

Trustees

The following trustees have served since 1 April 2021:

Mr AM Grange (Chairman)
Mr C Kerr (Treasurer)
Professor MD Peake
Ms S Hiom
Professor D Talbot

Method of Appointment or Election of Trustees

The management of the charity is the responsibility of the trustees elected under the Memorandum of Association of BTOG. Trustees set the policies for the recruitment, induction and training of new trustees. In selecting individuals for appointment as new trustees, the trustees will consider the skills, knowledge and experience needed for the effective running of the charity. Upon appointment, trustees are provided with an induction pack which includes various items such as the governing document, the latest financial statements, policy documents and Charity Commission guidance.

Pay Policy for Staff

BTOG does not employ its own staff. An NHS Trust employs the staff and charges the associated salary costs to the charity in accordance with a service level agreement. Pay levels for posts supported by the charity are determined through standard NHS procedures.

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

STRUCTURE GOVERNANCE AND MANAGEMENT (CONTINUED)

Organisational Structure and Decision Making

The trustees are responsible for BTOG; they safeguard the values and purpose of BTOG and check activities contribute to achieving the objects and ensure BTOG follows its legal obligations. Trustees are Non-Executive Directors of BTOG. The current trustees comprise a Consultant and Honorary Professor of respiratory medicine who is also Clinical Co-Director of the Centre for Cancer Outcomes at UCLH, Honorary Clinical Lead for NHS Digital and a Specialist Clinical Advisor at Cancer Research UK; a former senior policy figure from Cancer Research UK of 20 years' standing who is now Director of Cancer Intelligence at GRAIL Europe; a retired professor/medical oncologist; a retired tax inspector and a retired senior pharmaceutical professional. The trustees and Steering Committee Chair decide the policies which provide the framework for the work of BTOG; decide overall aims and objectives, priorities and strategy; monitor and evaluate progress and delegate day-to-day work to the BTOG Senior Executive Officer and other appointed staff/agents. The trustees meet 4 times/year and communicate by email at all other times. One trustee also attends Steering Committee meetings as an observer (subject to availability).

The Steering Committee Chair is an Executive Officer of BTOG, accountable to the trustees. The Steering Committee supports BTOG's aims and objectives; take an active role in the delivery of the BTOG educational programme; comments and advises on thoracic oncology guidelines for care or treatment; represents BTOG on other thoracic oncology boards/committees/groups and recognises their affiliation to BTOG in their work. The Steering Committee are Executive Officers of BTOG, accountable to the SC Chair. The Steering Committee meet in person 4 times/year and communicate by email at all other times. The Steering Committee members represent the thoracic oncology multi-disciplinary team. In addition, BTOG recognises the importance of input from advocates in improving outcomes for lung cancer and mesothelioma patients and therefore the Steering Committee includes two advocate members. BTOG defines advocates as those who sit on clinical studies or trial management groups, advisory boards/groups or other related groups related to lung cancer or mesothelioma.

BTOG is a member of the National Council for Voluntary Organisations (NCVO) and trustees have access to online resources and information for charities. The trustees are required to update their trustee knowledge and training regularly to ensure they understand their role and responsibilities. Trustees periodically attend both theoretical and practical training courses organised by the NCVO covering a wide variety of charitable issues and they also complete online training.

The Senior Executive Officer (SEO) carries out the work of BTOG; reports regularly on achievements and progress; makes decisions (where the power to do this has been delegated); provides information on issues, problems and policy matters and makes recommendations; draws up plans for the future development of BTOG's work for the Trustees and Steering Committee to decide upon; advises and informs the trustee board so that it is able to carry out its governing role and recruits and appoints staff/agents. The SEO is reportable to University Hospitals of Leicester NHS Trust (UHL) Line Manager and Steering Committee Chair and accountable to the trustees.

The relationship of the BTOG Executive is based on a shared vision for BTOG; a commitment to achieving the objectives of BTOG; clear and understood trustee roles to not interfere inappropriately with the day-to-day running of BTOG; confidence in the abilities of the SEO and willingness to back the judgement of the SEO in the event of problems (providing they have been kept informed); the provision of good information to enable informed decisions to be made and a clear management framework and lines of accountability.

The SEO and Executive Officer (EO) are paid roles employed by UHL, who charge the associated salary costs to the charity in accordance with a formal service level agreement. Communications/website, conference and accountancy services were contracted out to external commercial providers. All other roles in the BTOG Executive are unpaid.

For 15 years, BTOG was provided with office space by UHL and was based at Glenfield Hospital in Leicester. In August 2017, BTOG moved to external offices (within Mesothelioma UK) and from December 2018 to 30 September 2020, BTOG leased a dedicated office space adjacent to Mesothelioma UK. A formal Service Level Agreement was in place between BTOG and Mesothelioma UK (for use of IT equipment). With staff working from home during the pandemic, the charity made the decision to terminate the lease on 30 September 2020. Starting 1st February 2022, BTOG have leased an office from Mesothelioma UK in Mountsorrel, Leicester and there is a Memorandum of Understanding in place in this respect. BTOG staff do a combination of office and home working.

BTOG works collaboratively with many organisations including Mesothelioma UK (a related party) in the pursuit of its charitable activities.

BRITISH THORACIC ONCOLOGY GROUP



TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

STRUCTURE GOVERNANCE AND MANAGEMENT (CONTINUED)

Organisational Structure and Decision Making (continued)

BTOG recognised the need for appropriate governance to ensure transparent working and therefore has a comprehensive portfolio of policies covering charity structure, roles and responsibilities of trustees and the steering committee, conflict of interest, finance, procurement, reserves, endorsement, media and privacy, developed taking account of Charity Commission guidance. The policies are reviewed as per the review dates and new policies are developed as needed/identified and are available in the Governance section of the BTOG website.

The Trustees confirm that the major risks relating to BTOG have been reviewed and systems and procedures have been established to manage those risks, as detailed on page 26 under risk management.

Plans for future periods

The COVID-19 pandemic meant that BTOG adapted what we do to include a virtual CPD education programme, and this will be continued in the 2022/23 period and beyond. However, we plan to introduce in-person education again during 2022/23. BTOG will continue to work towards its strategic outcomes, mission and vision within the Strategic Plan 2020-2025 (on page 3). The next few years will be challenging as we all navigate further through the pandemic and hopefully continue through the recovery phase.

During the 2022/23 period and beyond we plan to:

- Continue to provide relevant CPD education (virtual and in-person). In-person will include an annual conference and essential updates;
- Provide networking, education and resources for trainees;
- Make www.btog.org the one-stop resource shop for trainees and all thoracic oncology health care professionals;
- Continue to provide "BTOG does ..." Podcasts;
- Develop BTOG's Research Strategy
- Identify other areas for the development of BTOG Special Interest Groups (SIG) complementing other external subgroups
- Begin work on developing a programme of Regional Updates including standard slide sets on relevant up-to-date research/data

This report has been prepared in accordance with the special provisions relating to small companies within Part 15 of the Companies Act 2006.

Approved by the Board of Trustees on 22 August 2022 and signed on its behalf by:

Mr AM Grange
Chair of the Board of Trustees

BRITISH THORACIC ONCOLOGY GROUP

INDEPENDENT EXAMINER'S REPORT

TO THE TRUSTEES OF BRITISH THORACIC ONCOLOGY GROUP

I report to the trustees on my examination of the accounts of the company for the year ended 31 March 2022.

Responsibilities and basis of report

As the trustees of the charity (and also its directors for the purposes of company law) you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006 (the 2006 Act).

Having satisfied myself that the accounts of the company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your company's accounts carried out under section 145 of the Charities Act 2011 (the 2011 Act). In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145 (5)(b) of the 2011 Act.

Independent examiner's statement

Since the charity's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of the Association of Chartered Certified Accountants, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

- 1 accounting records were not kept in respect of the charity as required by section 386 of the 2006 Act; or
- 2 the financial statements do not accord with those records; or
- 3 the financial statements do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
- 4 the financial statements have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

P T Barnett FCCA (Independent Examiner)

Newby Castleman LLP
West Walk Building
110 Regent Road
Leicester
LE1 7LT

22 September 2022

BRITISH THORACIC ONCOLOGY GROUP

STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT FOR THE YEAR ENDED 31 MARCH 2022

	Notes	Unrestricted Funds Total 2022 £	Unrestricted Funds Total 2021 £
Income from:			
Charitable activities	3	58,736	-
Other trading activities	4	467,798	19,500
Total		526,534	19,500
Expenditure on:			
Raising funds	5	32,475	29,466
Charitable activities	6	254,155	111,300
Other	9	310	3,000
Total		286,940	143,766
Net income/(expenditure) for the year/ Net movement in funds		239,594	(124,266)
Reconciliation of funds			
Total funds brought forward		500,121	624,387
Total funds carried forward		739,715	500,121

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

BRITISH THORACIC ONCOLOGY GROUP

BALANCE SHEET

AS AT 31 MARCH 2022

		2022		2021	
	Notes	£	£	£	£
Fixed assets					
Tangible assets	12		464		1,183
Current assets					
Debtors	13	195,210		141,882	
Cash at bank and in hand		671,482		591,233	
		<u>866,692</u>		<u>733,115</u>	
Liabilities					
Creditors: amounts falling due within one year	14	(127,441)		(234,177)	
Net current assets			739,251		498,938
Net assets			<u>739,715</u>		<u>500,121</u>
Total funds of the charity					
Designated funds		7,730		8,316	
General funds		<u>731,985</u>		<u>491,805</u>	
Total unrestricted funds	16		739,715		500,121
Total charity funds			<u>739,715</u>		<u>500,121</u>

The company is entitled to the exemption from the audit requirement contained in section 477 of the Companies Act 2006, for the year ended 31 March 2022.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

Trustees' responsibilities:

- The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476 of the Companies Act 2006;
- The trustees acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of the accounts.

The financial statements were approved and authorised for issue by the Board of Trustees on 22 August 2022 and are signed on its behalf by:

Mr C Kerr
Trustee and Treasurer

Company Registration No. 9816385

BRITISH THORACIC ONCOLOGY GROUP

STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED 31 MARCH 2022

	Notes	2022 £	£	2021 £	£
Cash flows from operating activities					
Cash generated from operations	21		80,249		220,479
Investing activities					
Purchase of tangible fixed assets		-		(592)	
Net cash used in investing activities			-		(592)
Net cash used in financing activities			-		-
Net increase in cash and cash equivalents			80,249		219,887
Cash and cash equivalents at beginning of year			591,233		371,346
Cash and cash equivalents at end of year			671,482		591,233

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2022

1 Accounting policies

Charity information

British Thoracic Oncology Group ("BTOG") is a private company limited by guarantee incorporated in England and Wales. The address of the registered office and place of business is given in the legal and administrative information page of these financial statements.

The members of the charity include the trustees named within the legal and administrative information. In the event of the trust being wound up, the liability in respect of the guarantee is limited to £1 per member of the charity.

1.1 Basis of preparation

The charity is a Public Benefit Entity as defined by FRS 102. The financial statements have been prepared in accordance with: the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102), Accounting and Reporting by Charities: the Statement of Recommended Practice for charities applying FRS 102 (2019), the Charities Act 2011, the Companies Act 2006 and UK Generally Accepted Accounting Practice.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below. These policies have been consistently applied.

1.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives.

Designated funds are unrestricted funds of the charity which have been set aside at the discretion of the trustees for specific purposes. The purposes and uses of the designated funds are set out in the notes to the financial statements.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The aim and use of each restricted fund is set out in the notes to the financial statements.

1.4 Income recognition

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Income from charitable activities primarily includes income received for conference and course registration fees. Such income is recognised at fair value when the charity has entitlement after any performance conditions have been met, if it is probable that the income will be received and the amount can be measured with reliability. If entitlement is not met, then the amounts are deferred.

Income from trading activities includes income earned from sponsorship.

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2022

1 Accounting policies

(Continued)

1.5 Expenditure recognition

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs relating to the category. Expenditure is recognised when there is legal or constructive obligation to make the payment to a third party, if it is probable that settlement will be required and the amount of the obligation can be measured reliably. It is recognised under the following headings:

- Expenditure on raising funds - this includes costs for advertising, marketing, direct mail and publicity.
- Expenditure on charitable activities - this includes services to further the delivery of the objectives of the charity.

Irrecoverable VAT is charged against the category of resources expensed for which it was incurred.

Support costs

Support costs are those that assist the work of the charity but do not directly represent charitable activities and costs of raising funds and include office costs and governance costs. They are incurred directly in support of expenditure on the objects of the charity. Support costs are allocated to costs of raising funds and expenditure on charitable activities on a basis consistent with use of the resources.

The analysis of these costs is included in note 9.

1.6 Tangible fixed assets

Tangible fixed assets are measured at cost, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost of assets less their residual values over their useful lives on the following bases:

Fixtures & fittings	15% of cost
Computer equipment	33.33% of cost

1.7 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less.

1.8 Financial instruments

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Debtors and creditors with no stated interest rate and receivable or payable within one year are measured at transaction price. Any losses arising from impairment are recognised in the SOFA.

1.9 Taxation

British Thoracic Oncology Group is a registered charity and no taxation provision is required as its income from charitable activities falls within the various exemptions available to registered charities.

1.10 Employee benefits

When employees have rendered service to the charity, short-term employee benefits to which the employees are entitled are recognised at the undiscounted amount expected to be paid in exchange for that service.

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2022

1 Accounting policies (Continued)

1.11 Leases

Rentals payable under operating leases, including any lease incentives received, are charged as an expense on a straight line basis over the term of the relevant lease.

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

The trustees do not consider there to be any key sources of estimation uncertainty that have a significant effect on the amounts recognised in the financial statements.

3 Charitable activities

	Unrestricted funds £	Restricted funds £	Total 2022 £	Total 2021 £
Conference and course registration fees	58,736	-	58,736	-
Unrestricted funds				-
Restricted funds				-
				-

4 Other trading activities

	Unrestricted funds 2022 £	Restricted funds 2022 £	Total 2022 £	Total 2021 £
Sponsorship	467,798	-	467,798	19,500
Unrestricted funds				19,500
Restricted funds				-
				19,500

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2022

5 Raising funds

	Unrestricted funds £	Restricted funds £	Total 2022 £	Total 2021 £
Advertising, marketing, direct mail and publicity	14,363	-	14,363	12,513
Support costs (see note 8)	18,112	-	18,112	16,953
	<u>32,475</u>	<u>-</u>	<u>32,475</u>	<u>29,466</u>
Unrestricted funds				29,466
Restricted funds				-
				<u>29,466</u>

6 Charitable activities

	Activities undertaken directly Note 7 £	Support Costs Note 8 £	Total 2022 £	Total 2021 £
Conference and courses	169,912	84,243	254,155	111,300
Unrestricted funds			254,155	111,300
Restricted funds			-	-
			<u>254,155</u>	<u>111,300</u>

7 Expenditure on activities undertaken directly

	2022 £	2021 £
Conference and courses		
Venue and accommodation management	29,499	-
Abstract publication	26,630	-
Prizes and bursaries	3,300	-
Course accreditation	695	360
Bank and card charges	1,714	-
Webinar activities	108,074	23,028
	<u>169,912</u>	<u>23,388</u>

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2022

8 Expenditure on support costs

	Basis of allocation	2022 £	2021 £
Staff costs	Raising funds and charitable activities	90,562	84,764
Travel	Charitable activities	665	725
Training	Charitable activities	-	753
Subscriptions	Charitable activities	486	402
Rent	Charitable activities	650	1,500
Insurance	Charitable activities	1,677	1,950
Office costs	Charitable activities	1,318	2,294
Software costs	Charitable activities	1,291	1,049
Bad debts	Charitable activities	-	2,910
Governance	Charitable activities	5,120	7,663
Sundry	Charitable activities	177	102
Depreciation	Charitable activities	409	753
		<u>102,355</u>	<u>104,865</u>
Analysed between:			
Raising funds		18,112	16,953
Charitable activities		84,243	87,912
		<u>102,355</u>	<u>104,865</u>

Support costs have been allocated to raising funds and charitable activities on a basis consistent with the use of the resource. Support costs include governance costs totalling £5,120 (2021: £7,663).

The amount charged to the SOFA in respect of governance costs includes the following:

Independent examination £4,000 (2021 - £3,850)

VAT advisory services £nil (2021 - £1,400)

Other financial services £1,120 (2021 - £2,413)

9 Other expenditure

	Unrestricted funds 2022 £	Total 2022 £	Unrestricted funds 2021 £	Total 2021 £
Net loss on disposal of tangible fixed assets	310	310	-	-
Interest	-	-	3,000	3,000
	<u>310</u>	<u>310</u>	<u>3,000</u>	<u>3,000</u>

The company classifies certain one-off charges and credits which have a material impact on the company's financial results as 'exceptional items'. These are disclosed separately to provide further understanding of the financial performance of the company.

Interest in the sum of £3,000 relates to late payment of the total VAT liability of £50,005 in respect of the four years ended 31 March 2020, following a review of the charity's VAT affairs.

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2022

10 Trustees

The trustees neither received nor waived any emoluments during the year (2020: £Nil).

No travel and subsistence expenses were reimbursed to trustees during the year or preceding year.

11 Employees

Number of employees

The average monthly number of employees during the year was:

	2022 Number	2021 Number
Total	2	2

Employment costs

	2022 £	2021 £
Wages and salaries	90,562	84,764

Staff working for the charity are employed directly by the University Hospitals of Leicester NHS Trust and their salary costs are charged to the charity in accordance with a service level agreement between BTOG and the Trust. The amount charged for the year was £90,562 (2021 - £87,764).

There were no employees whose annual remuneration was £60,000 or more.

12 Tangible fixed assets

	Fixtures & fittings £	Computer equipment £	Total £
Cost			
At 1 April 2021	1,257	1,689	2,946
Disposals	(565)	-	(565)
At 31 March 2022	692	1,689	2,381
Depreciation and impairment			
At 1 April 2021	489	1,274	1,763
Depreciation charged in the year	105	304	409
Eliminated in respect of disposals	(255)	-	(255)
At 31 March 2022	339	1,578	1,917
Carrying amount			
At 31 March 2022	353	111	464
At 31 March 2021	768	415	1,183

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2022

13 Debtors

	2022 £	2021 £
Amounts falling due within one year:		
Trade debtors	155,590	115,712
Other debtors	7,730	8,316
Prepayments and accrued income	31,890	17,854
	<u>195,210</u>	<u>141,882</u>

14 Creditors: amounts falling due within one year

	2022 £	2021 £
Other taxation and social security	43,565	35,002
Deferred income (see note 16)	74,866	190,000
Accruals	9,010	9,175
	<u>127,441</u>	<u>234,177</u>

15 Deferred income

	2022 £	2021 £
Arising from advanced registration fees and sponsorships	<u>74,866</u>	<u>190,000</u>

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2022

16 Unrestricted funds

The unrestricted funds of the charity include designated funds which have been set aside out of unrestricted funds by the trustees for a specific purpose:

	Balance at 1 April 2021 £	Income £	Movement in funds Expenditure £	Transfers £	Prior period Adjustment £	Balance at 31 March 2022 £
General funds	491,805	526,534	(196,354)	(90,000)	-	731,985
Designated funds - wages fund	8,316	-	(90,586)	90,000	-	7,730
	<u>500,121</u>	<u>526,534</u>	<u>(286,940)</u>	<u>-</u>	<u>-</u>	<u>739,715</u>

	Balance at 1 April 2020 £	Income £	Movement in funds Expenditure £	Transfers £	Prior period Adjustment £	Balance at 31 March 2021 £
General funds	591,758	19,500	(28,639)	(60,500)	(30,314)	491,805
Designated funds - wages fund	32,629	-	(84,813)	60,500	-	8,316
	<u>624,387</u>	<u>19,500</u>	<u>(113,452)</u>	<u>-</u>	<u>(30,314)</u>	<u>500,121</u>

The wages fund represents funds held by the University Hospitals of Leicester NHS Trust as Custodian Trustee on behalf of British Thoracic Oncology Group for primarily the payment of wages to staff working for the charity but who are employed by the NHS Trust.

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2022

17 Analysis of net assets between funds

	Unrestricted funds £	Designated funds £	Total £
Fund balances at 31 March 2022 are represented by:			
Tangible assets	464	-	464
Current assets/(liabilities)	731,521	7,730	739,251
	<u>731,985</u>	<u>7,730</u>	<u>739,715</u>
	Unrestricted funds £	Designated funds £	Total £
Fund balances at 31 March 2021 are represented by:			
Tangible assets	1,183	-	1,183
Current assets/(liabilities)	490,622	8,316	498,938
	<u>491,805</u>	<u>8,316</u>	<u>500,121</u>

18 Related party transactions

Remuneration of key management personnel

The remuneration of key management personnel is as follows.

	2022 £	2021 £
Aggregate compensation	<u>57,356</u>	<u>54,050</u>

During the year rent and office expenses in the sum of £1,478 (2021 - £1,968) were invoiced by Mesothelioma UK Charitable Incorporated Organisation (formerly Mesothelioma UK Charitable Trust) to the British Thoracic Oncology Group. Professor M D Peake and Ms D E McKinley are both trustees of these organisations. At the balance sheet date there was an outstanding balance of £nil (2021 - £nil) for these services.

No travel expenses were due to be reimbursed to any trustees at the year end or last year end.

Travel and subsistence expenses were reimbursed to 1 member (2021: 0) of key management personnel in the sum of £327 (2021: £nil) during the year.

There have been no further related party transactions in the reporting period that require disclosure in the financial statements, other than those noted in note 11 to the financial statements.

19 Controlling party

British Thoracic Oncology Group is a company limited by guarantee and not having a share capital; it is incorporated under the Companies Act and governed by the Memorandum and Articles of Association of the charity. The trustees of the charity are elected members and act as directors of the charity who are deemed to be the controlling party of the charity.

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2022

20 Operating lease commitments

At 31 March 2022 the charity had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

	2022 £	2021 £
Within one year	3,250	-

Lease payments totalling £650 (2021 - £1,500) have been recognised as an expense during the year.

21 Cash generated from operations

	2022 £	2021 £
Surplus/(deficit) for the year	239,594	(124,266)
Adjustments for:		
Loss on disposal of tangible fixed assets	310	-
Depreciation and impairment of tangible fixed assets	409	753
Movements in working capital:		
(Increase)/decrease in debtors	(53,328)	191,022
Increase/(decrease) in creditors	8,398	(29,530)
(Decrease)/increase in deferred income	(115,134)	182,500
Cash generated from operations	80,249	220,479